[{"Element":"<div class=\"WordSection1\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>ANNEX\r I<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>SUMMARY\r OF PRODUCT CHARACTERISTICS<\/span><\/b><\/p> <span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><img alt=\"BT_1000x858px\" height=\"20\" id=\"Picture 2\" src=\"data:image\/png;base64,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\" width=\"20\"\/><\/span><span style=\"font-size:11.0pt\">This medicinal product is subject to additional\r monitoring. This will allow quick identification of new safety information.\r Healthcare professionals are asked to report any suspected adverse reactions.\r See section 4.8 for how to report adverse reactions.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"FR\" style=\"font-size:11.0pt\">Zynteglo 1.2\u201120 \u00d7 10<sup>6<\/sup> cells\/mL\r dispersion for infusion. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>2.1     General description<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"FR\" style=\"font-size:11.0pt\">Zynteglo (betibeglogene autotemcel) is a<\/span><span lang=\"FR\" style=\"font-size:11.0pt\"> genetically modified autologous CD34<sup>+ <\/sup>cell\r enriched population that contains haematopoietic stem cells (HSC) transduced\r with lentiviral vector (LVV) encoding the <\/span><span style=\"font-size:11.0pt\">\u03b2<\/span><sup><span lang=\"FR\" style=\"font-size:11.0pt\">A\u2011T87Q<\/span><\/sup><span lang=\"FR\" style=\"font-size:11.0pt\">\u2011globin gene.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>2.2     Qualitative and\r quantitative composition<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The finished product is composed of one or more\r infusion bags which contain a dispersion of <span style=\"color:black\">1.2\u201120 \u00d7 <\/span>10<sup>6 <\/sup><span style=\"color:black\">cells\/mL <\/span>suspended in cryopreservative solution<span style=\"color:black\">. <\/span>Each infusion bag contains approximately\r 20 mL of Zynteglo.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The quantitative information regarding strength, CD34<sup>+<\/sup>\r cells, and dose for the medicinal product is provided in the Lot Information\r Sheet. The Lot Information Sheet is included inside the lid of the cryoshipper\r used to transport Zynteglo.  <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Excipient with known effect<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Each dose contains 391\u20111564 mg sodium.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">For the full list of excipients, see section 6.1.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>3.       PHARMACEUTICAL\r FORM<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Dispersion for infusion.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">A clear to slightly cloudy, colourless to yellow or\r pink dispersion.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.       CLINICAL\r PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.1     Therapeutic\r indication<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk500066939\"><span style=\"font-size:11.0pt\">Zynteglo is indicated for\r the treatment of patients 12 years and older with transfusion\u2011dependent\r \u03b2\u2011thalassaemia (TDT) who do not have a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype, for whom haematopoietic stem cell (HSC) transplantation is\r appropriate but a human leukocyte antigen (HLA)\u2011matched related HSC donor\r is not available (see sections 4.4 and 5.1).<\/span><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.2     Posology and\r method of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk497649473\"><span style=\"font-size:11.0pt\">Zynteglo must be\r administered in a qualified treatment centre by a physician(s) with experience\r in HSC transplantation and in the treatment of patients with TDT. <\/span><\/a><a name=\"_Hlk511314218\"><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients are expected to enrol in a registry and will\r be followed in the registry in order to better understand the long-term safety\r and efficacy of Zynteglo. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Posology<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The minimum recommended dose of Zynteglo is\r 5.0 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg. In clinical\r studies doses up to 20 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup>\r cells\/kg have been administered. The minimum recommended dose is the same for\r adults and adolescents 12 years of age and older.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is intended for autologous use (see section\r 4.4) and should only be administered once.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><i><span style='font-family:\"Times New Roman\",serif'>Mobilisation and apheresis<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients are required to undergo HSC mobilisation\r followed by apheresis to obtain CD34<sup>+<\/sup> stem cells which will be used\r for medicinal product manufacturing (see section 5.1 for a description of the\r mobilisation regimen used in clinical studies). <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The minimum target number of CD34<sup>+<\/sup> cells to\r be collected is 12 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg.\r If the minimum dose of Zynteglo of 5.0 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg\r is not met after initial medicinal product manufacturing, the patient may\r undergo one or more additional cycles of mobilisation and apheresis, separated\r by at least 14 days, in order to obtain more cells for additional\r manufacture.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">A back-up collection of CD34<sup>+<\/sup> stem cells of\r \u22651.5 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg (if\r collected by apheresis) or &gt;1.0 \u00d7 10<sup>8<\/sup> TNC\/kg (if\r collected by bone marrow harvest) is required. These cells must be collected\r from the patient and be cryopreserved prior to myeloablative conditioning and\r infusion with Zynteglo. The back\u2011up collection may be needed for rescue\r treatment if there is: 1) compromise of Zynteglo after initiation of myeloablative\r conditioning and before Zynteglo infusion, 2) primary engraftment failure, or\r 3) loss of engraftment after infusion with Zynteglo (see section 4.4). <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><i><span style='font-family:\"Times New Roman\",serif'>Pre-treatment conditioning <\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The treating physician should confirm that HSC\r transplantation is appropriate for the patient before myeloablative\r conditioning is initiated (see section 4.4). <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt;color:black\">Full myeloablative conditioning must be\r administered before infusion of Zynteglo (see section 5.1 for a description of\r the myeloablative regimen used in clinical studies). <\/span><span style=\"font-size:11.0pt\">It is recommended that patients maintain haemoglobin\r (Hb) \u226511 g\/dL for at least 30 days prior to mobilisation and\r during myeloablative conditioning. Iron chelation should be stopped at least\r 7 days prior to myeloablative conditioning. Prophylaxis for hepatic veno\u2011occlusive\r disease (VOD) is recommended. Prophylaxis for seizures should be considered\r (see section 5.1 for a description of the prophylaxis regimen used in clinical\r studies).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Myeloablative conditioning should not begin until the\r complete set of infusion bag(s) constituting the dose of Zynteglo has been\r received and stored at the administration site, and the availability of the\r back-up collection is confirmed. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><i><span style='font-family:\"Times New Roman\",serif'>Zynteglo administration<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">See Method of Administration below and section 6.6 for\r details on Zynteglo administration and handling.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><i><span style='font-family:\"Times New Roman\",serif'>After Zynteglo administration<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Any blood products required within the first\r 3 months after Zynteglo infusion should be irradiated. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Restarting iron chelation after Zynteglo infusion may\r be necessary and should be based on clinical practice (see sections 4.5 and\r 5.1). Phlebotomy can be used in lieu of iron chelation, when appropriate.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Special populations<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><i><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\">Elderly<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has not been studied in patients\r &gt;65 years of age. HSC transplantation must be appropriate for a patient\r with TDT to be treated with Zynteglo (see section 4.4). No dose adjustment is\r required.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Renal impairment<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has not been studied in patients with renal\r impairment. Patients should be assessed for renal impairment defined as\r creatinine clearance \u226470 mL\/min\/1.73 m<sup>2<\/sup> to ensure\r HSC transplantation is appropriate. No dose adjustment is required.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has not been studied in patients with hepatic\r impairment. Patients should be assessed for hepatic impairment to ensure HSC\r transplantation is appropriate (see section 4.4.). No dose adjustment is\r required.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Paediatric population<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The safety and efficacy of Zynteglo in children\r &lt;12 years of age have not yet been established. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Patients seropositive for human immunodeficiency virus\r (HIV) or human T\u2011lymphotropic virus (HTLV)<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has not been studied in patients with HIV\u20111,\r HIV\u20112, HTLV\u20111, or HTLV\u20112. A negative serology test for HIV is\r necessary to ensure acceptance of apheresis material for Zynteglo\r manufacturing. Apheresis material from patients with a positive test for HIV\r will not be accepted for Zynteglo manufacturing. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Method of administration <\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is for intravenous use only (see section 6.6\r for full details on the administration process).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">After completion of the 4\u2011day course of\r myeloablative conditioning, there must be a minimum of 48 hours of washout\r before Zynteglo infusion. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Before infusion, it must be confirmed that the\r patient\u2019s identity matches the unique patient information on the Zynteglo\r infusion bag(s). The total number of infusion bags to be administered should\r also be confirmed with the Lot Information Sheet (see section 4.4).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo infusion should be completed as soon as\r possible and no more than 4 hours after thawing. Each infusion bag should\r be administered in less than 30 minutes. In the event that more than one\r infusion bag is provided, all infusion bags must be administered. The entire\r volume of each infusion bag should be infused. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Standard procedures for patient management after HSC\r transplantation should be followed after Zynteglo infusion.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.3     Contraindications<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Hypersensitivity to the active substance or to any of\r the excipients listed in section 6.1.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Pregnancy and breast-feeding (see section 4.6).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Previous treatment with HSC gene therapy.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Contraindications to the mobilisation agents and the\r myeloablative conditioning agent must be considered.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.4     Special\r warnings and precautions for use<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><u><span style='font-family:\"Times New Roman\",serif'>Traceability<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><u><span style='font-family:\"Times New Roman\",serif'><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The traceability requirements of cell-based advanced\r therapy medicinal products must apply. To ensure traceability the name of the\r product, the batch number and the name of the treated patient should be kept\r for a period of 30 years.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">General<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Warnings and precautions of the mobilisation agents\r and the myeloablative conditioning agent must be considered.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients treated with Zynteglo should not donate\r blood, organs, tissues or cells for transplantation at any time in the future.\r This information is provided in the Patient Alert Card which must be given to\r the patient after treatment. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is intended solely for autologous use and\r must not be administered to other patients. Confirm that the patient\u2019s identity\r matches the unique patient identification information on the Zynteglo infusion\r bag(s) and metal cassette(s). Do not infuse Zynteglo if the information on the\r patient specific label on the infusion bag(s) or metal cassette(s) do not match\r the intended patient.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Risks associated with TDT and iron overload<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Patients with TDT experience iron\r overload due to chronic red blood cell (RBC) transfusions that can lead to end\r organ damage. HSC transplantation with myeloablative conditioning is not\r appropriate for patients with TDT who have evidence of severely elevated iron\r in the heart i.e., patients with cardiac T2* &lt;10 msec by magnetic\r resonance imaging (MRI). MRI of the liver should be performed on all patients\r prior to myeloablative conditioning. It is recommended that patients with MRI\r results demonstrating liver iron content \u226515 mg\/g undergo liver\r biopsy for further evaluation. If the liver biopsy demonstrates bridging\r fibrosis, cirrhosis, or active hepatitis, HSC transplantation with\r myeloablative conditioning is not appropriate.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Risk of insertional oncogenesis<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">No cases of leukaemia or lymphoma have been reported\r in clinical studies with Zynteglo in patients with TDT. There are no reports of\r LVV\u2011mediated insertional mutagenesis resulting in oncogenesis.\r Nevertheless, there is a theoretical risk of leukaemia or lymphoma after\r treatment with Zynteglo. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients should be monitored annually for leukaemia or\r lymphoma (including with a complete blood count) for 15 years post\r treatment with Zynteglo. If leukaemia or lymphoma is detected in any patient\r who received Zynteglo, blood samples should be collected for integration site\r analysis.  <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Serological testing<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients should be tested for HIV-1\/2 prior to\r mobilisation and apheresis to ensure acceptance of the apheresis material for\r Zynteglo manufacturing (see section 4.2). <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Interference with serology testing<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">It is important to note that patients who have\r received Zynteglo are likely to test positive by polymerase chain reaction\r (PCR) assays for HIV due to LVV provirus insertion, resulting in a false\r positive test for HIV. Therefore, patients who have received Zynteglo should\r not be screened for HIV infection using a PCR-based assay. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Engraftment failure as measured by neutrophil\r engraftment<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Treatment with Zynteglo involves the infusion and\r engraftment of CD34<sup>+<\/sup> HSCs that have been genetically modified <i>ex\r vivo<\/i> with a LVV. In clinical trials, no patients failed to engraft bone\r marrow, as measured by neutrophil engraftment (N=45). <span style=\"color:black\">Neutrophil\r engraftment occurred on median (min, max) Day 21.0 (13, 38)\r after medicinal product infusion. <\/span>Failure of neutrophil engraftment is a\r short-term but potentially severe risk, defined as failure to achieve\r 3 consecutive absolute neutrophil counts (ANC) \u2265500 cells\/\u00b5L\r obtained on different days by Day 43 after infusion of Zynteglo. Patients\r who experience neutrophil engraftment failure should receive rescue treatment\r with the back-up collection (see section 4.2).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Delayed platelet engraftment<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Platelet engraftment is defined as 3 consecutive\r platelet values \u226520 \u00d7 10<sup>9<\/sup>\/L obtained on different\r days after Zynteglo infusion, with no platelet transfusions administered for\r 7 days immediately preceding and during the evaluation period.<b><\/b>Patients\r with TDT treated with Zynteglo who achieved platelet engraftment had a median\r (min, max) platelet engraftment on Day 42.0 (19, 191) in clinical trials\r (N=45). No correlation was observed between incidence of bleeding and delayed\r platelet engraftment. Patients should be made aware of the risk of bleeding\r until platelet recovery has been achieved. Patients should be monitored for\r thrombocytopenia and bleeding according to standard guidelines. Platelet counts\r should be monitored according to medical judgment until platelet engraftment\r and platelet recovery are achieved. Blood cell count determination and other\r appropriate testing should be promptly considered whenever clinical symptoms\r suggestive of bleeding arise. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Anti-retroviral and hydroxyurea use<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients should not take anti\u2011retroviral\r medications or hydroxyurea from at least one month prior to mobilisation until\r at least 7 days after Zynteglo infusion (see section 4.5). <a name=\"_Hlk3111940\">If a patient requires anti\u2011retrovirals for HIV\r prophylaxis, Zynteglo treatment, including mobilisation and apheresis of CD34<\/a><\/span><sup>+<\/sup><span style=\"font-size:11.0pt\"> cells through Zynteglo infusion, should be delayed\r until an HIV infection could be adequately ruled out according to local\r guidance for HIV testing.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Sodium content<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">This medicinal product contains 391\u20111564 mg\r sodium per dose equivalent to 20 to 78% of the WHO recommended maximum daily\r intake of 2 g sodium for an adult. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.5     Interaction with\r other medicinal products and other forms of interaction<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients should not take anti\u2011retroviral\r medicinal products or hydroxyurea from at least one month prior to mobilisation\r until at least 7 days after Zynteglo infusion (see section 4.4).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Drug-drug interactions between iron chelators and the\r myeloablative conditioning agent must be considered. Iron chelators should be\r discontinued 7 days prior to initiation of conditioning. The Summary of\r Product Characteristics (SmPC) for the iron chelator and the myeloablative\r conditioning agent must be consulted for the recommendations regarding\r co-administration with CYP3A substrates.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Some iron chelators are myelosuppressive. After\r Zynteglo infusion, avoid use of these iron chelators for 6 months. If iron\r chelation is needed, consider administration of non-myelosuppressive iron\r chelators (see sections 4.2 and 5.1).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">No formal drug interaction studies have been\r performed. Zynteglo is not expected to interact with the hepatic cytochrome P\u2011450\r family of enzymes or drug transporters.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">There is no clinical experience with the use of\r erythropoiesis-stimulating agents in patients treated with Zynteglo.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The safety of immunisation with live viral vaccines\r during or following Zynteglo treatment has not been studied. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.6     Fertility,\r pregnancy and lactation<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Women of childbearing potential\/Contraception in males\r and females<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt;color:black\">There are insufficient exposure data to\r provide a precise recommendation on duration of <\/span><span style=\"font-size:\r 11.0pt\">contraception following treatment with Zynteglo. Women of childbearing\r potential and men capable of fathering a child must use a reliable method of\r contraception (intra-uterine device or combination of hormonal and barrier\r contraception) from start of mobilisation through at least 6 months after\r administration of Zynteglo. Consult the SmPC of the myeloablative conditioning\r agent for information on the need for effective contraception in patients who\r undergo conditioning. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Pregnancy<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">A negative serum pregnancy test must be confirmed\r prior to the start of mobilisation and re-confirmed prior to conditioning\r procedures and before medicinal product administration.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">No clinical data on exposed pregnancies are available.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Reproductive and developmental toxicity studies with\r Zynteglo were not performed. Zynteglo must not be used during pregnancy because\r of myeloablative conditioning (see section 4.3). It is unknown whether Zynteglo\r transduced cells have the potential to be transferred in utero to a foetus.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">There is no opportunity for germline transmission of\r the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin gene after treatment with\r Zynteglo, therefore the likelihood that an offspring would have general somatic\r expression of the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin gene is considered\r negligible.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Breast-feeding<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">It is unknown whether Zynteglo is excreted in human\r milk. The effect of administration of Zynteglo to mothers on their breast-fed\r children has not been studied.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo must not be administered to women who are\r breast-feeding.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Fertility<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">There are no data on the effects of Zynteglo on human\r fertility. Effects on male and female fertility have not been evaluated in\r animal studies. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Data are available on the risk of infertility with\r myeloablative conditioning. <span style=\"color:black\">It is therefore advised\r to cryopreserve semen or ova before treatment if possible.<\/span><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.7     Effects on\r ability to drive and use machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has no influence on the ability to drive or\r use machines.<br\/> <br\/> <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The effect of the mobilisation agents and the\r myeloablative conditioning agent on the ability to drive or use machines must\r be considered.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.8     Undesirable\r effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Summary of the safety profile<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The safety of Zynteglo was evaluated in\r 45 patients with TDT. The only serious adverse reaction attributed to\r Zynteglo was thrombocytopenia (2.2%). <span style=\"color:black\">Given the small\r patient population and size of cohorts, adverse reactions in the table below do\r not provide a complete perspective on the nature and frequency of these events.\r <\/span><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Tabulated list of adverse reactions<br\/> <br\/> <\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Adverse reactions are listed by MedDRA body system\r organ class and by frequency convention. Frequencies are defined as: very\r common <span style=\"color:#323232\">(\u22651\/10), and c<\/span>ommon\r (\u22651\/100 to &lt;1\/10). Within each frequency grouping, adverse reactions\r are presented in the order of decreasing seriousness.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Tables 1, 2, and 3 are lists of adverse reactions\r attributed to mobilisation\/apheresis, myeloablative conditioning, and Zynteglo,\r respectively, experienced by patients with TDT in clinical trials with Zynteglo.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid;\r text-autospace:none\"><b><span style='font-family:\"Times New Roman\",serif'>Table\r 1              Adverse reactions attributed to mobilisation\/apheresis<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a name=\"_Hlk4086514\"><b><span style='font-family:\"Times New Roman\",serif'>System\r   Organ Class (SOC)<\/span><\/b><\/a><\/p> <\/td> <td style=\"width:151.4pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very Common (\u226510%)<\/span><\/b><\/p> <\/td> <td style=\"width:151.4pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common (\u22651% - &lt;10%)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:8.5pt\"> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Blood and lymphatic\r   system disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Thrombocytopenia<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Splenomegaly,\r   Leukocytosis<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Metabolism and\r   nutrition disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypocalcaemia<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypokalaemia,\r   Hypomagnesaemia<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Psychiatric disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Agitation<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Nervous system\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Headache, Peripheral\r   sensory neuropathy<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Dizziness, Head\r   discomfort, Paraesthesia<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cardiac disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cardiac flutter<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vascular disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypotension<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Respiratory, thoracic\r   and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypoxia, Epistaxis<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Gastrointestinal\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Nausea<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vomiting, Lip\r   swelling, Abdominal pain, Abdominal pain upper, Paraesthesia oral <\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Skin and subcutaneous\r   tissue disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Rash, Hyperhidrosis<\/span><\/p> <\/td> <\/tr> <tr style=\"height:22.9pt\"> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Musculoskeletal and\r   connective tissue disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Bone pain<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Back pain,\r   Musculoskeletal discomfort<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>General disorders and\r   administration site conditions<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Pyrexia, Influenza\r   like illness, Chest discomfort, Chest pain, Injection site reaction, Catheter\r   site haemorrhage, Catheter site bruise, Injection site bruising, Fatigue,\r   Non-cardiac chest pain, Catheter site pain, Injection site pain, Puncture\r   site pain, Pain<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Investigations<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Blood magnesium\r   decreased<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Injury, poisoning and\r   procedural complications<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Citrate toxicity,\r   Contusion, Procedural pain<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always;\r page-break-after:avoid;text-autospace:none\"><a name=\"_Hlk4086533\"><b><span style='font-family:\"Times New Roman\",serif'>Table 2              Adverse\r reactions attributed to myeloablative conditioning<\/span><\/b><\/a><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\"> <thead> <tr style=\"height:10.3pt\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:10.3pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>SOC<\/span><\/b><\/p> <\/td> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.3pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very Common (\u226510%)<\/span><\/b><\/p> <\/td> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.3pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common (\u22651% - &lt;10%)<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Infections and\r   infestations<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Neutropenic sepsis,\r   Systemic infection, Staphylococcal infection, Pneumonia, Lower respiratory\r   tract infection, Urinary tract infection, Mucosal infection, Cellulitis,\r   Vaginal infection, Rash pustular, Folliculitis, Gingivitis, Vulvovaginal\r   candidiasis<\/span><\/p> <\/td> <\/tr> <tr style=\"height:8.5pt\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Blood\r   and lymphatic system disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span lang=\"IT\" style='font-family:\"Times New Roman\",serif;color:black'>Febrile\r   neutropenia, Neutropenia, Thrombocytopenia, Leukopenia, Anaemia<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Lymphopenia,\r   Leukocytosis, Monocyte count decreased, Neutrophilia, Mean cell haemoglobin\r   concentration increased<\/span><\/p> <\/td> <\/tr> <tr style=\"height:8.5pt\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Endocrine\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Primary\r   hypogonadism<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Metabolism and nutrition\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Decreased appetite<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypocalcaemia,\r   Hypokalaemia, Metabolic acidosis, Fluid overload, Fluid retention,\r   Hypomagnesaemia, Hyponatraemia, Hypophosphataemia, Hyperphosphataemia<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Psychiatric disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Insomnia<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Anxiety<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Nervous system\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Headache<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Dizziness, Lethargy,\r   Dysgeusia, Ageusia, Memory impairment<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Eye disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Conjunctival\r   haemorrhage<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Ear and labyrinth\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vertigo<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cardiac disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cardiac failure\r   congestive, Atrial fibrillation <\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vascular disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypotension,\r   Haematoma, Hot flush<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Respiratory, thoracic\r   and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Epistaxis, Pharyngeal\r   inflammation<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypoxia, Pulmonary\r   mass, Dyspnoea, Pleural effusion, Rales, Upper-airway cough syndrome, Cough,\r   Laryngeal pain, Hiccups, Oropharyngeal pain <\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Gastrointestinal\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Stomatitis, Vomiting,\r   Nausea, Diarrhoea, Gingival bleeding, Constipation, Abdominal pain, Anal\r   inflammation <\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Anal haemorrhage,\r   Gastritis, Gastrointestinal inflammation, Abdominal distension, Abdominal\r   pain upper, Anal fissure, Dyspepsia, Dysphagia, Oesophagitis, Haemorrhoids,\r   Proctalgia, Lip dry<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hepatobiliary\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Veno\u2011occlusive\r   liver disease, Alanine aminotransferase increased, Aspartate aminotransferase\r   increased, Blood bilirubin increased<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cholecystitis,\r   Cholelithiasis, Hepatomegaly, Jaundice, Transaminases increased,\r   Gamma-glutamyltransferase increased<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Skin and subcutaneous\r   tissue disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Alopecia, Pruritus,\r   Skin hyperpigmentation<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Petechiae,\r   Ecchymosis, Pain of skin, Palpable purpura, Pigmentation disorder, Pruritus\r   generalised, Purpura, Sweat gland disorder, Urticaria, Dry skin, Rash<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Musculoskeletal and\r   connective tissue disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Bone pain, Myalgia,\r   Pain in extremity, Back pain<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Renal and urinary\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Haematuria,\r   Pollakiuria<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Reproductive system\r   and breast disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vaginal haemorrhage<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Ovarian failure,\r   Menstruation irregular, Premature menopause, Blood follicle stimulating\r   hormone increased, Blood testosterone decreased<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>General disorders and\r   administration site conditions<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Pyrexia, Fatigue,\r   Mucosal inflammation<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Face oedema,\r   Hypothermia, Feeling cold, Pain, Xerosis<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Investigations<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>C\u2011reactive\r   protein increased, Aspergillus test positive, Blood potassium decreased,\r   Weight decreased, Blood alkaline phosphatase decreased, Blood magnesium\r   decreased, Forced expiratory flow decreased, Protein total decreased, Blood\r   albumin decreased, Reticulocyte count decreased, Reticulocyte percentage\r   decreased<\/span><\/p> <\/td> <\/tr> <tr style=\"height:23.8pt\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.8pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Injury, poisoning and\r   procedural complications<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:23.8pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:23.8pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Transfusion reaction,\r   Skin abrasion<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid;\r text-autospace:none\"><b><span style='font-family:\"Times New Roman\",serif'>Table\r 3              Adverse reactions attributed to Zynteglo<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"width:451.75pt;border-collapse:collapse;border:none\" width=\"602\"> <tr style=\"height:14.35pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>SOC<\/span><\/b><\/p> <\/td> <td style=\"width:150.6pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very Common (\u226510%)<\/span><\/b><\/p> <\/td> <td style=\"width:150.6pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common (\u22651% - &lt;10%)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:9.4pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Blood and lymphatic\r   system disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:9.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:9.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Thrombocytopenia, <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Leukopenia,\r   Neutropenia<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vascular disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hot flush<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.05pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.05pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Respiratory, thoracic\r   and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.05pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.05pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Dyspnoea<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Gastrointestinal\r   disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Abdominal pain<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Musculoskeletal and\r   connective tissue disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Pain in extremity<\/span><\/p> <\/td> <\/tr> <tr style=\"height:28.5pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.5pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>General disorders and\r   administration site conditions<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:28.5pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:28.5pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Non-cardiac chest\r   pain<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Description of selected adverse reactions<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk4059620\"><i><span style=\"font-size:11.0pt\">Bleeding<\/span><\/i><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Bleeding is a potential complication of\r thrombocytopenia subsequent to myeloablative conditioning and treatment with\r Zynteglo. The majority of all reported bleeding events were nonserious. A risk\r of bleeding exists before platelet engraftment and may continue after platelet\r engraftment in patients who have continued thrombocytopenia.   <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Following platelet engraftment, all patients\r maintained platelet levels of \u226520 \u00d7 10<sup>9<\/sup>\/L. Median\r (min, max) times to unsupported platelet counts of \u226550 \u00d7 10<sup>9<\/sup>\/L \r and \u2265100 \u00d7 10<sup>9<\/sup>\/L were 51 (20, 268) days (N=45) and\r 63.5 (20, 1231) days (N=42), respectively (see section 4.4 for guidance on\r platelet monitoring and management).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Hepatic veno-occlusive disease<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Serious events of hepatic VOD occurred in 11.1% of\r patients following myeloablative conditioning; 80% of these patients did not\r receive prophylaxis for VOD. All patients who experienced VOD received\r treatment with defibrotide and recovered. Patients with TDT may be at an\r increased risk of VOD following myeloablative conditioning compared with other\r patient populations.  <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\">Infusion related reactions to Zynteglo<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Pre-medication for infusion reactions was managed at\r physician discretion. Infusion related reactions to Zynteglo were observed in\r 13.3% of patients and occurred on the day of Zynteglo infusion. All reactions\r resolved and the majority were mild. Events included abdominal pain, dyspnoea,\r hot flush, and non\u2011cardiac chest pain in 11.1%, 2.2%, 2.2%, and 2.2% of\r patients, respectively.  <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk3021378\"><\/a><a name=\"_Hlk2980904\"><span style=\"font-size:11.0pt\">According to available data,\r the frequency, type, and severity of adverse reactions in adolescents 12\u201117 years\r of age are similar to adults with the exception that VOD and pyrexia occurred\r more frequently in adolescents.<\/span><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Reporting of suspected adverse reactions<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Reporting suspected adverse reactions after\r authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:lightgrey\">the national reporting system listed in <span class=\"MsoHyperlink\">Appendix V<\/span>.<\/span><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.9     Overdose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">No data from clinical studies are available regarding\r overdose of Zynteglo. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.       PHARMACOLOGICAL\r PROPERTIES<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.1     Pharmacodynamic\r properties<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Pharmacotherapeutic group: Other haematological\r agents, ATC code: B06AX02<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Mechanism of action<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo adds functional copies of a modified\r \u03b2-globin gene into the patients\u2019 HSCs through transduction of autologous\r CD34<sup>+<\/sup> cells with BB305 LVV, thereby addressing the underlying\r genetic cause of the disease. After Zynteglo infusion, transduced CD34<sup>+<\/sup>\r HSCs engraft in the bone marrow and differentiate to produce RBCs containing\r biologically active <span style=\"color:black\">\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r (a modified \u03b2\u2011globin protein) that will combine with \u03b1-globin\r to produce functional Hb containing <\/span>\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r (Hb<span style=\"color:black\">A<sup>T87Q<\/sup>). <\/span>\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r can be quantified relative to other globin species in peripheral blood using\r high performance liquid chromatography.\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r expression is designed to correct the \u03b2\/\u03b1\u2011globin imbalance in\r erythroid cells of patients with TDT and has the potential to increase total Hb\r to normal levels and eliminate dependence on chronic RBC transfusions. <a name=\"_Hlk2981031\">Following successful engraftment and achievement of\r transfusion independence, the effects of the product are expected to be life\u2011long.<\/a><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Pharmacodynamic effects <\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients with TDT with a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype\r who received Zynteglo with at least 3 months of follow-up produced HbA<sup>T87Q<\/sup>\r (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15, HGB\u2011207; N=3, HGB\u2011212).\r For patients with at least 6 months of follow-up, HbA<sup>T87Q<\/sup>\r generally increased steadily after Zynteglo infusion and stabilised by\r approximately Month 6. Patients had a Month 6 median (min, max)\r HbA<sup>T87Q<\/sup> of 4.901 (1.03, 9.59) g\/dL in the Phase 1\/2\r studies (N=14, HGB\u2011204 and HGB\u2011205) and 9.409 (3.35, 10.60) g\/dL\r in ongoing Phase 3 studies (N=16, HGB\u2011207 and HGB-212).  <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HbA<sup>T87Q<\/sup> remained generally stable through\r Month 24 with a median (min, max) of\r 6.444 (1.10, 10.13) g\/dL in the completed Phase 1\/2 studies (N=14,\r HGB\u2011204 and HGB\u2011205) and 8.766 (0.89, 11.40) g\/dL in\r the ongoing Phase 3 studies (N=3, HGB\u2011207). HbA<sup>T87Q<\/sup> continued\r to be stable at last follow-up through Month 60, demonstrating stable\r integration of the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin gene into long\u2011term\r HSCs and stable expression of the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r gene in cells of the erythroid lineage. <a name=\"IDX\"><\/a><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><a name=\"_Hlk535595211\"><u><span style=\"font-size:11.0pt\">Clinical efficacy <\/span><\/u><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Efficacy was based on 32 adult and adolescent\r patients with TDT and a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype treated with Zynteglo (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15,\r HGB\u2011207; N=3, HGB\u2011212) (see Table 4). <a name=\"_Hlk2977601\">A few\r patients have been included in the clinical studies with genotypes\r characterised by low endogenous \u03b2\u2011globin production phenotypically\r similar to patients with a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype, such\r as patients homozygous for IVS\u2011I\u2011110 or IVS\u2011I\u20115. <\/a><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal\"><b><span style=\"font-size:11.0pt\">Table 4              Baseline characteristics for non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r patients with TDT \u226512 years of age treated with Zynteglo (Studies HGB\u2011204,\r HGB\u2011205, HGB\u2011207, HGB\u2011212, LTF\u2011303)          <\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:48.6pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><b><span style=\"font-size:11.0pt\">Study<\/span><\/b><\/p> <\/td> <td style=\"width:76.65pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Total number\r   of patients <\/span><\/b><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">(young adults\/ adolescents)<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><\/p> <\/td> <td style=\"width:67.6pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><b><span style=\"font-size:11.0pt\">Age<\/span><\/b><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(years)<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">median (min, max)<\/span><\/p> <\/td> <td style=\"width:121.85pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><b><span style=\"font-size:11.0pt\">Pre-enrolment\r   transfusion volumes<\/span><\/b><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(mL\/kg\/year)<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">median (min, max)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><b><span style=\"font-size:11.0pt\">Pre-enrolment\r   transfusion frequency<\/span><\/b><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(number\/year)<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">median (min, max)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:11.9pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011205<\/span><\/p> <\/td> <td style=\"width:76.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">4<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(2)<\/span><\/p> <\/td> <td style=\"width:67.6pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>young\r   adults\/ adolescents*<\/span><\/p> <\/td> <td style=\"width:121.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>181.85<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(138.8,\r   197.3)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>12.50<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(10.5,\r   13.0) <\/span><\/p> <\/td> <\/tr> <tr style=\"height:11.9pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011204<\/span><\/p> <\/td> <td style=\"width:76.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">10<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(2)<\/span><\/p> <\/td> <td style=\"width:67.6pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>19.5<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(16, 34)<\/span><\/p> <\/td> <td style=\"width:121.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>151.28<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(140.0, 234.5)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>13.75<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(10.0, 16.5)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:11.9pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011207<\/span><\/p> <\/td> <td style=\"width:76.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">15<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(6)<\/span><\/p> <\/td> <td style=\"width:67.6pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>20.0<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(12, 34)<\/span><\/p> <\/td> <td style=\"width:121.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>192.92<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(152.3, 251.3)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>17.50<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(11.5, 37.0)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:12.3pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011212<\/span><\/p> <\/td> <td style=\"width:76.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">3<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(1)<\/span><\/p> <\/td> <td style=\"width:67.6pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span lang=\"PT\">adults\/ adolescents*<\/span><\/p> <\/td> <td style=\"width:121.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>175.51<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(170.7, 209.6)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>21.50<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(17.5, 39.5)<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">*Age range is not provided to protect patient identity.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Transfusion\u2011dependent \u03b2\u2011thalassaemia\r (TDT)<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk2977740\"><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients were considered to be transfusion\u2011dependent\r if they had a history of transfusions of at least 100 mL\/kg\/year of RBCs\r or with \u22658 transfusions of RBCs per year in the 2 years\r preceding enrolment. In the clinical studies, patients received a median (min,\r max) RBC transfusion volume of 175.74 (138.8, 251.3) mL\/kg\/year\r and a median (min, max) number of 14.75 (10.0, 39.5) RBC\r transfusions per year. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Adolescents were excluded from Phase 3 studies if\r they had a known and available HLA\u2011matched related HSC donor. The median\r (min, max) age in the studies was 19.0 (12, 34) years, 56.3% were\r females, 59.4% were Asian, and 40.6% White\/Caucasian. All patients had a\r Karnofsky\/Lansky performance score \u226580 and the majority (18\/32, 56.3%)\r had a performance score of 100 at baseline. Cardiac T2* at baseline was &gt;20\r msec. The median (min, max) serum ferritin at baseline was 3778.7 (784, 22517)\r pmol\/L and median (min, max) liver iron concentration was 6.75 (1.0, 41.0) mg\/g\r (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15, HGB\u2011207; N=3, HGB\u2011212).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Mobilisation and apheresis<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk433984\"><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients were administered G\u2011CSF and\r plerixafor to mobilise stem cells prior to the apheresis procedure. The planned\r dose of G\u2011CSF was 10 \u00b5g\/kg\/day in patients with a spleen, and 5 \u00b5g\/kg\/day\r in patients without a spleen, given on Days 1 through 5 of\r mobilisation in the morning. The planned dose of plerixafor was\r 0.24 mg\/kg\/day, given on Days 4 and 5 of mobilisation in the\r evening. If a third day of collection was needed, plerixafor and G\u2011CSF\r dosing was extended to Day 6. The dose of G\u2011CSF was decreased by\r half if white blood cell (WBC) count was &gt;100 \u00d7 10<sup>9<\/sup>\/L\r prior to the day of apheresis. For most patients, the minimum number of CD34<sup>+<\/sup>\r cells to manufacture Zynteglo was collected with 1 cycle of mobilisation\r and apheresis. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\">Pre-treatment conditioning<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><span style=\"font-size:11.0pt\">All patients received full myeloablative conditioning\r with busulfan prior to treatment with Zynteglo. The planned dose of busulfan\r was 3.2 mg\/kg\/day for patients \u226518 years as a 3\u2011hour IV\r infusion daily for 4 days with a recommended target AUC<sub>0-24h <\/sub>of\r 3800\u20114500 \u00b5M*min. The planned dose of busulfan was 0.8 mg\/kg\r for patients 12\u201117 years of age as a 2\u2011hour IV infusion every\r 6 hours for a total of 16 doses with a recommended target of AUC<sub>0-6h\r <\/sub>of 950\u20111125 \u00b5M*min. The busulfan SmPC was used for information\r on appropriate method for determination of patient weight\u2011based dosing. <a name=\"_Hlk2978225\">Busulfan dose adjustments were made as needed based on\r pharmacokinetic monitoring.<\/a><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The median (min, max) busulfan dose was 3.50 (2.5, 5.0)\r mg\/kg\/day (N=32). AUC<sub>0-24h<\/sub> was measured during Day 1 and\r informed the dose for Day 3; the median (min, max) estimated daily AUC was\r 4394.5 (3030, 9087) \u03bcM*min (N=32). All patients with non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotypes received anti-seizure prophylaxis with agents other than phenytoin\r prior to initiating busulfan. Phenytoin was not used for anti-seizure\r prophylaxis because of its well understood induction of glutathione\u2011S\u2011transferase\r and cytochrome P450 and resultant increased clearance of busulfan, and because\r of the widespread availability of effective anti\u2011seizure medications that\r do not affect busulfan metabolism.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">In HGB\u2011207 and HGB\u2011212 prophylaxis for\r VOD\/hepatic sinusoidal obstruction syndrome was required per institutional\r practice with ursodeoxycholic acid or defibrotide. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Zynteglo administration<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients were administered Zynteglo with a median\r (min, max) dose of 7.80 \u00d7 10<sup>6 <\/sup>(5.0, 19.4) CD34<sup>+<\/sup> cells\/kg\r as an intravenous infusion (N=32).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk956286\"><\/a><a name=\"_Hlk955665\"><i><span style=\"font-size:11.0pt\">After Zynteglo\r administration<\/span><\/i><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">A total of 31.1% of patients (14\/45; HGB\u2011204,\r HGB\u2011205, HGB\u2011207, HGB\u2011212) received G\u2011CSF within\r 21 days after Zynteglo infusion<\/span><span style=\"font-size:11.0pt\">.\r However, G\u2011CSF use was not recommended for 21 days after Zynteglo\r infusion in Phase 3 studies.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Studies HGB\u2011204 and HGB\u2011205<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011204 and HGB\u2011205 were Phase 1\/2\r open-label, single-arm 24\u2011month studies that included 22 patients\r with TDT treated with Zynteglo (N=18, HGB\u2011204; N=4, HGB\u2011205), of\r whom 14 had a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype (N=10,\r HGB\u2011204; N=4, HGB\u2011205) and 8 had a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype in HGB\u2011204. All patients completed HGB\u2011204 and HGB\u2011205\r and enrolled for long\u2011term follow\u2011up in the LTF\u2011303 study.\r The median (min, max) duration of follow-up of patients with a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype was 44.63 (35.8, 61.3)months.\r <a name=\"_Hlk4078994\">All patients remain alive at last follow-up.   <\/a><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The primary endpoint was transfusion independence (TI)\r by Month 24, defined as a weighted average Hb \u22659 g\/dL\r without any RBC transfusions for a continuous period of \u226512 months\r at any time during the study after infusion of Zynteglo. Of the patients with a\r non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype, 11\/14 (78.6%, 95%\r CI 49.2%\u201195.3%) achieved TI by Month 24 (Table 5). Among these\r 11 patients, the median (min, max) weighted average Hb during TI was 10.51 (9.3, 13.3) g\/dL\r (Table 5). <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients who have achieved TI at any time have\r maintained TI at Month 36 with a min, max duration of TI of 28.3+, 57.6+ months\r (N=11). The median (min, max) time to last RBC transfusion was\r 0.46 (0.2, 5.8)months\r following Zynteglo infusion. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">In the 3 patients who did not achieve TI, reductions\r of 100%, 86.9% and 26.8% in transfusion volume requirements and of 100%, 85.3%\r and 20.7% in transfusion frequency were observed between Month 6 through\r Month 24 visit when compared to their pre-study levels of RBC\r transfusions. Reductions in volume and frequency were maintained at last follow\u2011up\r in LTF\u2011303.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The median (min, max) total Hb at Month 6 for\r patients who had not received a transfusion for the prior 60 days was\r 10.60 (7.6, 13.4) g\/dL (N=11). Total Hb remained stable at\r Month 24 with a median (min, max) of 10.60 (8.8, 13.7) g\/dL\r (N=12) and at Month 36 with a median (min, max) of\r 10.60 (7.8, 13.5) g\/dL (N=13). <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoCommentText\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>After Zynteglo\r infusion, patient iron chelation was managed at physician discretion. Of the\r 14 non\u2011\u03b2<sup>0\/<\/sup>\u03b2<sup>0<\/sup> patients treated in HGB\u2011204\r and HGB\u2011205 that completed Month 6, 9 patients (64.3%) reported\r ongoing chelation use at last follow-up. The remaining 5 patients (35.7%)\r had stopped iron chelation, of whom 4 patients (28.6%) have stopped\r chelation for at least 6 months with median (min, max) time from stopping\r chelation to last follow-up of 26.40 (11.5, 42.2) months for these\r 4 patients. Additionally, of the 14 treated patients, 3 patients\r in HGB\u2011205 (21.4%) received phlebotomy to remove iron. For the\r 11 patients that achieved TI, 4 patients (36.4%) stopped chelation for at\r least 6 months and 3 patients (27.3%) received phlebotomy.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk4398701\"><span style=\"font-size:11.0pt\">At 48 months after infusion of Zynteglo for\r patients who achieved TI, the median reduction (min, max) in serum ferritin\r levels from baseline was 70.00% (39.2, 84.8) (N=5, HGB\u2011204;\r N=2, HGB\u2011205). The median reduction in liver iron content from baseline\r was 62.50%, ranging from an 83.3% reduction to a 269.2% increase (N=5, HGB\u2011204;\r N=2, HGB\u2011205).<\/span><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Studies HGB\u2011207 and HGB\u2011212<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk774161\"><span style=\"font-size:11.0pt\">HGB\u2011207 and HGB\u2011212 are ongoing\r Phase 3 open\u2011label, single-arm 24\u2011month studies that are\r planned to include approximately 39 adults, adolescents, and children with\r TDT (N=23, HGB\u2011207; N=16, HGB\u2011212), of whom 29 have a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype (N=23, HGB\u2011207; N=6, HGB\u2011212) and 10 have a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype in HGB\u2011212. <\/span><\/a><span style=\"font-size:11.0pt\">These\r studies are conducted with improved transduction compared to Phase 1\/2\r studies, resulting in increased average number of functional copies of the\r transgene (\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin) integrated in the\r autologous CD34<sup>+<\/sup> cells. <a name=\"_Hlk4244937\">Eighteen adults and\r adolescents with TDT with a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype have been treated with Zynteglo in Phase 3 studies (N=15, HGB\u2011207; N=3, HGB\u2011212)\r and their median (min, max) duration of follow-up was\r 15.92 (5.6, 26.3) months.<\/a> <a name=\"_Hlk4079020\">All patients\r remain alive at last follow\u2011up.<\/a><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The primary endpoint was transfusion independence (TI)\r by Month 24, defined as a weighted average Hb \u22659 g\/dL without\r any RBC transfusions for a continuous period of \u226512 months at any\r time during the study after infusion of Zynteglo. Ten patients are evaluable\r for assessment of TI. Of these, 9\/10 (90.0%, 95% CI 55.5\u201199.7%)\r achieved TI at last follow\u2011up. Among these 9 patients, the median\r (min, max) weighted average Hb during TI was 12.22 (11.4, 12.8) g\/dL\r (Table 5). <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients who have achieved TI have maintained TI\r with a min, max duration of TI of 12.1+, 21.3+ months (N=9). The\r median (min, max) time to last RBC transfusion was\r 1.08 (0.5, 2.2) months following Zynteglo infusion. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk517114053\"><span style=\"font-size:11.0pt\">For the only patient who\r did not achieve TI, a reduction of 51.5% in transfusion volume requirements and\r a reduction of 43.4% in transfusion frequency were observed from Month 12 to\r Month 24 when compared to their pre-study levels of RBC transfusions. <\/span><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The median (min, max) total Hb at Month 6 for\r patients who had not received a transfusion for the prior 60 days was 11.85 (8.4, 13.3) g\/dL\r (N=18). Total Hb remained stable at Month 24 with a median (min, max) of\r 12.85 (12.5, 13.2) g\/dL (N=2).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk536092762\"><span style=\"font-size:11.0pt\">After Zynteglo infusion,\r patient iron chelation was managed at physician discretion. Of the 18 non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r patients treated in HGB\u2011207 and HGB\u2011212 that completed\r Month 6, 5 patients (27.8%) reported ongoing chelation use at last\r follow-up. The remaining 13 patients (72.2%) had stopped iron chelation,\r of whom 9 patients (50.0%) have stopped chelation for at least\r 6 months with median (min, max) time from stopping chelation to last\r follow-up of 16.89 (6.9, 25.4) months for these 9 patients.\r Additionally, of the 18 treated patients, 5 patients in HGB\u2011207\r (27.8%) received phlebotomy to remove iron. For the 9 patients that\r achieved TI, 6 patients (66.7%) stopped chelation for at least\r 6 months and 2 patients (22.2%) received phlebotomy.<\/span><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"> <\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Exploratory analyses were performed to evaluate\r resolution of dyserythropoiesis, the fundamental pathophysiological\r characteristic of TDT, in the bone marrow. Bone marrow biopsies taken before\r treatment were consistent with a diagnosis of TDT, including a low\r myeloid\/erythroid ratio (N=15, HGB\u2011207; N=3, HGB\u2011212), reflective\r of erythroid hyperplasia. For 9 patients who achieved TI and had a\r Month 12 bone marrow assessment, myeloid\/erythroid ratios increased from a\r median (min, max) of 0.2 (0.1 to 0.7) at baseline to a median (min,\r max) of 0.83 (0.6 to 1.9) at Month 12 after Zynteglo infusion,\r suggesting that Zynteglo improves erythropoiesis in patients with TDT. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Ref442134\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/a><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Overall results<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoCaption\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;line-height:normal\"><span style=\"font-size:11.0pt\">Figure <\/span><span style=\"font-size:11.0pt\">1            Median total haemoglobin over time in\r non-\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> TDT patients treated with Zynteglo\r who have achieved transfusion independence (Studies HGB\u2011204, HGB\u2011205,\r HGB\u2011207, LTF\u2011303)<\/span><\/p> <p class=\"Default\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\"><img height=\"336\" id=\"Picture 3\" src=\"data:image\/jpg;base64,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\" width=\"576\"\/><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><i><span style='font-family:\"Times New Roman\",serif'>Bars represent\r interquartile ranges.<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><a name=\"_Hlk31017224\"><i><span style='font-family:\"Times New Roman\",serif'>Total\r Hb represents those without any acute or chronic RBC transfusions within 60\r days prior to the measurement date.<\/span><\/i><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a name=\"_Hlk4231781\"><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always\"><b><span style='font-family:\"Times New Roman\",serif'>Table 5              Efficacy\r outcomes for non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> TDT patients\r treated with Zynteglo (Studies HGB\u2011204, HGB\u2011205, HGB\u2011207, HGB\u2011212,\r LTF\u2011303)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\" width=\"591\"> <thead> <tr style=\"height:71.3pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>HbA<sup>T87Q<\/sup>\r    at 6 months<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median\r    (min, max)<\/span><\/p> <\/td> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>HbA<sup>T87Q\r    <\/sup>at 24 months<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Hb\r    at 6 months*<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Hb\r    at 24 months*<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <td style=\"width:.75in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>TI**<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>n\/N^\r    <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>(%)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span lang=\"FR\" style='font-family:\r    \"Times New Roman\",serif'>[95% CI]<\/span><\/p> <\/td> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span lang=\"DA\" style='font-family:\"Times New Roman\",serif'>WA\r    Hb during TI <\/span><\/b><span lang=\"DA\" style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Duration\r    of TI<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(months)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <\/tr> <\/thead> <tr style=\"height:2.35pt\"> <td colspan=\"7\" style=\"width:443.5pt;border:solid windowtext 1.0pt;\r   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:2.35pt\" valign=\"top\" width=\"591\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>HGB-205<\/span><\/p> <\/td> <\/tr> <tr style=\"height:37.55pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>7.543<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(4.94,\r   9.59)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8.147<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(6.72,\r   10.13)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.73<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(7.6,\r   13.4)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.91<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(8.8,\r   13.6)<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3\/4 <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(75.0%)<br\/>\r   [19.4, 99.4]<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>11.35<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(10.5,\r   13.0)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NR <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(38.2+,\r   57.6+)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:1.85pt\"> <td colspan=\"7\" style=\"width:443.5pt;border:solid windowtext 1.0pt;\r   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:1.85pt\" valign=\"top\" width=\"591\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>HGB-204<\/span><\/p> <\/td> <\/tr> <tr style=\"height:37.4pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4.153<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(1.03,\r   8.52)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>5.418<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(1.10,\r   9.60)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>7<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>9.20<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(7.7,\r   13.3)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.35<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(9.1,\r   13.7)<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8\/10\r   (80.0%)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>[44.4,\r   97.5]<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.27<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(9.3,\r   13.3)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NR <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(28.3+,\r   51.3+)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:5.3pt\"> <td colspan=\"7\" style=\"width:443.5pt;border:solid windowtext 1.0pt;\r   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:5.3pt\" valign=\"top\" width=\"591\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>HGB-207<\/span><\/p> <\/td> <\/tr> <tr style=\"height:37.4pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>13<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>9.324<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(3.35,\r   10.60)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>8.766<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(0.89,\r   11.40)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>15<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>11.80<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(8.4,\r   13.3)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>2<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>12.85<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(12.5,\r   13.2)<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>9\/10<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(90.0%)<br\/>\r   [55.5, 99.7]<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>9<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>12.22<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(11.4,\r   12.8)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>9<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NR<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(12.1+,\r   21.3+)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:.2in\"> <td colspan=\"7\" style=\"width:443.5pt;border:solid windowtext 1.0pt;\r   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:.2in\" width=\"591\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>HGB-212<\/span><\/p> <\/td> <\/tr> <tr style=\"height:37.4pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.094<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(5.06,\r   10.33)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>12.10<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(8.5,\r   12.2)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif;color:white'>*Patients\r who have not received transfusions in the prior 60 days. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif'>**Transfusion\r independence (TI): a weighted average Hb \u22659 g\/dL without any RBC\r transfusions for a continuous period of \u226512 months at any time during the\r study after medicinal product infusion.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif'>***No patients are\r currently evaluable for these endpoints.  <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif'>N^ represents the total\r number of patients evaluable for TI, defined as patients who have completed\r their parent study (i.e., 24 months of follow\u2011up), or achieved TI, or\r will not achieve TI in their parent study. <\/span><\/p> <p class=\"Default\"><span style=\"font-size:11.0pt\">NR = Not reached. NA = Not\r applicable. Hb = Total Hb. WA Hb = Weighted average Hb.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The European Medicines Agency has deferred the\r obligation to submit the results of studies with Zynteglo in one or more subsets\r of the paediatric population in \u03b2\u2011thalassaemia (see section 4.2 for\r information on paediatric use).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">This medicinal product has been authorised under a\r so-called \u2018conditional approval\u2019 scheme. This means that further evidence on\r this medicinal product is awaited. The European Medicines Agency will review\r new information on this medicinal product at least every year and this SmPC\r will be updated as necessary.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.2     Pharmacokinetic\r properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is an autologous gene therapy medicinal\r product consisting of autologous cells that have been genetically modified <i>ex\r vivo<\/i>. The nature of Zynteglo is such that conventional studies on\r pharmacokinetics, absorption, distribution, metabolism, and elimination are not\r applicable.<a name=\"_Hlk500249629\"><\/a><\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.3     Preclinical\r safety data<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Conventional mutagenicity, carcinogenicity and\r reproductive and developmental toxicity studies have not been conducted.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The pharmacology, toxicology and genotoxicity of the\r BB305 LVV used for transduction in the manufacture of Zynteglo were evaluated <i>in\r vitro<\/i> and <i>in vivo<\/i>. An <i>in vitro<\/i> immortalisation (IVIM) assay\r conducted with BB305 LVV\u2011transduced mouse bone marrow cells (BMCs) showed\r minimal mutagenic potential (Fitness Score \u2248 0.1 \u00d7 10<sup>-4<\/sup>).\r Insertion site analysis (ISA) of pre-transplantation transduced mouse BMCs and\r human CD34<sup>+<\/sup> HSCs showed no enrichment for insertion in or near\r cancer-related genes. A pharmacology, biodistribution, toxicity and\r genotoxicity study was conducted in a mouse model of \u03b2\u2011thalassaemia.\r In this study, there was no evidence of toxicity, genotoxicity or oncogenesis\r (tumorigenicity) related to BB305 LVV integration, and no toxicity related to\r production of \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin. ISA of\r post-transplantation BMCs demonstrated no preferred integration in the\r proximity of or within genes associated clinically (for gamma retroviral\r vectors) with either clonal dominance or leukaemia, and no evidence of clonal\r dominance was observed. Additional studies with human CD34<sup>+<\/sup> HSCs\r administered to immunodeficient, myeloablated mice demonstrated no toxicity,\r tumorigenicity or genotoxicity.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.       PHARMACEUTICAL\r PARTICULARS<\/span><\/b><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.1     List of\r excipients<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Cryostor CS5<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Sodium chloride<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.2     Incompatibilities<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">In the absence of compatibility studies, this\r medicinal product must not be mixed with other medicinal products.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.3     Shelf life<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Frozen: 1 year at \u2264-140\u00b0C.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Once thawed: maximum 4 hours at room temperature\r (20\u00b0C\u201125\u00b0C).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.4     Special\r precautions for storage<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Store in the vapour phase of liquid nitrogen at\r \u2264-140\u00b0C until ready for thaw and administration. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Keep the infusion bag(s) in the metal cassette(s). <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Do not re-freeze after thawing.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.5     Nature and\r contents of container <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">20 mL fluorinated ethylene propylene infusion\r bag(s), each packed in a transparent pouch inside a metal cassette. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is shipped from the manufacturing facility to\r the infusion centre storage facility in a cryoshipper, which may contain\r multiple metal cassettes intended for a single patient. Each metal cassette\r contains one infusion bag with Zynteglo. A patient may have multiple infusion\r bags. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.6     <a name=\"_Hlk31012748\">Special precautions for disposal and other handling<\/a><\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Irradiation could lead to inactivation of the product.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Precautions to be taken before handling or\r administering the medicinal product<\/span><\/i><\/p> <p class=\"C-BodyText\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-size:\r 11.0pt;font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">This medicinal product contains\r genetically modified human blood cells. Healthcare professionals handling\r Zynteglo should take appropriate precautions (wearing gloves, protective\r clothing and eye protection) to avoid potential transmission of infectious\r diseases.  <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Preparation for the infusion<\/span><\/i><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Remove each metal cassette from liquid nitrogen\r storage and remove each infusion bag from the metal cassette.<\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Confirm that Zynteglo is printed on the infusion\r bag(s).<\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Confirm that patient identity matches the unique\r patient identification information located on the Zynteglo infusion bag(s). Do\r not infuse Zynteglo if the information on the patient specific\u2011label on\r the infusion bag does not match the intended patient.<\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Account for all infusion bags and confirm each\r infusion bag is within the expiry date using the accompanying Lot Information\r Sheet. <\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Each infusion bag should be inspected for any breaches\r of integrity before thawing and infusion. If an infusion bag is compromised,\r follow the local guidelines and contact bluebird bio immediately.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Thaw and administration<\/span><\/i><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Thaw Zynteglo at 37\u00b0C in a water\r bath or dry bath. Thawing of each infusion bag takes approximately 2 to 4 minutes.\r Do not overthaw the medicinal product. Do not leave the medicinal product\r unattended and do not submerge the infusion ports if thawed in a water bath.<\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">After thaw, mix the medicinal\r product gently by massaging the infusion bag until all of the contents are\r uniform. Expose the sterile port on the infusion bag by tearing off a\r protective wrap covering the port. <\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Access the medicinal product\r infusion bag and infuse per the administration site\u2019s standard procedures for\r administration of cell therapy products. Do not use an in-line blood filter or\r an infusion pump.<\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Do not sample, alter, or irradiate\r the medicinal product.<\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Administer each infusion bag of\r Zynteglo via intravenous infusion over a period of less than 30 minutes.\r If more than one infusion bag is provided, administer each infusion bag\r completely before proceeding to thaw and infuse the next bag.<\/span><\/p> <p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Infuse Zynteglo as soon as\r possible and no more than 4 hours after thawing. Flush all Zynteglo\r remaining in the infusion bag and any associated tubing with at least\r 50 mL of 0.9% sodium chloride solution to ensure as many cells as possible\r are infused into the patient.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Precautions to be taken for the disposal of the\r medicinal product<\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The medicinal product contains genetically\u2011modified\r cells. Local guidelines on handling human-derived material should be followed\r for unused medicinal products or waste material. All material that has been in\r contact with Zynteglo (solid and liquid waste) should be handled and disposed\r of as potentially infectious waste in accordance with local guidelines on\r handling human-derived material. <\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">bluebird bio (Netherlands) B.V.<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stadsplateau 7<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">WTC Utrecht<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">3521AZ Utrecht<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The Netherlands<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>8.       MARKETING\r AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>EU\/1\/19\/1367\/001<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>9.       DATE OF FIRST\r AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Date of first authorisation: 29 May\r 2019<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>10.     DATE OF REVISION\r OF THE TEXT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>{DD month YYYY}<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Detailed\r information on this medicinal product is available on the website of the\r European Medicines Agency <\/span><a href=\"http:\/\/www.ema.europa.eu\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>http:\/\/www.ema.europa.eu<\/span><\/a><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>&lt;, and on the website\r of {name of MS Agency (link)}&gt;. <br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;\r margin-bottom:0in;margin-left:27.0pt;text-align:center;text-indent:-27.0pt;\r line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;\r margin-bottom:0in;margin-left:27.0pt;text-align:center;text-indent:-27.0pt;\r line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>ANNEX\r II<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>A. MANUFACTURER(S) OF\r THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH\r RELEASE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>B. CONDITIONS OR\r RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>C. OTHER CONDITIONS AND\r REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>D. CONDITIONS OR\r RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>E. SPECIFIC OBLIGATION\r TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING\r AUTHORISATION<\/span><\/b><\/p> <span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>A.      MANUFACTURER(S) OF THE\r BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH\r RELEASE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'>Name and address of the manufacturer(s) of the\r biological active substance(s)<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Minaris\r Regenerative Medicine GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Haidgraben\r 5<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>85521\r Ottobrunn<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>GERMANY<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'>Name and address of the manufacturer(s) responsible\r for batch release<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Minaris\r Regenerative Medicine GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Haidgraben\r 5<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>85521\r Ottobrunn<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>GERMANY<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><a name=\"OLE_LINK2\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>B.<\/span><\/b><\/a><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       CONDITIONS OR\r RESTRICTIONS REGARDING SUPPLY AND USE <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Medicinal\r product subject to special and restricted medical prescription (see Annex I:\r Summary of Product Characteristics, section 4.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>C.   OTHER CONDITIONS AND\r REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><b><span style='font-family:\"Times New Roman\",serif'>Periodic\r Safety Update Reports (PSURs)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r requirements for submission of PSURs for this medicinal product are set out in\r the list of Union reference dates (EURD list) <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>provided for under Article 107c(7)\r of Directive 2001\/83\/EC and any subsequent updates published on the European\r medicines web-portal.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r marketing authorisation holder (MAH) shall submit the first PSUR for this\r product within 6 months following authorisation. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>D.   CONDITIONS OR RESTRICTIONS\r WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT  <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><b><span style='font-family:\"Times New Roman\",serif'>Risk\r management plan (RMP)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The marketing\r authorisation holder (MAH) shall perform the required pharmacovigilance\r activities and interventions detailed in the agreed RMP presented in Module\r 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>An updated RMP should be\r submitted:<\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>At\r the request of the European Medicines Agency;<\/span><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Whenever\r the risk management system is modified, especially as the result of new\r information being received that may lead to a significant change to the\r benefit\/risk profile or as the result of an important (pharmacovigilance or\r risk minimisation) milestone being reached.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span style='font-family:\"Times New Roman\",serif'>Additional\r risk minimisation measures <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Prior to launch of\r Zynteglo in each Member State the Marketing Authorisation Holder (MAH) must\r agree about the content and format of the educational and controlled\r distribution programme, including communication media, distribution modalities,\r and any other aspects of the programme, with the National Competent Authority. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r educational and controlled distribution programme is aimed at providing\r information on the safe use of Zynteglo.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r MAH shall ensure that in each Member State where Zynteglo is marketed, all\r healthcare professionals and patients\/carers who are expected to prescribe,\r dispense and\/or use Zynteglo have access to\/are provided with the following\r educational package to be disseminated through professional bodies:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Physician\r educational material<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Patient\r information pack<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The physician\r educational material <\/span><\/b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>should\r contain:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r Summary of Product Characteristics <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Guide\r for healthcare professionals <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Guide\r for handling and method of administration.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r Guide for healthcare professionals<\/span><\/b><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'> shall contain the following key elements:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Warnings\r and precautions of the mobilisation agents and the myeloablative conditioning\r agent must be considered.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Treatment\r with Zynteglo in the clinical trials was associated with delayed platelet\r engraftment. No correlation was observed between incidence of bleeding adverse\r events (AEs) and time to platelet engraftment. Precautions regarding bleeding\r consequences of thrombocytopenia need to be taken. Patients should be made\r aware of the risk of bleeding events that are not easily identifiable, such as\r internal bleeding. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Treatment\r with Zynteglo is in theory associated with the risk of insertional mutagenesis,\r potentially leading to development of malignancy. All patients must be advised\r on signs of leukaemia and to seek immediate medical attention if these signs\r are present.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>A\r negative serology test for HIV is necessary to ensure acceptance of apheresis\r material for Zynteglo manufacturing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r potential risk of loss of response to gene therapy may lead to loss of\r transfusion independence or increase transfusion needs for patients who did not\r reach transfusion\u00adindependence.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>All\r patients should receive annual monitoring of complete blood counts and total\r haemoglobin levels to monitor for leukaemia\/lymphoma and maintenance of\r efficacy, respectively.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r short-term potential risk of treatment with Zynteglo represents failure of\r engraftment, which shall be managed by administration of rescue cells. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r need to explain and to ensure that patients understand:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.25in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u2013<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>potential\r risks of treatment with Zynteglo <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.25in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u2013<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>signs\r of leukaemia\/lymphoma and what action to take<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.25in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u2013<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>content\r of patient\u2019s guide<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.25in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u2013<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>the\r need to carry the patient alert card and show it to every healthcare\r professional<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.25in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\u2013<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>enrolment\r in the drug product Registry.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Scope\r of the Registry and how to enrol patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r Guide to handling and method of administration for healthcare professionals<\/span><\/b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'> shall contain the\r following key elements:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Instructions\r on receiving and storing of Zynteglo and how to check Zynteglo prior to\r administration<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Instructions\r about the thawing of Zynteglo<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Instructions\r on protective equipment and treatment of spills.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r patient information pack<\/span><\/b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\r should contain:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Package\r leaflet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>A\r patient\/carer guide<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>A\r patient alert card.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.5in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r patient\/carer<\/span><\/b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'> <b>guide <\/b>shall contain the following key messages:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Treatment\r with Zynteglo is in theory associated with the risk of development of\r malignancy. Signs of leukaemia and the need to obtain urgent medical care if\r these signs are present. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Patient\r alert card and the need to carry it on their person and tell any treating\r healthcare professional that they were treated with Zynteglo.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r potential risk of loss of response to gene therapy may lead to loss of\r transfusion independence or increase transfusion needs for patients who did not\r reach transfusion-independence.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r importance of annual check-ups.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Treatment\r with Zynteglo is associated with the risk of delayed platelet engraftment that\r could lead to an increased tendency for bleeding. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Signs\r and symptoms of bleeding and the need to contact the physician if any signs of\r unusual or prolonged bleeding or any other relevant signs are present.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Enrolment\r in the drug product Registry.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.5in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r patient alert card<\/span><\/b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>\r shall contain the following key messages:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Information\r of risk of delayed platelet engraftment, potentially leading to bleeds, and\r theoretical risks.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Statement\r that the patient was treated with gene therapy and should not donate blood,\r organs, tissues, or cells.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Statement\r that the patient was treated with Zynteglo, including LOT number and treatment\r date(s).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Details\r on reporting of adverse effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Information\r on the possibility of false positivity of certain commercial HIV tests because\r of Zynteglo.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.75in;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Contact\r details where a health care professional can receive further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The MAH shall ensure\r that in each Member State where Zynteglo is marketed, a system aimed to control\r distribution to Zynteglo beyond the level of control ensured by routine risk\r minimisation measures. The following requirements need to be fulfilled before\r the product is prescribed, manufactured, dispensed and used:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <ul style=\"margin-top:0in\" type=\"disc\"> <li class=\"MsoNormal\" style=\"margin-right:-.1pt;margin-bottom:0in;line-height:\r      normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Zynteglo\r      will only be available through bluebird bio qualified treatment centres to\r      ensure traceability of the patient`s cells and manufactured drug product\r      between the treating hospital and manufacturing site. The selection of the\r      treatment centres will be conducted in collaboration with national health\r      authorities as appropriate.<\/span><\/li> <\/ul> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><b><span style='font-family:\"Times New Roman\",serif'>Obligation\r to conduct post-authorisation measures <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>The\r MAH shall complete, within the stated timeframe, the below measures:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.0%;border-collapse:collapse;border:none\" width=\"98%\"> <tr> <td style=\"width:81.28%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Description<\/span><\/b><\/p> <\/td> <td style=\"width:18.72%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"18%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Due date<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:81.28%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>In\r   order to further confirm the appropriateness of the acceptance criteria, the\r   MAH should re-evaluate the acceptance criteria for attributes related to\r   potency tests using batch release data and clinical results after 6 months\r   follow-up of 20 patients treated with commercial batches.   <\/span><\/p> <\/td> <td style=\"width:18.72%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"18%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Interim report: at each annual renewal <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>When 20 patients have been treated with 6 months\r   follow-up<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:81.28%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Non interventional post-authorisation safety study\r   (PASS): In order to further characterise and contextualise the long-term\r   safety and efficacy of Zynteglo in patients 12 years and older with\r   transfusion-dependent \u03b2\u2011thalassaemia (TDT) who do not have a\r   \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype, the MAH should conduct and\r   submit the results of a study based on data from a product registry (REG-501)\r   and use data on HLA\u2011matched allogenic HSCT treated patients from an\r   established European registry as a comparator group.<\/span><\/p> <\/td> <td style=\"width:18.72%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"18%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Protocol submission: December 2020<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Interim results: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>- at each annual renewal <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>- Dec. 2024<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>- Dec. 2034<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Final results: Q4 2039<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:21.3pt;text-indent:-21.3pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>E.    SPECIFIC OBLIGATION TO\r COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING\r AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>This\r being a conditional marketing authorisation and pursuant to Article 14(7) of\r Regulation (EC) No 726\/2004, the MAH shall complete, within the stated\r timeframe, the following measures:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"98%\"> <thead> <tr> <td style=\"width:81.1%;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r    0in;margin-left:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Description<\/span><\/b><\/p> <\/td> <td style=\"width:18.9%;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"18%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r    0in;margin-left:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Due date<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr> <td style=\"width:81.1%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>In order to confirm the efficacy and safety of\r   Zynteglo in patients 12 years and older with transfusion-dependent\r   \u03b2-thalassaemia (TDT) who do not have a \u03b2<sup>0<\/sup>\/\u03b2<sup>0 <\/sup>genotype,\r   the MAH should submit interim and final data on Study HGB\u2011207<\/span><\/p> <\/td> <td style=\"width:18.9%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"18%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Interim results: at each annual renewal <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Final results: December 2021<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:81.1%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>In order to confirm the efficacy and safety of\r   Zynteglo in patients 12 years and older with transfusion-dependent \u03b2-thalassaemia\r   (TDT) who do not have a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype, the\r   MAH should submit interim and final data from patients with a severe\r   non-\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype such as IVS-I-110 included\r   in Study HGB\u2011212.<\/span><\/p> <\/td> <td style=\"width:18.9%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"18%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Interim results: at each annual renewal <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Final results: December 2021<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:81.1%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"81%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>In order to confirm the efficacy and safety of\r   Zynteglo in patients 12 years and older with transfusion-dependent\r   \u03b2-thalassaemia (TDT) who do not have a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r   genotype, the MAH should submit interim data and the 5 years follow-up\r   results of Study LTF-303.<\/span><\/p> <\/td> <td style=\"width:18.9%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"18%\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Interim results: at each annual renewal <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>Final results: December 2024<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>ANNEX\r III<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>LABELLING\r AND PACKAGE LEAFLET<\/span><\/b><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>A.\r LABELLING<\/span><\/b><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;background:white\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>PARTICULARS\r TO APPEAR ON THE OUTER PACKAGING \u2013 METAL CASSETTE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>1.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Zynteglo 1.2\u201120 \u00d7 10<sup>6<\/sup> cells\/mL\r dispersion for infusion <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>(betibeglogene\r autotemcel)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><a name=\"_Hlk793172\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>2.<\/span><\/b><\/a><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>A genetically modified autologous\r CD34<sup>+<\/sup> cell enriched population that contains haematopoietic stem\r cells transduced with lentiviral vector encoding the \u03b2<sup>A-T87Q<\/sup>-globin\r gene with a strength of 1.2\u201120 \u00d7 10<sup>6<\/sup> cell\/mL. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>3.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       LIST OF\r EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;vertical-align:\r baseline\"><span style='font-family:\"Times New Roman\",serif'>Also contains\r Cryostor CS5 and sodium chloride.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;vertical-align:\r baseline\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;background:lightgrey'>Dispersion\r for infusion<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>20 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>See Lot Information Sheet for\r number of infusion bags and CD34<sup>+<\/sup> cells per kg for this patient.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Read the package leaflet\r before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>For intravenous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Keep out of the sight\r and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>7.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>For autologous use only.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>8.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>EXP:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;page-break-after:\r avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>9.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       SPECIAL STORAGE\r CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Store in the vapour\r phase of liquid nitrogen at \u2264-140\u00b0C until ready for thaw and\r administration. Keep infusion bag(s) in the metal cassette(s). Once thawed do\r not re-freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>10.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>     SPECIAL PRECAUTIONS\r FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH\r MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>This medicine contains\r genetically\u2011modified cells. Unused medicine must be disposed of in\r compliance with the local guidelines on handling human-derived material. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>11.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>     NAME AND ADDRESS OF\r THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>bluebird bio (Netherlands) B.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Stadsplateau 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>WTC Utrecht<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3521AZ Utrecht<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"PT\" style='font-family:\"Times New Roman\",serif'>Tel: +31 (0) 303 100 450<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"PT\" style='font-family:\"Times New Roman\",serif'>e-mail: medinfo@bluebirdbio.com<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>12.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>     MARKETING\r AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>EU\/1\/19\/1367\/001<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>13.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>     BATCH NUMBER,\r DONATION AND PRODUCT CODES<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Patient ID:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>COI ID:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Last Name:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>First Name: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Date of Birth:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>DIN:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Lot: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Bag ID:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>14.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>     GENERAL\r CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>15.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>16.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>     INFORMATION IN\r BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;color:black;background:\r #CCCCCC'>Justification for not including Braille accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>17.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>        UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;color:black;background:\r #CCCCCC'>Not applicable.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>18.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>        UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;color:black;background:\r lightgrey'>Not applicable.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>MINIMUM\r PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>INFUSION\r BAG <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>1.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Zynteglo 1.2\u201120 \u00d7 10<sup>6<\/sup> cells\/mL\r dispersion for infusion <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>(betibeglogene\r autotemcel)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>For intravenous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>2.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       METHOD OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Read the package leaflet\r before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>3.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>EXP:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       BATCH NUMBER,\r DONATION AND PRODUCT CODES<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Patient ID:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>COI ID:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Last Name <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>First Name:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Date of Birth:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>DIN:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Lot: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Bag ID:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>See Lot Information Sheet for\r number of infusion bags and CD34<sup>+<\/sup> cells per kg for this patient.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'>20 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       OTHER<\/span><\/b><\/p> <\/div> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>For autologous use only.<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>PARTICULARS\r TO APPEAR ON THE LOT INFORMATION SHEET INCLUDED WITH EACH SHIPMENT FOR ONE\r PATIENT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>1.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Zynteglo 1.2\u201120 \u00d7 10<sup>6<\/sup>\r cells\/mL dispersion for infusion <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>(betibeglogene\r autotemcel)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>2.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo is a genetically modified\r autologous CD34<sup>+<\/sup> cell enriched population that contains\r haematopoietic stem cells transduced with lentiviral vector encoding the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r gene.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span style='font-family:\"Times New Roman\",serif'>3.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>       <b>DONATION AND PRODUCT\r CODES<\/b><\/span><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>PATIENT INFORMATION<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Name (Last, First):<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Date of Birth\r (DD\/MM\/YYYY):<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'>Weight at First Collection (kg): <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'>Patient ID:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.       BATCH\r NUMBER, CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT, AND EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'>INFORMATION ON SUPPLIED LOT(S)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>The\r following lot(s) was manufactured and included in the shipment:<\/span><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\" width=\"615\"> <tr> <td style=\"width:67.25pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:3.5pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Lot Number \/ COI ID <\/span><\/b><\/p> <\/td> <td style=\"width:69.55pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:3.5pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>DIN<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:3.5pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(List all collections)<\/span><\/p> <\/td> <td style=\"width:64.85pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Number\r   of Infusion Bags<\/span><\/b><\/p> <\/td> <td style=\"width:64.85pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Bag ID<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:2.0pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>(List each infusion bag)<\/span><\/p> <\/td> <td style=\"width:64.85pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:4.0pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Strength<\/span><\/b><span style='font-family:\"Times New Roman\",serif'> (\u00d7 10<sup>6<\/sup> cells\/mL)<\/span><\/p> <\/td> <td style=\"width:64.85pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>CD34<sup>+<\/sup> Cells<\/span><\/b><span style='font-family:\"Times New Roman\",serif'><br clear=\"all\"\/>\r   (\u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells)<\/span><\/p> <\/td> <td style=\"width:64.85pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Expiry Date<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(DD\/MM\/YYYY)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:67.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:69.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:67.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:69.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:67.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:69.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:67.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:69.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:64.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;\r   margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>       DOSE OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\r \"Times New Roman\",serif'>Total Number of Infusion Bags: __<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Dose:\r {N.N}\u00d7<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>10<sup>6<\/sup> CD34<sup>+<\/sup>\r cells\/kg <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The minimum recommended dose of Zynteglo is\r 5.0 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg. In clinical\r studies doses up to 20 \u00d7 10<sup>6<\/sup> CD34+ cells\/kg have been\r administered.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;page-break-after:\r avoid;border:none;padding:0in\"><b><span style='font-family:\"Times New Roman\",serif'>6.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>       <b>OTHER SPECIAL WARNING(S),\r IF NECESSARY<\/b><\/span><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a name=\"_Hlk520301262\"><span style='font-family:\"Times New Roman\",serif'>SAVE\r THIS DOCUMENT AND PREPARE TO HAVE IT AVAILABLE AT THE TIME OF ZYNTEGLO\r INFUSION.<\/span><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Read the package leaflet\r before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>For autologous use only.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;page-break-after:\r avoid;border:none;padding:0in\"><b><span style='font-family:\"Times New Roman\",serif'>7.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>       <b>SPECIAL STORAGE\r CONDITIONS<\/b><\/span><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>INSTRUCTIONS FOR STORAGE\r AND USE<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Store in the vapour\r phase of liquid nitrogen at \u2264-140\u00b0C until ready for thaw and\r administration. Keep infusion bag(s) in the metal cassette(s). Once thawed do\r not re-freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;border:none;\r padding:0in\"><b><span style='font-family:\"Times New Roman\",serif'>8.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>       <b>SPECIAL PRECAUTIONS FOR\r DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH\r MEDICINAL PRODUCTS, IF APPROPRIATE<\/b><\/span><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>This medicine contains\r genetically-modified cells. Unused medicine must be disposed of in compliance\r with the local guidelines on handling human-derived material.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span style='font-family:\"Times New Roman\",serif'>9.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>       <b>NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER<\/b><\/span><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>MARKETING AUTHORISATION HOLDER AND\r NUMBER<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>bluebird bio (Netherlands) B.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Stadsplateau 7<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>WTC Utrecht<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3521AZ Utrecht<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>e-mail: <\/span><span style='font-family:\"Times New Roman\",serif'>medinfo@bluebirdbio.com<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;border:none;\r padding:0in\"><b><span style='font-family:\"Times New Roman\",serif'>10.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>     <b>MARKETING AUTHORISATION\r NUMBER(S) <\/b><\/span><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>EU\/1\/19\/1367\/001<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:5.65pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>B.\r PACKAGE LEAFLET<\/span><\/b><\/p> <span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Package\r leaflet: Information for the patient or carer<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Zynteglo\r 1.2\u201120 \u00d7 10<sup>6 <\/sup>cells\/mL dispersion for infusion<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>betibeglogene\r autotemcel <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'><img alt=\"BT_1000x858px\" border=\"0\" height=\"18\" id=\"Picture 1882439266\" src=\"data:image\/png;base64,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\" width=\"21\"\/><\/span><span style='font-family:\"Times New Roman\",serif'>This\r medicine is subject to additional monitoring. This will allow quick\r identification of new safety information. You can help by reporting any side\r effects you may get. See the end of section 4 for how to report side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Read all of this leaflet carefully\r before you are given this medicine because it contains important information\r for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif'>You will be given a <b>Patient\r Alert Card<\/b> which contains important safety information that you need to\r know about your treatment with Zynteglo. You should carry the Patient Alert\r Card with you at all times and show it to your doctor or nurse when you see\r them or if you are admitted to the hospital.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>Keep this\r leaflet. You may need to read it again. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>If you have any\r further questions, ask your doctor or nurse.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>If you get any\r side effects, talk to your doctor or nurse.This\r includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>Read the\r Patient Alert Card carefully and follow the instructions on it. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>What\r is in this leaflet<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>1.     What\r Zynteglo is and what it is used for <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>2.     What\r you need to know before you are given Zynteglo<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3.     How\r Zynteglo is given<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4.     Possible\r side effects <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>5.     How\r to store Zynteglo <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>6.     Contents\r of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>1.<\/span><\/b><b><span style='font-family:\"Times New Roman\",serif'>       What Zynteglo is and what it\r is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo<\/span><span style='font-family:\"Times New Roman\",serif'> is used to treat a serious genetic\r disease called transfusion\u2011dependent beta\u2011thalassaemia (TDT), which\r includes the disease commonly known as beta\u2011thalassaemia major, in people\r 12 years and older. People with this condition cannot make enough haemoglobin,\r a protein in the blood that carries oxygen. More specifically, people with TDT\r do not make enough of a part of the haemoglobin called beta-globin, due to a\r gene defect. Because of this defect, people with TDT are anaemic and need\r frequent blood transfusions to survive.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo\r is a type of medicine called gene therapy. It is made specifically for each\r patient, using the patient\u2019s own (also called autologous) blood stem cells.\r Zynteglo works by adding functional copies of the beta-globin gene into these cells,\r so that the patient can make enough beta-globin to increase total haemoglobin,\r improve anaemia, and carry more oxygen around their body. This reduces or\r eliminates the need for blood transfusions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>2.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>       <b>What you need to know\r before you are given Zynteglo<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>You must not be given Zynteglo if\r you<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>are allergic to\r any of the ingredients of this medicine (listed in section 6)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>are pregnant or\r breast-feeding<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><a name=\"_Hlk817587\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>have previously\r received gene therapy of your blood stem cells<\/span><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>are allergic to\r any of the ingredients in the medicines you will be given for mobilisation and\r chemotherapy (see section 3).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Warnings and precautions <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Talk to your doctor before you are\r given Zynteglo.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Before treatment with Zynteglo, you will be given\r medicines know as mobilisation medicine and chemotherapy medicine (see sections\r 3 and 4 for more information on these medicines, including possible side\r effects).<\/span><\/p> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Before treatment with Zynteglo,\r your doctor will perform tests to make sure your heart and liver are\r functioning properly so you can be treated safely with Zynteglo. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo<\/span><span style='font-family:\"Times New Roman\",serif'> is made specifically for you,\r using your own blood stem cells. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>After you have been treated with\r Zynteglo, you will not be able to donate blood, organs, or tissues in the\r future. This is because Zynteglo is a gene therapy medicine. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Adding a new gene into the DNA of\r your blood stem cells could theoretically cause leukaemia or lymphoma, although\r no patients have developed leukaemia or lymphoma in clinical trials with\r Zynteglo. After treatment with Zynteglo, you will be asked to enrol in a\r registry for at least 15 years in order to better understand the long-term\r effects of Zynteglo. During the long-term follow-up, your doctor will monitor\r you for any signs of leukaemia or lymphoma. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo is prepared using parts of\r the human immunodeficiency virus (HIV), which have been altered so that they\r cannot cause HIV infection. The modified virus is used to insert a functional\r beta-globin gene into your blood stem cells. Although this medicine will not\r give you HIV infection, having Zynteglo in your blood may cause a false\r positive HIV test result with some commercial tests that recognise a piece of\r HIV used to make Zynteglo. If you test positive for HIV following treatment,\r please contact your doctor or nurse. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Before receiving Zynteglo you will\r be given chemotherapy in order to remove your existing bone marrow. If Zynteglo\r cannot be administered after chemotherapy or if the modified stem cells do not\r take hold (engraft) in your body, the doctor may give you an infusion of your\r own original blood stem cells that were collected and stored before the\r treatment started (see also section 3, How Zynteglo is given)<i>. <\/i><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>After you receive Zynteglo, you may\r have a low number of platelets in your blood. This means that your blood may\r not be able to clot as well as normal and you may be prone to bleeding. You\r must get medical attention if you: <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>bump your head\r or have a head injury<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>have symptoms\r that could be from internal bleeding, such as unusual stomach or back pain, or\r severe headache<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>have abnormal\r bruising or bleeding (such as bruising without injury, blood in your urine,\r stool, vomit, or cough up blood).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Your doctor will tell you when your\r platelet count has recovered to normal levels.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Other medicines and Zynteglo <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Tell your doctor if you are taking,\r have recently taken or might take any other medicines.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>You should not take hydroxyurea (a\r medicine for blood disorders) or any medicines for HIV infection from at least\r one month before you undergo mobilisation until at least 7 days after Zynteglo\r infusion (see also section 3, How Zynteglo is given).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>You should stop taking medicines to\r remove iron from your body (so-called chelating agents: deferoxamine,\r deferiprone and\/or deferasirox) 7 days before you start the chemotherapy before\r the infusion of Zynteglo (see section 3, How Zynteglo is given). Your doctor\r will advise you if and when you should start taking these medicines after\r Zynteglo infusion. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Talk to your doctor if you need to\r have any vaccinations. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><b><span style='font-family:\"Times New Roman\",serif'>Pregnancy,\r breast-feeding and fertility<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>If you are pregnant or\r breast-feeding, think you may be pregnant or are planning to have a baby, tell\r your doctor before you are given this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>If you are a woman, you will be\r given a pregnancy test before starting mobilisation, before you are given\r chemotherapy, and before Zynteglo treatment in order to confirm that you are\r not pregnant.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Women who could become pregnant and\r men capable of fathering a child must start using a reliable method of\r contraception from before their blood stem cells are collected and continue\r until at least 6 months after receiving Zynteglo.  Reliable methods of contraception\r include intra-uterine device or a combination of oral contraceptive (also know\r as the pill) and condoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>The added gene from Zynteglo will\r not be passed on to your children. Your children are still at risk of\r inheriting your original beta\u2011globin gene.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>You should not be given Zynteglo if\r you are breast-feeding. It is not known whether the ingredients of Zynteglo can\r pass into breast milk.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>It may no longer be possible for\r you to become pregnant or father a child after receiving chemotherapy medicine.\r If you are concerned about having children, you should discuss this with your\r doctor before treatment. Options may include providing reproductive material\r for storage in a tissue bank to use at a later time. For men, this may be sperm\r or testicular tissue. For women, this may be eggs (oocytes) or ovarian tissue.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Driving\r and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><a name=\"_Hlk32575891\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo has no influence on the\r ability to drive or use machines. However, the mobilisation and chemotherapy medicines\r may cause dizziness and fatigue. Avoid driving or using machines if you feel\r dizzy, tired or unwell.<\/span><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Sodium\r content<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>This\r medicine contains 391\u20111564 mg sodium (main component of\r cooking\/table salt) in each dose. This is equivalent to <span style=\"color:\r black\">20\u201178% <\/span>of the recommended maximum daily dietary intake of sodium\r for an adult.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>3.<\/span><\/b><b><span style='font-family:\"Times New Roman\",serif'>       How Zynteglo is given<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo\r is given by a drip (infusion) into a vein. It can only be given in a\r specialised hospital by doctors who are experienced in treating patients with\r TDT, administering bone marrow transplants, and using gene therapy medicines.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo\r can only be made if enough of the right kind of blood stem cells can be\r collected from your blood (CD34<sup>+<\/sup> blood stem cells). Approximately 2\r months before treatment with Zynteglo, you will be given a mobilisation\r medicine that will move your blood stem cells from your bone marrow into your\r blood stream. The blood stem cells can then be collected by a machine that\r separates blood components (apheresis machine). It may take more than 1 day to\r collect enough blood stem cells to make Zynteglo and to store as replacement\r cells if Zynteglo cannot be given or does not work.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <thead> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r    0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Time<\/span><\/b><\/p> <\/td> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r    0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>What\r    happens<\/span><\/b><\/p> <\/td> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r    0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Why<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Approximately\r   2 months before Zynteglo infusion<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Mobilisation\r   medicine is given<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>To\r   move the blood stem cells from your bone marrow into your blood stream.<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Approximately\r   2 months before Zynteglo infusion<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Blood\r   stem cells are collected <\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>To\r   make Zynteglo and to serve as replacement cells if needed.<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>At\r   least 6 days before Zynteglo infusion<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>A\r   chemotherapy medicine is given for 4 days in a hospital<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>To\r   prepare your bone marrow for treatment with Zynteglo.<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Start\r   of Zynteglo treatment<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo\r   is given by a drip (infusion) into a vein. This will take place in a hospital\r   and will take less than 30 minutes for each infusion bag. The number of bags\r   will vary by patient.<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:\r   0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>To\r   add blood stem cells containing functional copies of the beta-globin into\r   your bone marrow.<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif'>After Zynteglo\r   infusion<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif'>You will remain in\r   the hospital for approximately 3\u20116 weeks<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif'>To recover and be monitored\r   until your doctor is satisfied that it is safe for you to leave the hospital.<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><a name=\"_Hlk512253721\"><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>4.<\/span><\/b><b><span style='font-family:\"Times New Roman\",serif'>       Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Like\r all medicines, this medicine can cause side effects, although not everybody\r gets them. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Some\r side effects observed in clinical studies with Zynteglo are related to\r mobilisation and blood stem cell collection or to the chemotherapy medicine\r used to prepare your bone marrow for treatment with Zynteglo. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>You\r should discuss possible side effects due to the mobilisation medicines and\r chemotherapy medicine with your doctor. You should also read the package\r leaflets for these medicines.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><u><span style='font-family:\"Times New Roman\",serif'>Mobilisation\r and blood stem cell collection<\/span><\/u><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Most\r of these side effects occur during or within a few days after mobilisation and\r blood stem cell collection but can occur later. Tell your doctor immediately if\r side effects become severe or serious. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very\r common side effects <\/span><\/b><span style='font-family:\"Times New Roman\",serif'>(may\r affect more than 1 in 10 people)<\/span><\/p> <ul style=\"margin-top:0in\" type=\"disc\"> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><a name=\"_Hlk542621\"><span style='font-family:\"Times New Roman\",serif'>a\r      low level of blood platelets, which may reduce the ability of blood to\r      clot<\/span><\/a><\/li> <\/ul> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>bone pain<\/span><\/p> <ul style=\"margin-top:0in\" type=\"disc\"> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>numbness and\r      pain in hands and feet<\/span><\/li> <\/ul> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>feeling sick\r (nausea)<\/span><\/p> <ul style=\"margin-top:0in\" type=\"disc\"> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>headache<\/span><\/li> <\/ul> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>low blood\r calcium level<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common\r side effects <\/span><\/b><span style='font-family:\"Times New Roman\",serif'>(may\r affect up to 1 in 10 people)<\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><a name=\"_Hlk540035\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>bleeding <\/span><\/a><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>low oxygen\r level in blood <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>low blood\r pressure<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>abdominal pain<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>back pain<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>bone or muscle\r pain<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>chest pain or\r discomfort<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>other pain<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>agitation <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>abnormal blood\r test results (decrease in magnesium and potassium, too much citrate, or\r increase in white blood cells)<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>abnormal heart\r rhythm <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>bruising,\r bleeding or pain from catheter or injection site<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>injection site\r reaction <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>bruising  <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>dizziness,\r tiredness<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>head discomfort<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>excessive\r sweating<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>flu like illness<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>lip swelling<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>tingling or\r numbness of the hands, feet, or mouth<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>fever<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>rash<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>enlarged spleen\r which may result in pain in your upper left belly or left shoulder<\/span><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>vomiting <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><u><span style='font-family:\"Times New Roman\",serif'><\/span><\/u><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><u><span style='font-family:\"Times New Roman\",serif'>Chemotherapy\r medicine<\/span><\/u><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Tell\r your doctor immediately <\/span><\/b><span style='font-family:\"Times New Roman\",serif'>if\r you get any of the following side effects after receiving chemotherapy\r medicine. They usually happen within the first few days and several weeks after\r receiving chemotherapy medicine, but can also develop much later.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very\r common <\/span><\/b><span style='font-family:\"Times New Roman\",serif'>(may affect\r more than 1 in 10 people)<\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>Pain in the\r right upper abdomen under the ribs, yellowing of eyes or skin, rapid weight\r gain, swelling of arms, legs and abdomen, and trouble breathing. These may be\r signs of a serious liver condition called veno-occlusive disease.<\/span><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>Prolonged\r bleeding or bleeding without injury such as nosebleeds, bleeding from gums, or\r vaginal bleeding.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Other\r possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Tell\r your doctor immediately if side effects become severe or serious.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very\r common side effects <\/span><\/b><span style='font-family:\"Times New Roman\",serif'>(may\r affect more than 1 in 10 people)<\/span><\/p> <ul style=\"margin-top:0in\" type=\"disc\"> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><a name=\"_Hlk543255\"><span style='font-family:\"Times New Roman\",serif'>low\r      level of red and white blood cells, sometimes with a fever<\/span><\/a><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>increase of\r      certain enzymes in the blood which may indicate a problem with your liver<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>a low level of\r      blood platelets, which may reduce the ability of blood to clot<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>unusual hair\r      loss or thinning<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>stomach pain, constipation,\r      diarrhoea<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>feeling sick\r      (nausea), being sick (vomiting)<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>fever<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>soreness of the\r      mouth<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>inflammation of\r      the throat<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>dark patches on\r      skin<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>soreness of the\r      rectum area<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>trouble sleeping<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>decreased\r      appetite<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>headache<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>tiredness<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>itchy skin<\/span><\/li> <\/ul> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>soreness and swelling\r of the digestive tract lining which runs from the mouth to the anus<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:.5in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common\r side effects <\/span><\/b><span style='font-family:\"Times New Roman\",serif'>(may\r affect up to 1 in 10 people)<\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>life-threatening\r inflammatory response to an infection along with low white blood cell count<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>heart failure<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>infections\r which may make you feel warm, chilly, or sweaty<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>mass in the\r lungs<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>enlarged\r abdomen<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>enlarged liver<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>difficulty\r breathing <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>abdominal pain<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>bleeding or\r bruising <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>blood in urine<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>yellowing of\r eyes or skin<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>small tear in\r tissue that lines the anus<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>dizziness, or\r sensation of feeling off balance or like the room is spinning<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>memory problems\r <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>anxiety <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>positive test\r for Aspergillus (lung disease caused by fungus)<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>changes and\r abnormalities in heart rhythm<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>pain, including\r in back, bone, skin, limbs, anus, or muscles<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>vaginal yeast\r infection<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>heartburn<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>inflammation of\r the gallbladder<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>gallstones<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>cough<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>abnormal sense\r of taste or loss of taste<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>difficulty\r swallowing<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>swelling of the\r face<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>feeling cold<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>excess water in\r the body<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>inflammation or\r infection of hair follicles<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>decrease in\r speed of air leaving your lungs<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>stomach\r discomfort with nausea and vomiting<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>inflammation in\r the digestive tract<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>gum disease<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>piles\r (haemorrhoids)<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>hiccups<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>low blood\r pressure<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>low body\r temperature<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>low oxygen\r level in blood<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>pain in mouth,\r throat or larynx (voice box)<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>lack of energy<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>irregular\r menstruation<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>loss of\r function or decreased function of your ovaries or testes<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>premature\r menopause <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>spots on skin\r from bleeding under the skin<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>skin that is\r discoloured, blotchy, or darker or lighter than normal <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>fluid in or\r around the lung<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>hot flush<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>increased\r frequency of urination<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>dry, itchy skin\r <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>dry lips<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>rash sometimes\r with lesions or pus <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>inflamed skin\r lesions<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>skin\r abrasion\/scrape<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>sweat gland\r disorder<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>transfusion\r reaction<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>weight\r decreased<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>abnormal liver\r tests<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>increased\r concentration of haemoglobin in cells<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span lang=\"DE\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"DE\" style='font-family:\"Times New Roman\",serif'>changes\r in magnesium, calcium, potassium, phosphate, albumin, protein, sodium in blood<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>increase in\r blood test for inflammation<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>excess acid in\r the body not removed by the kidneys<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>increase or\r decrease in white blood cells<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>low number of\r immature (not fully developed) red blood cells <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>increase in\r female hormones<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-bottom:0in;text-indent:-.25in;\r line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>decreased\r testosterone<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><u><span style='font-family:\"Times New Roman\",serif'><\/span><\/u><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal;page-break-after:avoid\"><b><u><span style='font-family:\"Times New Roman\",serif'>Zynteglo<\/span><\/u><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Most\r side effects occur during or within a few days after treatment with Zynteglo\r but can occur later. <\/span><span style='font-family:\"Times New Roman\",serif'>Tell\r your doctor immediately if side effects become severe or serious.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very\r common side effects <\/span><\/b><span style='font-family:\"Times New Roman\",serif'>(may\r affect more than 1 in 10 people)<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>stomach pain<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common\r side effects <\/span><\/b><span style='font-family:\"Times New Roman\",serif'>(may\r affect up to 1 in 10 people)<\/span><\/p> <ul style=\"margin-top:0in\" type=\"disc\"> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>low level of\r      blood platelets, which may reduce the ability of blood to clot<\/span><\/li> <li class=\"MsoNormal\" style=\"margin-right:-1.45pt;margin-bottom:0in;line-height:\r      normal\"><span style='font-family:\"Times New Roman\",serif'>low level of\r      white blood cells<\/span><\/li> <\/ul> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>shortness of\r breath<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>chest pain not\r due to a heart problem<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>flushing\r (redness and warmth of skin)<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style='font-family:\"Times New Roman\",serif'>pain in legs<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-top:0in;margin-right:-1.45pt;\r margin-bottom:0in;margin-left:.5in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>If\r you get any side effects, talk to your doctor or nurse. This includes any\r possible side effects not listed in this leaflet. You can also report side\r effects directly via <span style=\"background:lightgrey\">the national reporting\r system listed in <\/span><\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style='font-family:\"Times New Roman\",serif;background:lightgrey'>Appendix V<\/span><\/a><span style='font-family:\"Times New Roman\",serif;background:lightgrey'>.<\/span><span style='font-family:\"Times New Roman\",serif'> By reporting side effects you can\r help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.45pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>5.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>       <b>How to store Zynteglo<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>This\r information is intended for doctors only.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>As\r this medicine will be given by a qualified doctor, they are responsible for the\r correct storage of the medicine before and during its use, as well as for its\r correct disposal. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Keep\r this medicine out of the sight and reach of children. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Do\r not use this medicine after the expiry date which is stated on the outer\r container label(s) and infusion bag label(s).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Store\r at \u2264-140\u00b0C for up to a year. Do not thaw the product until it is ready to\r be used. Once thawed store at room temperature (20\u00b0C\u201125\u00b0C) and use within\r 4 hours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>This\r medicine contains genetically-modified cells. Unused medicine must be disposed\r of in compliance with the local guidelines on handling human-derived material. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>6.<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>       <b>Contents of the pack and\r other information<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>What\r Zynteglo contains <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>The active\r substance of Zynteglo consists of your own blood stem cells that contain\r functional copies of the beta-globin gene that can be measured in your blood.\r The concentration is 1.2\u201120 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup>\r cells (blood stem cells) per millilitre.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-<\/span><span style='font-family:\"Times New Roman\",serif'>The other ingredients\r are a solution used to preserve frozen cells and sodium chloride. See section\r 2, Sodium content.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>What\r Zynteglo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a name=\"_Hlk511315491\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo\r is a clear to slightly cloudy, colourless to yellow or pink dispersion of cells<\/span><\/a><span style='font-family:\"Times New Roman\",serif'> that is supplied in one or more\r clear infusion bags, each packed in a transparent pouch inside a closed metal\r container. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Your name and date of birth, as\r well as coded information identifying you as the patient, are printed onto each\r infusion bag and each metal container.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Marketing\r Authorisation Holder and Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>bluebird bio (Netherlands)\r B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"NL\" style='font-family:\"Times New Roman\",serif'>Stadsplateau 7 <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"NL\" style='font-family:\"Times New Roman\",serif'>WTC Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"NL\" style='font-family:\"Times New Roman\",serif'>3521AZ Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"NL\" style='font-family:\"Times New Roman\",serif'>The Netherlands <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a href=\"mailto:medinfo@bluebirdbio.com\"><span lang=\"PT\" style='font-family:\"Times New Roman\",serif'>medinfo@bluebirdbio.com<\/span><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span lang=\"PT\" style='font-family:\"Times New Roman\",serif'>Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"PT\" style='font-family:\"Times New Roman\",serif'>Minaris Regenerative Medicine GmbH <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Haidgraben 5<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>85521 Ottobrunn<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Germany<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>For\r any information about this medicine, please contact the local representative of\r the Marketing Authorisation Holder:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\"> <tr> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a name=\"_Hlk1050692\"><b><span lang=\"DE\" style='font-family:\"Times New Roman\",serif'>Deutschland<\/span><\/b><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"DE\" style='font-family:\"Times New Roman\",serif'>bluebird bio (Germany)\r   GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"DE\" style='font-family:\"Times New Roman\",serif'>Tel: +49 (0) 893 803 7456\r   (0800 181 0702)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"ES\" style='font-family:\"Times New Roman\",serif'>Italia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"ES\" style='font-family:\"Times New Roman\",serif'>bluebird bio (Italy)\r   S.r.l.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"DE\" style='font-family:\"Times New Roman\",serif'>Tel: <\/span><span style='font-family:\"Times New Roman\",serif'>+39 029 475 9755 (800 728 026)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <\/tr> <tr> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>France<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>bluebird bio (France) SAS<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r   none\"><span style='font-family:\"Times New Roman\",serif'>T\u00e9l: +33 (0)1 85 14\r   97 89 (0800 914 510)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r   none\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"NL\" style='font-family:\"Times New Roman\",serif'>Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"NL\" style='font-family:\"Times New Roman\",serif'>bluebird bio\r   (Netherlands) B.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Tel: +<\/span><span lang=\"DE\" style='font-family:\"Times New Roman\",serif'>31 (0) 303 100 450<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Belgi\u00eb\/Belgique\/Belgien,\r   \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f, \u010cesk\u00e1\r   republika, Danmark, Eesti, \u0395\u03bb\u03bb\u03ac\u03b4\u03b1, Espa\u00f1a, <\/span><\/b><b><span style='font-family:\"Times New Roman\",serif'>Hrvatska, Ireland, \u00cdsland,\r   \u039a\u03cd\u03c0\u03c1\u03bf\u03c2, Latvija, Lietuva, Luxembourg\/Luxemburg,\r   Magyarorsz\u00e1g, Malta, Norge, \u00d6sterreich, Polska, Portugal, Rom\u00e2nia, Slovenija,\r   Slovensk\u00e1 republika, Suomi\/Finland, Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>bluebird bio (Netherlands) B.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>T\u00e9l\/Tel\/Te\u043b\/Tlf\/\u03a4\u03b7\u03bb\/S\u00edmi\/Puh:\r   <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>+31 (0) <\/span><span lang=\"DE\" style='font-family:\"Times New Roman\",serif'>303 100 450<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a href=\"mailto:medinfo@bluebirdbio.com\"><span lang=\"DE\" style='font-family:\"Times New Roman\",serif'>medinfo@bluebirdbio.com<\/span><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>bluebird bio (UK) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Tel: +44 (0) 207 660 0754<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'> (0800-069-8046)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>This\r leaflet was last revised in &lt;<\/span><\/b><span style='font-family:\"Times New Roman\",serif'>{<b>MM\/YYYY<\/b>}&gt;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>This\r medicine has been given \u2018conditional approval\u2019. This means that there is more\r evidence to come about this medicine. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>The\r European Medicines Agency will review new information on this medicine at least\r every year and this leaflet will be updated as necessary.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Detailed\r information on this medicine is available on the European Medicines Agency web\r site: <\/span><u><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;\r color:blue'>http:\/\/www.ema.europa.eu<\/span><\/u><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>&lt;, and on the website of {name\r of MS Agency (link)}&gt;.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>This\r leaflet is available in all EU\/EEA languages on the European Medicines Agency\r website.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>-----------------------------------------------------------------------------------------------------------------<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom:\r 0in;margin-left:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom:\r 0in;margin-left:-2.0pt;line-height:normal;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>The following information is\r intended for healthcare professionals only: <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom:\r 0in;margin-left:-2.0pt;line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo is shipped from the\r manufacturing facility to the infusion centre storage facility in a\r cryoshipper, which may contain multiple metal cassettes intended for a single\r patient. Each metal cassette contains one infusion bag with Zynteglo. A patient\r may have multiple infusion bags. The infusion bag(s) must be kept inside the\r metal cassette(s) until ready to thaw and use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Confirm that Zynteglo is printed on\r the infusion bag(s). Confirm that patient identity matches the unique patient\r information located on the infusion bag(s) and metal cassette(s) prior to\r infusion.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Account for all infusion bags and\r confirm each infusion bag of Zynteglo is within the expiry date using the\r accompanying Lot Information Sheet. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Inspect each infusion bag for any\r breaches of integrity before thawing and infusion. If an infusion bag is\r compromised, follow the local guidelines on handling human-derived material and\r contact bluebird bio immediately.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo is intended solely for\r autologous use. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>After carefully removing the outer\r metal container, thaw each infusion bag at 37\u00b0C in a water bath or dry bath for\r approximately 2\u20114 minutes. Do not overthaw the medicinal product. Do\r not leave the medicinal product unattended and do not submerge the infusion\r ports if thawed in a water bath. After thaw, mix the medicinal product gently\r by massaging the infusion bag until all of the contents are uniform. Expose the\r sterile port on the infusion bag by tearing off the protective wrap covering\r the port. Access the infusion bag and infuse per the administration site\u2019s\r standard procedures for administration of cell therapy products. Do not use an\r in-line blood filter or an infusion pump. Do not sample, alter, or irradiate\r the medicinal product. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Administer each infusion bag via\r intravenous infusion over a period of less than 30 minutes. If more than\r one infusion bag is provided, administer each infusion bag completely before\r proceeding to thaw and infuse the next bag. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Zynteglo must not be re\u2011frozen.\r Infuse as soon as possible and no more than 4 hours after thawing. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Flush all Zynteglo remaining in the\r infusion bag and any associated tubing with at least 50 mL of 0.9% sodium\r chloride solution to ensure as many cells as possible are infused into the\r patient.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>This medicinal product contains\r genetically-modified cells. Local guidelines on handling and waste of human-derived\r material applicable for such products should be followed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Healthcare professionals handling\r Zynteglo should take standard precautions (wearing gloves, protective clothing\r and eye protection) to avoid potential transmission of infectious diseases.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Work surfaces and material which\r have potentially been in contact with Zynteglo must be decontaminated with a\r viricidal disinfectant according to the manufacturer's instructions. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/div>","ID":"29f465f1-cfca-48b7-b426-ef815c7da2e6","Styles":"None","Classes":"['WordSection1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ","ParentId":"1ffb9744-8002-404c-841e-adb4467af8a1"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"ffbe9f57-7fb9-4a7a-8828-4b79cece5907","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"5be564af-0abe-481c-9153-33465fe2a3ed","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"228aa92b-88e2-4691-9306-cb8799cbeca0","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"c56690e6-f1c5-401e-8854-d6eb4ca85848","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"2f0245e6-da9f-4996-8f61-cd49c801b1e5","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"fb804e84-92e1-4807-993c-e280a783b060","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"0a45d335-f90c-4852-9c0b-b0ab7bdac267","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"76436efb-7f9b-4d77-87a6-795c48974740","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"645cf71a-4b60-4e43-b000-3ead496bc960","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"a29dc7b5-63dc-47e3-8fe6-bd5cdfd25408","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"80ed0822-1086-4a98-8a46-d6c2a2588711","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"b166f6b6-c664-40ea-9959-b015451ece10","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"f9b11cb8-2326-45b9-b6c3-997d9594886a","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"b1980620-6582-4ad3-845f-437268a80b9a","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"2b773542-15ee-42d9-8abd-a6419b8e978a","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"ac96feee-1689-4901-9c55-6efebfe8accd","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"01e019fb-8c63-41a8-8cb7-720325e86b62","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"fb95ec70-72b1-495c-a41b-dc09dec8ecef","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"5e38a367-d30d-4a63-88ff-7217e5969a32","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"f948ba6d-cdb5-4574-9641-67afd0caacda","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"ebc4239f-b148-4405-8bee-c42eb42eb955","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"47d4bc36-a6d1-4def-b34f-9f04ac085129","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"7686158d-59c3-48d1-b4bb-3985968cc235","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>ANNEX\r I<\/span><\/b><\/p>","ID":"2402505e-e758-44c5-ab05-45414fef2430","Styles":"margin-bottom:0in;text-align:center;\r\nline-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":null,"IsULTag":null,"Text":"ANNEX\r I","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><\/p>","ID":"5c686e67-6e97-4cd9-b4aa-295e092665b3","Styles":"margin-bottom:0in;text-align:center;\r\nline-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>SUMMARY\r OF PRODUCT CHARACTERISTICS<\/span><\/b><\/p>","ID":"1cd6e3bd-0b91-48e6-ac3c-cbe879226494","Styles":"margin-bottom:0in;text-align:center;\r\nline-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"SUMMARY\r OF PRODUCT CHARACTERISTICS","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"8efc498b-7e5e-4706-affc-5cd7e3584f50","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"6c57a147-66b1-469c-b991-c50a08864221","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"8efc498b-7e5e-4706-affc-5cd7e3584f50"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"2032bd35-f1e3-4c70-9225-54c6b3d0783e","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><img alt=\"BT_1000x858px\" height=\"20\" id=\"Picture 2\" src=\"data:image\/png;base64,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\" width=\"20\"\/><\/span><span style=\"font-size:11.0pt\">This medicinal product is subject to additional\r monitoring. This will allow quick identification of new safety information.\r Healthcare professionals are asked to report any suspected adverse reactions.\r See section 4.8 for how to report adverse reactions.<\/span><\/p>","ID":"a296cab1-a8f5-40c1-9d15-3f5cf283f4a2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"This medicinal product is subject to additional\r monitoring. This will allow quick identification of new safety information.\r Healthcare professionals are asked to report any suspected adverse reactions.\r See section 4.8 for how to report adverse reactions.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d16258df-0975-4cde-9e42-18ff68651fbc","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"6beea5e0-d2e6-4e5c-ab1d-d1ac0fae8f50","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p>","ID":"8379e36f-01af-4fcd-8784-e5061493f43e","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.       NAME OF THE\r MEDICINAL PRODUCT","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"0dea6d28-3b72-49c2-a7a6-8d3736073fd5","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"FR\" style=\"font-size:11.0pt\">Zynteglo 1.2\u201120 \u00d7 10<sup>6<\/sup> cells\/mL\r dispersion for infusion. <\/span><\/p>","ID":"5470698f-2747-4009-aee2-1dbf4bfb3a43","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo 1.2\u201120 \u00d7 106 cells\/mL\r dispersion for infusion. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"5798ed90-1963-40a1-b1b8-54700b4c1ed7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"517d3d72-5e04-4a17-8c3b-66e37cb36dd3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION<\/span><\/b><\/p>","ID":"a801a9e5-88c4-45ee-a9ad-7ac75b1467a6","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"86138a45-aeb1-4ee0-bc8e-ca017bd73aa9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>2.1     General description<\/span><\/b><\/p>","ID":"f1a3675c-ef32-408b-b25f-72362686cbc6","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"2.1     General description","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"516df272-077c-4091-a045-cf581f28027c","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"FR\" style=\"font-size:11.0pt\">Zynteglo (betibeglogene autotemcel) is a<\/span><span lang=\"FR\" style=\"font-size:11.0pt\"> genetically modified autologous CD34<sup>+ <\/sup>cell\r enriched population that contains haematopoietic stem cells (HSC) transduced\r with lentiviral vector (LVV) encoding the <\/span><span style=\"font-size:11.0pt\">\u03b2<\/span><sup><span lang=\"FR\" style=\"font-size:11.0pt\">A\u2011T87Q<\/span><\/sup><span lang=\"FR\" style=\"font-size:11.0pt\">\u2011globin gene.<\/span><\/p>","ID":"bd31f5d0-7046-44ec-bf54-065dfbcdb75b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo (betibeglogene autotemcel) is a genetically modified autologous CD34+ cell\r enriched population that contains haematopoietic stem cells (HSC) transduced\r with lentiviral vector (LVV) encoding the \u03b2A\u2011T87Q\u2011globin gene.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"eb66d979-a605-4951-9960-a6af4092bff8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>2.2     Qualitative and\r quantitative composition<\/span><\/b><\/p>","ID":"6d6e4097-2fe5-44fc-87b9-a16dbf0968b1","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"2.2     Qualitative and\r quantitative composition","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"a99382dd-98e9-40f0-864b-297b237225c0","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The finished product is composed of one or more\r infusion bags which contain a dispersion of <span style=\"color:black\">1.2\u201120 \u00d7 <\/span>10<sup>6 <\/sup><span style=\"color:black\">cells\/mL <\/span>suspended in cryopreservative solution<span style=\"color:black\">. <\/span>Each infusion bag contains approximately\r 20 mL of Zynteglo.<\/span><\/p>","ID":"ed7cf4c5-803f-4103-bb16-d871563a2a96","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The finished product is composed of one or more\r infusion bags which contain a dispersion of 1.2\u201120 \u00d7 106 cells\/mL suspended in cryopreservative solution. Each infusion bag contains approximately\r 20 mL of Zynteglo.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"8d34c12e-9c88-4ebd-954d-89973e8e14e9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The quantitative information regarding strength, CD34<sup>+<\/sup>\r cells, and dose for the medicinal product is provided in the Lot Information\r Sheet. The Lot Information Sheet is included inside the lid of the cryoshipper\r used to transport Zynteglo.  <\/span><\/p>","ID":"aa8eabd4-d7a5-409e-afc5-08aa4e909b23","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The quantitative information regarding strength, CD34+\r cells, and dose for the medicinal product is provided in the Lot Information\r Sheet. The Lot Information Sheet is included inside the lid of the cryoshipper\r used to transport Zynteglo.  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"0db9c0b5-1b89-49ae-ba17-6a55a2fbdff8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Excipient with known effect<\/span><\/u><\/p>","ID":"dde5567b-479d-425f-b8c6-e6ed50df1bb1","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Excipient with known effect","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"a9052917-0ac2-40c8-ab50-3d5fd6e24c9e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Each dose contains 391\u20111564 mg sodium.<\/span><\/p>","ID":"5290564b-5756-4978-87bc-682a63d92623","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each dose contains 391\u20111564 mg sodium.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"ec7a67b9-c3df-40d2-89fe-b57d634abe10","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">For the full list of excipients, see section 6.1.<\/span><\/p>","ID":"2b99aaf3-1570-4ba6-b6db-79ffdec10ec8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of excipients, see section 6.1.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"5bdf5734-21cd-4d01-bd34-df5ffe02c864","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"40fd98d0-a424-4363-be3a-82ac95df5fac","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>3.       PHARMACEUTICAL\r FORM<\/span><\/b><\/p>","ID":"bb919eab-914f-4e71-b87f-822049cb2726","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.       PHARMACEUTICAL\r FORM","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"efb997a1-70b4-4a2c-a246-cd664f4d90d9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Dispersion for infusion.<\/span><\/p>","ID":"243ee64b-5cc1-48fd-bd6e-69a1f3988de4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dispersion for infusion.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"a6857551-136f-4059-b012-0b4b4dd29f20","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">A clear to slightly cloudy, colourless to yellow or\r pink dispersion.<\/span><\/p>","ID":"5c1143fd-2eb4-4c6a-b91d-05cca03c5281","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A clear to slightly cloudy, colourless to yellow or\r pink dispersion.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"ab137611-57da-4c07-8ccd-7c898222a113","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"fde3ed93-8ce3-4fb4-ab93-cc3dd0ce0ac0","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.       CLINICAL\r PARTICULARS<\/span><\/b><\/p>","ID":"7b60bb40-e44b-435f-a547-26434ac48491","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.       CLINICAL\r PARTICULARS","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p>","ID":"20396332-665a-44d3-9ec7-5136fb63a8cd","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.1     Therapeutic\r indication<\/span><\/b><\/p>","ID":"d7ae6afd-f8e8-4741-9113-995e656878cd","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1     Therapeutic\r indication","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"b305f2ab-f543-4054-9935-d1c8ee3e9876","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk500066939\"><span style=\"font-size:11.0pt\">Zynteglo is indicated for\r the treatment of patients 12 years and older with transfusion\u2011dependent\r \u03b2\u2011thalassaemia (TDT) who do not have a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype, for whom haematopoietic stem cell (HSC) transplantation is\r appropriate but a human leukocyte antigen (HLA)\u2011matched related HSC donor\r is not available (see sections 4.4 and 5.1).<\/span><\/a><\/p>","ID":"7e01117f-3af4-4ec7-9f72-7fe5e1d2488a","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo is indicated for\r the treatment of patients 12 years and older with transfusion\u2011dependent\r \u03b2\u2011thalassaemia (TDT) who do not have a \u03b20\/\u03b20\r genotype, for whom haematopoietic stem cell (HSC) transplantation is\r appropriate but a human leukocyte antigen (HLA)\u2011matched related HSC donor\r is not available (see sections 4.4 and 5.1).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"049a650e-f6f5-4b6b-aade-b5c87ffd90d7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.2     Posology and\r method of administration<\/span><\/b><\/p>","ID":"045e6a0a-0bed-47d0-ae76-121f4159705e","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2     Posology and\r method of administration","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"03ed8b90-6949-4aab-ad01-2159452fafb7","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk497649473\"><span style=\"font-size:11.0pt\">Zynteglo must be\r administered in a qualified treatment centre by a physician(s) with experience\r in HSC transplantation and in the treatment of patients with TDT. <\/span><\/a><a name=\"_Hlk511314218\"><\/a><\/p>","ID":"55810e62-90fc-407b-a9dc-d7336a8aebb6","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo must be\r administered in a qualified treatment centre by a physician(s) with experience\r in HSC transplantation and in the treatment of patients with TDT. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"640bddee-b3c3-444a-b166-283f6d146230","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients are expected to enrol in a registry and will\r be followed in the registry in order to better understand the long-term safety\r and efficacy of Zynteglo. <\/span><\/p>","ID":"48a511f3-02bc-4d9e-9350-fcf4eaa7bb31","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients are expected to enrol in a registry and will\r be followed in the registry in order to better understand the long-term safety\r and efficacy of Zynteglo. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"bee10369-1d3c-4734-b4e1-2458623ceb60","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Posology<\/span><\/u><\/p>","ID":"89576a4d-1c57-474f-82a9-ce8196684730","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"801bf53d-a972-4021-9626-c9379d009b0c","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The minimum recommended dose of Zynteglo is\r 5.0 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg. In clinical\r studies doses up to 20 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup>\r cells\/kg have been administered. The minimum recommended dose is the same for\r adults and adolescents 12 years of age and older.<\/span><\/p>","ID":"7c11d703-385f-4478-9ca5-2297cd557c7f","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The minimum recommended dose of Zynteglo is\r 5.0 \u00d7 106 CD34+ cells\/kg. In clinical\r studies doses up to 20 \u00d7 106 CD34+\r cells\/kg have been administered. The minimum recommended dose is the same for\r adults and adolescents 12 years of age and older.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"731aa772-63d2-4a1d-9257-90c8bbc7ebc3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is intended for autologous use (see section\r 4.4) and should only be administered once.<\/span><\/p>","ID":"4a307d73-e9bb-496e-b6ee-c4eea8bbaf0b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo is intended for autologous use (see section\r 4.4) and should only be administered once.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"eb3a05e9-8e47-43cb-9fc7-fa93a32492a3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><i><span style='font-family:\"Times New Roman\",serif'>Mobilisation and apheresis<\/span><\/i><\/p>","ID":"ad13c483-4e58-42a2-9cd9-73097d9a3f69","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Mobilisation and apheresis","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d6a9b3d8-d942-4d22-8366-cfd6a0f02786","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients are required to undergo HSC mobilisation\r followed by apheresis to obtain CD34<sup>+<\/sup> stem cells which will be used\r for medicinal product manufacturing (see section 5.1 for a description of the\r mobilisation regimen used in clinical studies). <\/span><\/p>","ID":"09fb6470-1a03-4568-a9ff-289b745eb196","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients are required to undergo HSC mobilisation\r followed by apheresis to obtain CD34+ stem cells which will be used\r for medicinal product manufacturing (see section 5.1 for a description of the\r mobilisation regimen used in clinical studies). ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"9a99d5de-f71f-4fcc-a335-7b60cd1db124","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The minimum target number of CD34<sup>+<\/sup> cells to\r be collected is 12 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg.\r If the minimum dose of Zynteglo of 5.0 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg\r is not met after initial medicinal product manufacturing, the patient may\r undergo one or more additional cycles of mobilisation and apheresis, separated\r by at least 14 days, in order to obtain more cells for additional\r manufacture.<\/span><\/p>","ID":"d0dcb5af-3ccd-4e45-864d-4542b69744d3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The minimum target number of CD34+ cells to\r be collected is 12 \u00d7 106 CD34+ cells\/kg.\r If the minimum dose of Zynteglo of 5.0 \u00d7 106 CD34+ cells\/kg\r is not met after initial medicinal product manufacturing, the patient may\r undergo one or more additional cycles of mobilisation and apheresis, separated\r by at least 14 days, in order to obtain more cells for additional\r manufacture.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"808f145a-86d4-452b-9cfc-b19557f26375","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">A back-up collection of CD34<sup>+<\/sup> stem cells of\r \u22651.5 \u00d7 10<sup>6<\/sup> CD34<sup>+<\/sup> cells\/kg (if\r collected by apheresis) or &gt;1.0 \u00d7 10<sup>8<\/sup> TNC\/kg (if\r collected by bone marrow harvest) is required. These cells must be collected\r from the patient and be cryopreserved prior to myeloablative conditioning and\r infusion with Zynteglo. The back\u2011up collection may be needed for rescue\r treatment if there is: 1) compromise of Zynteglo after initiation of myeloablative\r conditioning and before Zynteglo infusion, 2) primary engraftment failure, or\r 3) loss of engraftment after infusion with Zynteglo (see section 4.4). <\/span><\/p>","ID":"8ca9deda-dec4-4b98-900d-1ea692b68ba3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A back-up collection of CD34+ stem cells of\r \u22651.5 \u00d7 106 CD34+ cells\/kg (if\r collected by apheresis) or >1.0 \u00d7 108 TNC\/kg (if\r collected by bone marrow harvest) is required. These cells must be collected\r from the patient and be cryopreserved prior to myeloablative conditioning and\r infusion with Zynteglo. The back\u2011up collection may be needed for rescue\r treatment if there is: 1) compromise of Zynteglo after initiation of myeloablative\r conditioning and before Zynteglo infusion, 2) primary engraftment failure, or\r 3) loss of engraftment after infusion with Zynteglo (see section 4.4). ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"c46fdf59-0cbf-4563-b9e4-4b5176ee9f92","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><i><span style='font-family:\"Times New Roman\",serif'>Pre-treatment conditioning <\/span><\/i><\/p>","ID":"40b21ec1-89b1-483b-99c7-853b845164e5","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Pre-treatment conditioning ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"e7cd4879-2711-496b-ab1f-ffb6b8900535","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The treating physician should confirm that HSC\r transplantation is appropriate for the patient before myeloablative\r conditioning is initiated (see section 4.4). <\/span><\/p>","ID":"59f9410f-1b05-4b8f-b987-3dd67f1656f6","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The treating physician should confirm that HSC\r transplantation is appropriate for the patient before myeloablative\r conditioning is initiated (see section 4.4). ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"3a243586-c47f-4766-bbd8-02a2a6215e8e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt;color:black\">Full myeloablative conditioning must be\r administered before infusion of Zynteglo (see section 5.1 for a description of\r the myeloablative regimen used in clinical studies). <\/span><span style=\"font-size:11.0pt\">It is recommended that patients maintain haemoglobin\r (Hb) \u226511 g\/dL for at least 30 days prior to mobilisation and\r during myeloablative conditioning. Iron chelation should be stopped at least\r 7 days prior to myeloablative conditioning. Prophylaxis for hepatic veno\u2011occlusive\r disease (VOD) is recommended. Prophylaxis for seizures should be considered\r (see section 5.1 for a description of the prophylaxis regimen used in clinical\r studies).<\/span><\/p>","ID":"c7cdf89f-5143-4ddb-91b6-918125637b70","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Full myeloablative conditioning must be\r administered before infusion of Zynteglo (see section 5.1 for a description of\r the myeloablative regimen used in clinical studies). It is recommended that patients maintain haemoglobin\r (Hb) \u226511 g\/dL for at least 30 days prior to mobilisation and\r during myeloablative conditioning. Iron chelation should be stopped at least\r 7 days prior to myeloablative conditioning. Prophylaxis for hepatic veno\u2011occlusive\r disease (VOD) is recommended. Prophylaxis for seizures should be considered\r (see section 5.1 for a description of the prophylaxis regimen used in clinical\r studies).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d93ef16f-d36f-4cfd-b756-36a9270b254b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Myeloablative conditioning should not begin until the\r complete set of infusion bag(s) constituting the dose of Zynteglo has been\r received and stored at the administration site, and the availability of the\r back-up collection is confirmed. <\/span><\/p>","ID":"706a2c21-d600-4b20-9a48-931b3b5d0a72","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Myeloablative conditioning should not begin until the\r complete set of infusion bag(s) constituting the dose of Zynteglo has been\r received and stored at the administration site, and the availability of the\r back-up collection is confirmed. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"10362830-7503-43c7-b1d1-12af59dbb568","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><i><span style='font-family:\"Times New Roman\",serif'>Zynteglo administration<\/span><\/i><\/p>","ID":"faf362d1-58fd-461a-9b3d-879c09b25637","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Zynteglo administration","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"98ae25dd-be7a-4dc6-817e-51fc247f24e7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">See Method of Administration below and section 6.6 for\r details on Zynteglo administration and handling.<\/span><\/p>","ID":"f3aac1fe-89d7-45c6-a6ab-027ff0333d37","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"See Method of Administration below and section 6.6 for\r details on Zynteglo administration and handling.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"24bfacea-ce6a-471b-b91b-4defdbd91012","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><i><span style='font-family:\"Times New Roman\",serif'>After Zynteglo administration<\/span><\/i><\/p>","ID":"d53511d6-0037-4f4d-ba2c-65471c751139","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"After Zynteglo administration","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"0ef5a7c7-8133-443b-9b44-57acb74a7db3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Any blood products required within the first\r 3 months after Zynteglo infusion should be irradiated. <\/span><\/p>","ID":"87067a47-14a2-449c-99e9-13dc2ecde8bb","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Any blood products required within the first\r 3 months after Zynteglo infusion should be irradiated. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"0cf71bf4-8845-4af4-be86-f41f623216ef","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Restarting iron chelation after Zynteglo infusion may\r be necessary and should be based on clinical practice (see sections 4.5 and\r 5.1). Phlebotomy can be used in lieu of iron chelation, when appropriate.<\/span><\/p>","ID":"8be69ff7-6d6e-4d57-9d2a-675e01e72126","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Restarting iron chelation after Zynteglo infusion may\r be necessary and should be based on clinical practice (see sections 4.5 and\r 5.1). Phlebotomy can be used in lieu of iron chelation, when appropriate.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"3309ab0a-5075-4317-9025-f6ffa2bcf910","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Special populations<\/span><\/u><\/p>","ID":"5036a6f8-da58-44d3-950b-00defaa5792c","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Special populations","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><i><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p>","ID":"c16eecda-ff0e-4093-8e15-f1e77f9c2c80","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\">Elderly<\/span><\/i><\/p>","ID":"1867e710-b8f1-4f8f-b6a4-4eeca493a416","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Elderly","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has not been studied in patients\r &gt;65 years of age. HSC transplantation must be appropriate for a patient\r with TDT to be treated with Zynteglo (see section 4.4). No dose adjustment is\r required.<\/span><\/p>","ID":"ebdf5fe1-900e-49ff-b801-4af962e98637","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo has not been studied in patients\r >65 years of age. HSC transplantation must be appropriate for a patient\r with TDT to be treated with Zynteglo (see section 4.4). No dose adjustment is\r required.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"20fb87e1-607b-44a7-9577-03598e2af95b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Renal impairment<\/span><\/i><\/p>","ID":"0b9345fe-808f-4772-b38d-57dc4a30adc2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Renal impairment","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has not been studied in patients with renal\r impairment. Patients should be assessed for renal impairment defined as\r creatinine clearance \u226470 mL\/min\/1.73 m<sup>2<\/sup> to ensure\r HSC transplantation is appropriate. No dose adjustment is required.<\/span><\/p>","ID":"3d823a1a-c9a5-4ff7-afe2-cf17dd7f316d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo has not been studied in patients with renal\r impairment. Patients should be assessed for renal impairment defined as\r creatinine clearance \u226470 mL\/min\/1.73 m2 to ensure\r HSC transplantation is appropriate. No dose adjustment is required.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"369d9fc7-f7fb-4116-89fb-85572b955c2e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/i><\/p>","ID":"0f1931a3-932b-4032-b1fb-ab478b542021","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hepatic impairment","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has not been studied in patients with hepatic\r impairment. Patients should be assessed for hepatic impairment to ensure HSC\r transplantation is appropriate (see section 4.4.). No dose adjustment is\r required.<\/span><\/p>","ID":"60c14a2d-db1a-4566-b712-b1732ef7de6d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo has not been studied in patients with hepatic\r impairment. Patients should be assessed for hepatic impairment to ensure HSC\r transplantation is appropriate (see section 4.4.). No dose adjustment is\r required.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"ee6e1d56-45d8-4ea3-8495-aa23aac06e91","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Paediatric population<\/span><\/i><\/p>","ID":"f2c962ff-ea52-4f03-bcf7-2ef002f2d939","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Paediatric population","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The safety and efficacy of Zynteglo in children\r &lt;12 years of age have not yet been established. <\/span><\/p>","ID":"42d8014c-fa10-4202-ba29-663966606fe8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety and efficacy of Zynteglo in children\r <12 years of age have not yet been established. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"3be3efed-bba1-4480-b143-a7b6cf6f5a47","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Patients seropositive for human immunodeficiency virus\r (HIV) or human T\u2011lymphotropic virus (HTLV)<\/span><\/i><\/p>","ID":"c17aefcb-60b1-4cb0-9a3f-926e6f96af6f","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Patients seropositive for human immunodeficiency virus\r (HIV) or human T\u2011lymphotropic virus (HTLV)","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has not been studied in patients with HIV\u20111,\r HIV\u20112, HTLV\u20111, or HTLV\u20112. A negative serology test for HIV is\r necessary to ensure acceptance of apheresis material for Zynteglo\r manufacturing. Apheresis material from patients with a positive test for HIV\r will not be accepted for Zynteglo manufacturing. <\/span><\/p>","ID":"727ddaeb-d666-42b7-b650-ba05ae00f81a","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo has not been studied in patients with HIV\u20111,\r HIV\u20112, HTLV\u20111, or HTLV\u20112. A negative serology test for HIV is\r necessary to ensure acceptance of apheresis material for Zynteglo\r manufacturing. Apheresis material from patients with a positive test for HIV\r will not be accepted for Zynteglo manufacturing. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"c949b35b-9fe2-417b-9a1b-d6c5fe005e6b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Method of administration <\/span><\/u><\/p>","ID":"cac99778-d8d1-4344-ab80-7c82a68c427e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Method of administration ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/i><\/p>","ID":"cd1cb2ea-3992-4530-9299-5b683735c7dc","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is for intravenous use only (see section 6.6\r for full details on the administration process).<\/span><\/p>","ID":"12550cec-fde2-4c85-b724-b9dd779376ea","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo is for intravenous use only (see section 6.6\r for full details on the administration process).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"c6d4c803-2463-477d-85b8-4d8a043c1c79","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">After completion of the 4\u2011day course of\r myeloablative conditioning, there must be a minimum of 48 hours of washout\r before Zynteglo infusion. <\/span><\/p>","ID":"b5daac8a-047d-4521-80f1-b27447c9d28f","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After completion of the 4\u2011day course of\r myeloablative conditioning, there must be a minimum of 48 hours of washout\r before Zynteglo infusion. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"f129d7f4-bdf2-41b3-b0d3-deed84a47453","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Before infusion, it must be confirmed that the\r patient\u2019s identity matches the unique patient information on the Zynteglo\r infusion bag(s). The total number of infusion bags to be administered should\r also be confirmed with the Lot Information Sheet (see section 4.4).<\/span><\/p>","ID":"a9784a4e-a241-4b0c-a0a5-0aa41ce6db44","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Before infusion, it must be confirmed that the\r patient\u2019s identity matches the unique patient information on the Zynteglo\r infusion bag(s). The total number of infusion bags to be administered should\r also be confirmed with the Lot Information Sheet (see section 4.4).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"9e58de99-ee90-4800-8903-35b4b9d3accc","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo infusion should be completed as soon as\r possible and no more than 4 hours after thawing. Each infusion bag should\r be administered in less than 30 minutes. In the event that more than one\r infusion bag is provided, all infusion bags must be administered. The entire\r volume of each infusion bag should be infused. <\/span><\/p>","ID":"038f6686-35ac-4f8b-ae26-46b04864e125","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo infusion should be completed as soon as\r possible and no more than 4 hours after thawing. Each infusion bag should\r be administered in less than 30 minutes. In the event that more than one\r infusion bag is provided, all infusion bags must be administered. The entire\r volume of each infusion bag should be infused. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"a7229cb9-41b3-4e31-88db-a49a9236d493","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Standard procedures for patient management after HSC\r transplantation should be followed after Zynteglo infusion.<\/span><\/p>","ID":"981cf6fd-1e26-440e-a8cd-7d0ee97801e2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Standard procedures for patient management after HSC\r transplantation should be followed after Zynteglo infusion.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"434624fd-73ec-4748-a0f6-e7ec15a5b297","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.3     Contraindications<\/span><\/b><\/p>","ID":"d0de925b-8d20-416d-82ce-f16c0bf15738","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3     Contraindications","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"fb7a621a-3eaf-4d21-81d0-30cf8d1790ac","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Hypersensitivity to the active substance or to any of\r the excipients listed in section 6.1.<\/span><\/p>","ID":"db3128d5-327d-4e89-8f05-03ab60f286cf","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypersensitivity to the active substance or to any of\r the excipients listed in section 6.1.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"b7ee7980-91f3-47ed-b6fd-03a5654908ee","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Pregnancy and breast-feeding (see section 4.6).<\/span><\/p>","ID":"bc9ff711-c1f5-4bae-b346-919ba48a4114","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregnancy and breast-feeding (see section 4.6).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"2fd7857e-1032-41c0-9131-ceb19cf83ccd","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Previous treatment with HSC gene therapy.<\/span><\/p>","ID":"50b9964b-5bae-4a6b-9bfe-3b6881f2b162","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Previous treatment with HSC gene therapy.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"82c055f1-0a81-4316-8748-645bd7d58fb0","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Contraindications to the mobilisation agents and the\r myeloablative conditioning agent must be considered.<\/span><\/p>","ID":"9b407416-9b8a-4325-9a1a-50c0483c2309","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Contraindications to the mobilisation agents and the\r myeloablative conditioning agent must be considered.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"ec77a4ba-35c4-440b-9e00-6ec7358c071f","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.4     Special\r warnings and precautions for use<\/span><\/b><\/p>","ID":"a86e7700-a22f-45fe-8adb-9c877c0f251c","Styles":"margin-bottom:0in;line-height:normal;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special\r warnings and precautions for use","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"f822ffbe-30a5-4d31-8630-6fe2fff6257e","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><u><span style='font-family:\"Times New Roman\",serif'>Traceability<\/span><\/u><\/p>","ID":"a323cff1-d317-4305-9ae9-529fd428f8db","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Traceability","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><u><span style='font-family:\"Times New Roman\",serif'><\/span><\/u><\/p>","ID":"5228ef1c-027d-4891-a739-bfc78678331b","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The traceability requirements of cell-based advanced\r therapy medicinal products must apply. To ensure traceability the name of the\r product, the batch number and the name of the treated patient should be kept\r for a period of 30 years.<\/span><\/p>","ID":"e86a8e90-cd52-4624-9582-87384ce252db","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The traceability requirements of cell-based advanced\r therapy medicinal products must apply. To ensure traceability the name of the\r product, the batch number and the name of the treated patient should be kept\r for a period of 30 years.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"af211740-e919-4cbe-91bb-c4d8d36828df","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">General<\/span><\/u><\/p>","ID":"2b8ca069-211e-4860-9cfb-bcb9f18a8bff","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"General","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"b98d6c09-8af0-4e96-8ebb-6194123bfb35","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Warnings and precautions of the mobilisation agents\r and the myeloablative conditioning agent must be considered.<\/span><\/p>","ID":"714d7021-17f2-43f4-947e-dbc2a1c894ed","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Warnings and precautions of the mobilisation agents\r and the myeloablative conditioning agent must be considered.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"e213a31f-1b5d-4082-b58a-bf299cb790ee","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients treated with Zynteglo should not donate\r blood, organs, tissues or cells for transplantation at any time in the future.\r This information is provided in the Patient Alert Card which must be given to\r the patient after treatment. <\/span><\/p>","ID":"adb5d6e6-54ac-4f1b-a48f-07febe0cfddd","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients treated with Zynteglo should not donate\r blood, organs, tissues or cells for transplantation at any time in the future.\r This information is provided in the Patient Alert Card which must be given to\r the patient after treatment. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"69619a8c-547b-441b-a1cf-ffbd437df1ca","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is intended solely for autologous use and\r must not be administered to other patients. Confirm that the patient\u2019s identity\r matches the unique patient identification information on the Zynteglo infusion\r bag(s) and metal cassette(s). Do not infuse Zynteglo if the information on the\r patient specific label on the infusion bag(s) or metal cassette(s) do not match\r the intended patient.<\/span><\/p>","ID":"9fe55687-a9fb-491b-b894-197ed1121631","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo is intended solely for autologous use and\r must not be administered to other patients. Confirm that the patient\u2019s identity\r matches the unique patient identification information on the Zynteglo infusion\r bag(s) and metal cassette(s). Do not infuse Zynteglo if the information on the\r patient specific label on the infusion bag(s) or metal cassette(s) do not match\r the intended patient.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"32d8e02f-3636-4926-a26c-f0d55408cd70","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Risks associated with TDT and iron overload<\/span><\/u><\/p>","ID":"0a9f1d50-2856-4b90-b7cd-c46e36b1b22c","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Risks associated with TDT and iron overload","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"677d382d-171b-457f-8adb-4ec313935c1d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Patients with TDT experience iron\r overload due to chronic red blood cell (RBC) transfusions that can lead to end\r organ damage. HSC transplantation with myeloablative conditioning is not\r appropriate for patients with TDT who have evidence of severely elevated iron\r in the heart i.e., patients with cardiac T2* &lt;10 msec by magnetic\r resonance imaging (MRI). MRI of the liver should be performed on all patients\r prior to myeloablative conditioning. It is recommended that patients with MRI\r results demonstrating liver iron content \u226515 mg\/g undergo liver\r biopsy for further evaluation. If the liver biopsy demonstrates bridging\r fibrosis, cirrhosis, or active hepatitis, HSC transplantation with\r myeloablative conditioning is not appropriate.<\/span><\/p>","ID":"0fcfb3c2-9aa7-4070-bbb8-71cbad02b424","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients with TDT experience iron\r overload due to chronic red blood cell (RBC) transfusions that can lead to end\r organ damage. HSC transplantation with myeloablative conditioning is not\r appropriate for patients with TDT who have evidence of severely elevated iron\r in the heart i.e., patients with cardiac T2* <10 msec by magnetic\r resonance imaging (MRI). MRI of the liver should be performed on all patients\r prior to myeloablative conditioning. It is recommended that patients with MRI\r results demonstrating liver iron content \u226515 mg\/g undergo liver\r biopsy for further evaluation. If the liver biopsy demonstrates bridging\r fibrosis, cirrhosis, or active hepatitis, HSC transplantation with\r myeloablative conditioning is not appropriate.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"18522c26-57e2-43da-824a-5ed5b34e0abf","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Risk of insertional oncogenesis<\/span><\/u><\/p>","ID":"5c2e513c-e573-4117-b420-0ca6a8397b79","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Risk of insertional oncogenesis","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"4a572222-24ba-4a10-91da-c6bc1b3d194d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">No cases of leukaemia or lymphoma have been reported\r in clinical studies with Zynteglo in patients with TDT. There are no reports of\r LVV\u2011mediated insertional mutagenesis resulting in oncogenesis.\r Nevertheless, there is a theoretical risk of leukaemia or lymphoma after\r treatment with Zynteglo. <\/span><\/p>","ID":"f9a364db-1874-40e9-bc12-d38108f1c4a8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No cases of leukaemia or lymphoma have been reported\r in clinical studies with Zynteglo in patients with TDT. There are no reports of\r LVV\u2011mediated insertional mutagenesis resulting in oncogenesis.\r Nevertheless, there is a theoretical risk of leukaemia or lymphoma after\r treatment with Zynteglo. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"3a463018-6b5b-4b57-a711-539cf63823bb","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients should be monitored annually for leukaemia or\r lymphoma (including with a complete blood count) for 15 years post\r treatment with Zynteglo. If leukaemia or lymphoma is detected in any patient\r who received Zynteglo, blood samples should be collected for integration site\r analysis.  <\/span><\/p>","ID":"152a7c49-0c0f-4bd3-8fe4-8e959685d731","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients should be monitored annually for leukaemia or\r lymphoma (including with a complete blood count) for 15 years post\r treatment with Zynteglo. If leukaemia or lymphoma is detected in any patient\r who received Zynteglo, blood samples should be collected for integration site\r analysis.  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"0825f959-7b04-41f2-872e-f5b62798a8e7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Serological testing<\/span><\/u><\/p>","ID":"d5297b88-4ca9-4a11-babc-535a6c52f427","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Serological testing","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"e1b30750-c4a7-4a0f-9aee-c2219c534ac5","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients should be tested for HIV-1\/2 prior to\r mobilisation and apheresis to ensure acceptance of the apheresis material for\r Zynteglo manufacturing (see section 4.2). <\/span><\/p>","ID":"2e33730f-d7e4-411d-a336-5420495cf2a6","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"All patients should be tested for HIV-1\/2 prior to\r mobilisation and apheresis to ensure acceptance of the apheresis material for\r Zynteglo manufacturing (see section 4.2). ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"7157275c-8131-475a-840a-9eac57ba9ea8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Interference with serology testing<\/span><\/u><\/p>","ID":"bab11e50-424c-4bdc-b7a7-6eacd9639f29","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Interference with serology testing","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"8551a3b4-f8ef-44d2-9d83-5bf4b1d0624f","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">It is important to note that patients who have\r received Zynteglo are likely to test positive by polymerase chain reaction\r (PCR) assays for HIV due to LVV provirus insertion, resulting in a false\r positive test for HIV. Therefore, patients who have received Zynteglo should\r not be screened for HIV infection using a PCR-based assay. <\/span><\/p>","ID":"2640ecb5-5332-479b-af28-99bae9f8916a","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is important to note that patients who have\r received Zynteglo are likely to test positive by polymerase chain reaction\r (PCR) assays for HIV due to LVV provirus insertion, resulting in a false\r positive test for HIV. Therefore, patients who have received Zynteglo should\r not be screened for HIV infection using a PCR-based assay. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"ec62f232-796e-4ab8-8d4b-cef270ccd13c","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Engraftment failure as measured by neutrophil\r engraftment<\/span><\/u><\/p>","ID":"ab24e35c-f4b3-4cc1-94da-e6927ad1f848","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Engraftment failure as measured by neutrophil\r engraftment","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"4adff8b6-6f8b-46f7-9977-c84e3b80f11b","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Treatment with Zynteglo involves the infusion and\r engraftment of CD34<sup>+<\/sup> HSCs that have been genetically modified <i>ex\r vivo<\/i> with a LVV. In clinical trials, no patients failed to engraft bone\r marrow, as measured by neutrophil engraftment (N=45). <span style=\"color:black\">Neutrophil\r engraftment occurred on median (min, max) Day 21.0 (13, 38)\r after medicinal product infusion. <\/span>Failure of neutrophil engraftment is a\r short-term but potentially severe risk, defined as failure to achieve\r 3 consecutive absolute neutrophil counts (ANC) \u2265500 cells\/\u00b5L\r obtained on different days by Day 43 after infusion of Zynteglo. Patients\r who experience neutrophil engraftment failure should receive rescue treatment\r with the back-up collection (see section 4.2).<\/span><\/p>","ID":"8e1b87c6-1dea-47d6-b0b6-760a6d35c9d4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Treatment with Zynteglo involves the infusion and\r engraftment of CD34+ HSCs that have been genetically modified ex\r vivo with a LVV. In clinical trials, no patients failed to engraft bone\r marrow, as measured by neutrophil engraftment (N=45). Neutrophil\r engraftment occurred on median (min, max) Day 21.0 (13, 38)\r after medicinal product infusion. Failure of neutrophil engraftment is a\r short-term but potentially severe risk, defined as failure to achieve\r 3 consecutive absolute neutrophil counts (ANC) \u2265500 cells\/\u00b5L\r obtained on different days by Day 43 after infusion of Zynteglo. Patients\r who experience neutrophil engraftment failure should receive rescue treatment\r with the back-up collection (see section 4.2).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"fe5ab81e-0d3e-4e98-8c7f-d3195ffe27bb","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Delayed platelet engraftment<\/span><\/u><\/p>","ID":"19554b58-0f7d-4595-bcc9-e7cac87cd641","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Delayed platelet engraftment","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"c03d6b18-613e-4634-8a28-230dfcdfcd0d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Platelet engraftment is defined as 3 consecutive\r platelet values \u226520 \u00d7 10<sup>9<\/sup>\/L obtained on different\r days after Zynteglo infusion, with no platelet transfusions administered for\r 7 days immediately preceding and during the evaluation period.<b><\/b>Patients\r with TDT treated with Zynteglo who achieved platelet engraftment had a median\r (min, max) platelet engraftment on Day 42.0 (19, 191) in clinical trials\r (N=45). No correlation was observed between incidence of bleeding and delayed\r platelet engraftment. Patients should be made aware of the risk of bleeding\r until platelet recovery has been achieved. Patients should be monitored for\r thrombocytopenia and bleeding according to standard guidelines. Platelet counts\r should be monitored according to medical judgment until platelet engraftment\r and platelet recovery are achieved. Blood cell count determination and other\r appropriate testing should be promptly considered whenever clinical symptoms\r suggestive of bleeding arise. <\/span><\/p>","ID":"4f77f5dc-de2a-49c8-93e5-c826f7825275","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Platelet engraftment is defined as 3 consecutive\r platelet values \u226520 \u00d7 109\/L obtained on different\r days after Zynteglo infusion, with no platelet transfusions administered for\r 7 days immediately preceding and during the evaluation period.Patients\r with TDT treated with Zynteglo who achieved platelet engraftment had a median\r (min, max) platelet engraftment on Day 42.0 (19, 191) in clinical trials\r (N=45). No correlation was observed between incidence of bleeding and delayed\r platelet engraftment. Patients should be made aware of the risk of bleeding\r until platelet recovery has been achieved. Patients should be monitored for\r thrombocytopenia and bleeding according to standard guidelines. Platelet counts\r should be monitored according to medical judgment until platelet engraftment\r and platelet recovery are achieved. Blood cell count determination and other\r appropriate testing should be promptly considered whenever clinical symptoms\r suggestive of bleeding arise. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"911c3ca2-f6b1-4177-a3c7-defb2b0ff8a4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Anti-retroviral and hydroxyurea use<\/span><\/u><\/p>","ID":"ea88ed81-4d08-4bc2-8841-1b54eafcdbac","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Anti-retroviral and hydroxyurea use","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"64f04b51-ac58-416a-a81a-db66647eae1d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients should not take anti\u2011retroviral\r medications or hydroxyurea from at least one month prior to mobilisation until\r at least 7 days after Zynteglo infusion (see section 4.5). <a name=\"_Hlk3111940\">If a patient requires anti\u2011retrovirals for HIV\r prophylaxis, Zynteglo treatment, including mobilisation and apheresis of CD34<\/a><\/span><sup>+<\/sup><span style=\"font-size:11.0pt\"> cells through Zynteglo infusion, should be delayed\r until an HIV infection could be adequately ruled out according to local\r guidance for HIV testing.<\/span><\/p>","ID":"8e4f0231-f3aa-4edd-a23a-9555be832a28","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients should not take anti\u2011retroviral\r medications or hydroxyurea from at least one month prior to mobilisation until\r at least 7 days after Zynteglo infusion (see section 4.5). If a patient requires anti\u2011retrovirals for HIV\r prophylaxis, Zynteglo treatment, including mobilisation and apheresis of CD34+ cells through Zynteglo infusion, should be delayed\r until an HIV infection could be adequately ruled out according to local\r guidance for HIV testing.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"82458575-5900-47ef-b5b9-f34b6939bed1","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Sodium content<\/span><\/u><\/p>","ID":"ae157c80-8cda-4231-9ace-6642e958f10b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Sodium content","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"37be87d8-3c2e-46ce-b8a5-bd4a9547d0ec","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">This medicinal product contains 391\u20111564 mg\r sodium per dose equivalent to 20 to 78% of the WHO recommended maximum daily\r intake of 2 g sodium for an adult. <\/span><\/p>","ID":"553dfd60-3b6a-41c0-8b93-12fbd54f14ad","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"This medicinal product contains 391\u20111564 mg\r sodium per dose equivalent to 20 to 78% of the WHO recommended maximum daily\r intake of 2 g sodium for an adult. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"461c89bd-e591-44eb-96f8-872d583963cd","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.5     Interaction with\r other medicinal products and other forms of interaction<\/span><\/b><\/p>","ID":"7f889af0-725c-427c-b1c5-afde9f432949","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5     Interaction with\r other medicinal products and other forms of interaction","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"82f0559d-1c20-4d72-8441-e9e1da384785","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients should not take anti\u2011retroviral\r medicinal products or hydroxyurea from at least one month prior to mobilisation\r until at least 7 days after Zynteglo infusion (see section 4.4).<\/span><\/p>","ID":"2a007835-6e6b-4fdc-957a-81bdd4bc3445","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients should not take anti\u2011retroviral\r medicinal products or hydroxyurea from at least one month prior to mobilisation\r until at least 7 days after Zynteglo infusion (see section 4.4).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"aaaf1036-f520-481f-bd0c-dd3f44b27da2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Drug-drug interactions between iron chelators and the\r myeloablative conditioning agent must be considered. Iron chelators should be\r discontinued 7 days prior to initiation of conditioning. The Summary of\r Product Characteristics (SmPC) for the iron chelator and the myeloablative\r conditioning agent must be consulted for the recommendations regarding\r co-administration with CYP3A substrates.<\/span><\/p>","ID":"7b65eef3-03f7-4018-9442-96234b24cba9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Drug-drug interactions between iron chelators and the\r myeloablative conditioning agent must be considered. Iron chelators should be\r discontinued 7 days prior to initiation of conditioning. The Summary of\r Product Characteristics (SmPC) for the iron chelator and the myeloablative\r conditioning agent must be consulted for the recommendations regarding\r co-administration with CYP3A substrates.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"dc8cb300-513b-4e1f-8183-caba0030cd57","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Some iron chelators are myelosuppressive. After\r Zynteglo infusion, avoid use of these iron chelators for 6 months. If iron\r chelation is needed, consider administration of non-myelosuppressive iron\r chelators (see sections 4.2 and 5.1).<\/span><\/p>","ID":"122fd665-e849-410a-8845-4e0ee35d0bff","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Some iron chelators are myelosuppressive. After\r Zynteglo infusion, avoid use of these iron chelators for 6 months. If iron\r chelation is needed, consider administration of non-myelosuppressive iron\r chelators (see sections 4.2 and 5.1).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"4dd903dd-47ca-4b8a-90ae-2ac7023afc12","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">No formal drug interaction studies have been\r performed. Zynteglo is not expected to interact with the hepatic cytochrome P\u2011450\r family of enzymes or drug transporters.<\/span><\/p>","ID":"8bdbafee-75e9-4e43-82de-8da57b3f8b84","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No formal drug interaction studies have been\r performed. Zynteglo is not expected to interact with the hepatic cytochrome P\u2011450\r family of enzymes or drug transporters.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"018b7e30-071d-48ca-a21f-417afa2c0c87","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">There is no clinical experience with the use of\r erythropoiesis-stimulating agents in patients treated with Zynteglo.<\/span><\/p>","ID":"d2492b84-cc98-4731-9590-20c64a771bbc","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no clinical experience with the use of\r erythropoiesis-stimulating agents in patients treated with Zynteglo.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"554c2967-c4e7-4698-a437-5e083de1cb2c","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The safety of immunisation with live viral vaccines\r during or following Zynteglo treatment has not been studied. <\/span><\/p>","ID":"3c170c23-9dfa-4e35-9bbc-60eedaf55b4a","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety of immunisation with live viral vaccines\r during or following Zynteglo treatment has not been studied. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"baaf681d-ea07-4ec5-b320-5194a5ced9c3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.6     Fertility,\r pregnancy and lactation<\/span><\/b><\/p>","ID":"4f79790a-da3a-46f1-93ab-a98613f2eda5","Styles":"margin-bottom:0in;line-height:normal;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility,\r pregnancy and lactation","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><\/p>","ID":"0dd58c40-7df4-4e73-b21e-4256533a5e12","Styles":"margin-bottom:0in;line-height:normal;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Women of childbearing potential\/Contraception in males\r and females<\/span><\/u><\/p>","ID":"008f944d-d410-4705-8d78-726dc6734e37","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Women of childbearing potential\/Contraception in males\r and females","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"5090a75d-870a-4ae9-b505-66e2f544db2e","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt;color:black\">There are insufficient exposure data to\r provide a precise recommendation on duration of <\/span><span style=\"font-size:\r 11.0pt\">contraception following treatment with Zynteglo. Women of childbearing\r potential and men capable of fathering a child must use a reliable method of\r contraception (intra-uterine device or combination of hormonal and barrier\r contraception) from start of mobilisation through at least 6 months after\r administration of Zynteglo. Consult the SmPC of the myeloablative conditioning\r agent for information on the need for effective contraception in patients who\r undergo conditioning. <\/span><\/p>","ID":"d446eb62-400d-4d1a-900b-8b8950b01917","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There are insufficient exposure data to\r provide a precise recommendation on duration of contraception following treatment with Zynteglo. Women of childbearing\r potential and men capable of fathering a child must use a reliable method of\r contraception (intra-uterine device or combination of hormonal and barrier\r contraception) from start of mobilisation through at least 6 months after\r administration of Zynteglo. Consult the SmPC of the myeloablative conditioning\r agent for information on the need for effective contraception in patients who\r undergo conditioning. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"c411c6f6-8c2d-4078-87ba-30e4f9a78075","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Pregnancy<\/span><\/u><\/p>","ID":"5d9939de-6f50-45c4-92df-172fa400e515","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pregnancy","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"4fdba272-b396-4440-8ea5-e66c2dbe2614","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">A negative serum pregnancy test must be confirmed\r prior to the start of mobilisation and re-confirmed prior to conditioning\r procedures and before medicinal product administration.<\/span><\/p>","ID":"9e22d59e-1132-4dd1-850d-6aea49c3b50c","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A negative serum pregnancy test must be confirmed\r prior to the start of mobilisation and re-confirmed prior to conditioning\r procedures and before medicinal product administration.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"683a1111-336f-4407-adf9-784ec5161f80","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">No clinical data on exposed pregnancies are available.<\/span><\/p>","ID":"899d50c5-e554-453f-9f55-33c845d02ecf","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No clinical data on exposed pregnancies are available.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"b56a7663-d104-4ba4-94c7-518a81ae5526","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Reproductive and developmental toxicity studies with\r Zynteglo were not performed. Zynteglo must not be used during pregnancy because\r of myeloablative conditioning (see section 4.3). It is unknown whether Zynteglo\r transduced cells have the potential to be transferred in utero to a foetus.<\/span><\/p>","ID":"b0a7de04-8b47-47a9-9548-bc0ca3707e4e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reproductive and developmental toxicity studies with\r Zynteglo were not performed. Zynteglo must not be used during pregnancy because\r of myeloablative conditioning (see section 4.3). It is unknown whether Zynteglo\r transduced cells have the potential to be transferred in utero to a foetus.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"202038e5-3928-44d0-a257-7090a713ffee","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">There is no opportunity for germline transmission of\r the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin gene after treatment with\r Zynteglo, therefore the likelihood that an offspring would have general somatic\r expression of the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin gene is considered\r negligible.<\/span><\/p>","ID":"cbf95f72-cb11-46ff-a2c0-7e334e01d5b4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no opportunity for germline transmission of\r the \u03b2A\u2011T87Q\u2011globin gene after treatment with\r Zynteglo, therefore the likelihood that an offspring would have general somatic\r expression of the \u03b2A\u2011T87Q\u2011globin gene is considered\r negligible.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"2c3a0fc9-8bc9-41c9-b5c9-0bef4a6e7f12","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Breast-feeding<\/span><\/u><\/p>","ID":"827eca1c-930a-4c91-892a-669ad66342b6","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Breast-feeding","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"d54db46f-0ac0-44a4-acca-0849b95790ad","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">It is unknown whether Zynteglo is excreted in human\r milk. The effect of administration of Zynteglo to mothers on their breast-fed\r children has not been studied.<\/span><\/p>","ID":"4af29085-02cc-400e-99ed-dfb385dacbee","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is unknown whether Zynteglo is excreted in human\r milk. The effect of administration of Zynteglo to mothers on their breast-fed\r children has not been studied.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"dad7e659-48f5-4e9d-842a-f673e1761138","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo must not be administered to women who are\r breast-feeding.<\/span><\/p>","ID":"96e47121-970c-4024-9bc0-087e860aed4c","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo must not be administered to women who are\r breast-feeding.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"af245323-535f-4b1f-8045-1b2a58e9da45","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Fertility<\/span><\/u><\/p>","ID":"49a5a9ec-9969-47ff-b9b6-3a7d38da5627","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Fertility","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"3ee352fb-d557-48af-9f1f-229c2eadb0de","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">There are no data on the effects of Zynteglo on human\r fertility. Effects on male and female fertility have not been evaluated in\r animal studies. <\/span><\/p>","ID":"eb54243c-e95d-4750-85c8-a61f544915b3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There are no data on the effects of Zynteglo on human\r fertility. Effects on male and female fertility have not been evaluated in\r animal studies. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"6e620656-7a02-4d24-b844-9d86794defb4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Data are available on the risk of infertility with\r myeloablative conditioning. <span style=\"color:black\">It is therefore advised\r to cryopreserve semen or ova before treatment if possible.<\/span><\/span><\/p>","ID":"2e481678-abf3-4941-a636-2be4b048928a","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Data are available on the risk of infertility with\r myeloablative conditioning. It is therefore advised\r to cryopreserve semen or ova before treatment if possible.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"bd5040bd-e51e-467e-a188-4f7622ad8025","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.7     Effects on\r ability to drive and use machines<\/span><\/b><\/p>","ID":"4e6ec28f-3fef-4410-b78a-fa20650b0773","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on\r ability to drive and use machines","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"ed0dbe0a-cae6-4aa2-8ab6-02c3138d2799","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo has no influence on the ability to drive or\r use machines.<br\/> <br\/> <\/span><\/p>","ID":"aa4f2f4e-fe8b-49ad-bc5c-9639b67b1dbf","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo has no influence on the ability to drive or\r use machines.  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The effect of the mobilisation agents and the\r myeloablative conditioning agent on the ability to drive or use machines must\r be considered.<\/span><\/p>","ID":"3a4271ab-1ea1-4164-9b38-8cc5955a893f","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The effect of the mobilisation agents and the\r myeloablative conditioning agent on the ability to drive or use machines must\r be considered.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"913e0d59-0a3b-4703-84a5-c79a02904969","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.8     Undesirable\r effects<\/span><\/b><\/p>","ID":"a3b8d3d9-57f2-43f2-8204-c69cd7372859","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable\r effects","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"ad7d8e30-083b-486e-9508-b6edfd2420a5","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Summary of the safety profile<\/span><\/u><\/p>","ID":"86a7b832-09b7-4c46-946c-9002433fc302","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Summary of the safety profile","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"ed361dae-a415-40e4-b2b1-4c3beb3f1b88","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The safety of Zynteglo was evaluated in\r 45 patients with TDT. The only serious adverse reaction attributed to\r Zynteglo was thrombocytopenia (2.2%). <span style=\"color:black\">Given the small\r patient population and size of cohorts, adverse reactions in the table below do\r not provide a complete perspective on the nature and frequency of these events.\r <\/span><\/span><\/p>","ID":"7eeaa541-6d56-48f0-88fd-a87e70d55ee1","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety of Zynteglo was evaluated in\r 45 patients with TDT. The only serious adverse reaction attributed to\r Zynteglo was thrombocytopenia (2.2%). Given the small\r patient population and size of cohorts, adverse reactions in the table below do\r not provide a complete perspective on the nature and frequency of these events.\r ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"b2a8a7c3-ce5c-47fe-bc9e-246fb6438dd6","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Tabulated list of adverse reactions<br\/> <br\/> <\/span><\/u><\/p>","ID":"a775a1d6-2c28-496a-8804-05a1f98421c4","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Tabulated list of adverse reactions  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Adverse reactions are listed by MedDRA body system\r organ class and by frequency convention. Frequencies are defined as: very\r common <span style=\"color:#323232\">(\u22651\/10), and c<\/span>ommon\r (\u22651\/100 to &lt;1\/10). Within each frequency grouping, adverse reactions\r are presented in the order of decreasing seriousness.<\/span><\/p>","ID":"503e3348-f694-4d50-a9b3-a3d638a6b3fa","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions are listed by MedDRA body system\r organ class and by frequency convention. Frequencies are defined as: very\r common (\u22651\/10), and common\r (\u22651\/100 to <1\/10). Within each frequency grouping, adverse reactions\r are presented in the order of decreasing seriousness.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d8f9e5c7-368e-4a0c-b728-53bceb11c18e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Tables 1, 2, and 3 are lists of adverse reactions\r attributed to mobilisation\/apheresis, myeloablative conditioning, and Zynteglo,\r respectively, experienced by patients with TDT in clinical trials with Zynteglo.<\/span><\/p>","ID":"cfabf376-1724-4f02-aa42-d48ee408a8c6","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Tables 1, 2, and 3 are lists of adverse reactions\r attributed to mobilisation\/apheresis, myeloablative conditioning, and Zynteglo,\r respectively, experienced by patients with TDT in clinical trials with Zynteglo.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"01106724-9f14-4cd7-bd25-8979e0c33690","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid;\r text-autospace:none\"><b><span style='font-family:\"Times New Roman\",serif'>Table\r 1              Adverse reactions attributed to mobilisation\/apheresis<\/span><\/b><\/p>","ID":"09586a96-c12f-46ff-a318-7979c198dc0f","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Table\r 1              Adverse reactions attributed to mobilisation\/apheresis","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a name=\"_Hlk4086514\"><b><span style='font-family:\"Times New Roman\",serif'>System\r   Organ Class (SOC)<\/span><\/b><\/a><\/p> <\/td> <td style=\"width:151.4pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very Common (\u226510%)<\/span><\/b><\/p> <\/td> <td style=\"width:151.4pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common (\u22651% - &lt;10%)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:8.5pt\"> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Blood and lymphatic\r   system disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Thrombocytopenia<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Splenomegaly,\r   Leukocytosis<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Metabolism and\r   nutrition disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypocalcaemia<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypokalaemia,\r   Hypomagnesaemia<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Psychiatric disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Agitation<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Nervous system\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Headache, Peripheral\r   sensory neuropathy<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Dizziness, Head\r   discomfort, Paraesthesia<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cardiac disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cardiac flutter<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vascular disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypotension<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Respiratory, thoracic\r   and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypoxia, Epistaxis<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Gastrointestinal\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Nausea<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vomiting, Lip\r   swelling, Abdominal pain, Abdominal pain upper, Paraesthesia oral <\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Skin and subcutaneous\r   tissue disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Rash, Hyperhidrosis<\/span><\/p> <\/td> <\/tr> <tr style=\"height:22.9pt\"> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Musculoskeletal and\r   connective tissue disorders<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Bone pain<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:22.9pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Back pain,\r   Musculoskeletal discomfort<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>General disorders and\r   administration site conditions<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Pyrexia, Influenza\r   like illness, Chest discomfort, Chest pain, Injection site reaction, Catheter\r   site haemorrhage, Catheter site bruise, Injection site bruising, Fatigue,\r   Non-cardiac chest pain, Catheter site pain, Injection site pain, Puncture\r   site pain, Pain<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Investigations<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Blood magnesium\r   decreased<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:150.95pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Injury, poisoning and\r   procedural complications<\/span><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.4pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Citrate toxicity,\r   Contusion, Procedural pain<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"f7ef346b-5141-484c-b0a6-ca98b06dc4a5","Styles":"border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"   System\r   Organ Class (SOC)   Very Common (\u226510%)   Common (\u22651% - <10%)     Blood and lymphatic\r   system disorders   Thrombocytopenia   Splenomegaly,\r   Leukocytosis     Metabolism and\r   nutrition disorders   Hypocalcaemia   Hypokalaemia,\r   Hypomagnesaemia     Psychiatric disorders      Agitation     Nervous system\r   disorders   Headache, Peripheral\r   sensory neuropathy   Dizziness, Head\r   discomfort, Paraesthesia     Cardiac disorders      Cardiac flutter     Vascular disorders      Hypotension     Respiratory, thoracic\r   and mediastinal disorders      Hypoxia, Epistaxis     Gastrointestinal\r   disorders   Nausea   Vomiting, Lip\r   swelling, Abdominal pain, Abdominal pain upper, Paraesthesia oral      Skin and subcutaneous\r   tissue disorders      Rash, Hyperhidrosis     Musculoskeletal and\r   connective tissue disorders   Bone pain   Back pain,\r   Musculoskeletal discomfort     General disorders and\r   administration site conditions      Pyrexia, Influenza\r   like illness, Chest discomfort, Chest pain, Injection site reaction, Catheter\r   site haemorrhage, Catheter site bruise, Injection site bruising, Fatigue,\r   Non-cardiac chest pain, Catheter site pain, Injection site pain, Puncture\r   site pain, Pain     Investigations      Blood magnesium\r   decreased     Injury, poisoning and\r   procedural complications      Citrate toxicity,\r   Contusion, Procedural pain   ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none\"><\/p>","ID":"1ecfdfc4-aff6-4b0d-9400-e3c664d2785c","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always;\r page-break-after:avoid;text-autospace:none\"><a name=\"_Hlk4086533\"><b><span style='font-family:\"Times New Roman\",serif'>Table 2              Adverse\r reactions attributed to myeloablative conditioning<\/span><\/b><\/a><\/p>","ID":"1d1aac33-ec1b-487b-b0da-8a86a055039b","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always;\r\npage-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Table 2              Adverse\r reactions attributed to myeloablative conditioning","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\"> <thead> <tr style=\"height:10.3pt\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:10.3pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>SOC<\/span><\/b><\/p> <\/td> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.3pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very Common (\u226510%)<\/span><\/b><\/p> <\/td> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.3pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common (\u22651% - &lt;10%)<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Infections and\r   infestations<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Neutropenic sepsis,\r   Systemic infection, Staphylococcal infection, Pneumonia, Lower respiratory\r   tract infection, Urinary tract infection, Mucosal infection, Cellulitis,\r   Vaginal infection, Rash pustular, Folliculitis, Gingivitis, Vulvovaginal\r   candidiasis<\/span><\/p> <\/td> <\/tr> <tr style=\"height:8.5pt\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Blood\r   and lymphatic system disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span lang=\"IT\" style='font-family:\"Times New Roman\",serif;color:black'>Febrile\r   neutropenia, Neutropenia, Thrombocytopenia, Leukopenia, Anaemia<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Lymphopenia,\r   Leukocytosis, Monocyte count decreased, Neutrophilia, Mean cell haemoglobin\r   concentration increased<\/span><\/p> <\/td> <\/tr> <tr style=\"height:8.5pt\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Endocrine\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.5pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Primary\r   hypogonadism<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Metabolism and nutrition\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Decreased appetite<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypocalcaemia,\r   Hypokalaemia, Metabolic acidosis, Fluid overload, Fluid retention,\r   Hypomagnesaemia, Hyponatraemia, Hypophosphataemia, Hyperphosphataemia<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Psychiatric disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Insomnia<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Anxiety<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Nervous system\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Headache<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Dizziness, Lethargy,\r   Dysgeusia, Ageusia, Memory impairment<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Eye disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Conjunctival\r   haemorrhage<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Ear and labyrinth\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vertigo<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cardiac disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cardiac failure\r   congestive, Atrial fibrillation <\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vascular disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypotension,\r   Haematoma, Hot flush<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Respiratory, thoracic\r   and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Epistaxis, Pharyngeal\r   inflammation<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hypoxia, Pulmonary\r   mass, Dyspnoea, Pleural effusion, Rales, Upper-airway cough syndrome, Cough,\r   Laryngeal pain, Hiccups, Oropharyngeal pain <\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Gastrointestinal\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Stomatitis, Vomiting,\r   Nausea, Diarrhoea, Gingival bleeding, Constipation, Abdominal pain, Anal\r   inflammation <\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Anal haemorrhage,\r   Gastritis, Gastrointestinal inflammation, Abdominal distension, Abdominal\r   pain upper, Anal fissure, Dyspepsia, Dysphagia, Oesophagitis, Haemorrhoids,\r   Proctalgia, Lip dry<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hepatobiliary\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Veno\u2011occlusive\r   liver disease, Alanine aminotransferase increased, Aspartate aminotransferase\r   increased, Blood bilirubin increased<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Cholecystitis,\r   Cholelithiasis, Hepatomegaly, Jaundice, Transaminases increased,\r   Gamma-glutamyltransferase increased<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Skin and subcutaneous\r   tissue disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Alopecia, Pruritus,\r   Skin hyperpigmentation<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Petechiae,\r   Ecchymosis, Pain of skin, Palpable purpura, Pigmentation disorder, Pruritus\r   generalised, Purpura, Sweat gland disorder, Urticaria, Dry skin, Rash<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Musculoskeletal and\r   connective tissue disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Bone pain, Myalgia,\r   Pain in extremity, Back pain<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Renal and urinary\r   disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Haematuria,\r   Pollakiuria<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Reproductive system\r   and breast disorders<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vaginal haemorrhage<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Ovarian failure,\r   Menstruation irregular, Premature menopause, Blood follicle stimulating\r   hormone increased, Blood testosterone decreased<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>General disorders and\r   administration site conditions<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Pyrexia, Fatigue,\r   Mucosal inflammation<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Face oedema,\r   Hypothermia, Feeling cold, Pain, Xerosis<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>Investigations<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>C\u2011reactive\r   protein increased, Aspergillus test positive, Blood potassium decreased,\r   Weight decreased, Blood alkaline phosphatase decreased, Blood magnesium\r   decreased, Forced expiratory flow decreased, Protein total decreased, Blood\r   albumin decreased, Reticulocyte count decreased, Reticulocyte percentage\r   decreased<\/span><\/p> <\/td> <\/tr> <tr style=\"height:23.8pt\"> <td style=\"width:151.25pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.8pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Injury, poisoning and\r   procedural complications<\/span><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:23.8pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:151.25pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:23.8pt\" valign=\"top\" width=\"202\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Transfusion reaction,\r   Skin abrasion<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"2e56750e-d6c9-4463-aeb0-6c864c87d8ff","Styles":"border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"    SOC   Very Common (\u226510%)   Common (\u22651% - <10%)      Infections and\r   infestations       Neutropenic sepsis,\r   Systemic infection, Staphylococcal infection, Pneumonia, Lower respiratory\r   tract infection, Urinary tract infection, Mucosal infection, Cellulitis,\r   Vaginal infection, Rash pustular, Folliculitis, Gingivitis, Vulvovaginal\r   candidiasis     Blood\r   and lymphatic system disorders   Febrile\r   neutropenia, Neutropenia, Thrombocytopenia, Leukopenia, Anaemia   Lymphopenia,\r   Leukocytosis, Monocyte count decreased, Neutrophilia, Mean cell haemoglobin\r   concentration increased     Endocrine\r   disorders      Primary\r   hypogonadism     Metabolism and nutrition\r   disorders   Decreased appetite   Hypocalcaemia,\r   Hypokalaemia, Metabolic acidosis, Fluid overload, Fluid retention,\r   Hypomagnesaemia, Hyponatraemia, Hypophosphataemia, Hyperphosphataemia     Psychiatric disorders   Insomnia   Anxiety     Nervous system\r   disorders   Headache   Dizziness, Lethargy,\r   Dysgeusia, Ageusia, Memory impairment     Eye disorders      Conjunctival\r   haemorrhage     Ear and labyrinth\r   disorders      Vertigo     Cardiac disorders      Cardiac failure\r   congestive, Atrial fibrillation      Vascular disorders      Hypotension,\r   Haematoma, Hot flush     Respiratory, thoracic\r   and mediastinal disorders   Epistaxis, Pharyngeal\r   inflammation   Hypoxia, Pulmonary\r   mass, Dyspnoea, Pleural effusion, Rales, Upper-airway cough syndrome, Cough,\r   Laryngeal pain, Hiccups, Oropharyngeal pain      Gastrointestinal\r   disorders   Stomatitis, Vomiting,\r   Nausea, Diarrhoea, Gingival bleeding, Constipation, Abdominal pain, Anal\r   inflammation    Anal haemorrhage,\r   Gastritis, Gastrointestinal inflammation, Abdominal distension, Abdominal\r   pain upper, Anal fissure, Dyspepsia, Dysphagia, Oesophagitis, Haemorrhoids,\r   Proctalgia, Lip dry     Hepatobiliary\r   disorders   Veno\u2011occlusive\r   liver disease, Alanine aminotransferase increased, Aspartate aminotransferase\r   increased, Blood bilirubin increased   Cholecystitis,\r   Cholelithiasis, Hepatomegaly, Jaundice, Transaminases increased,\r   Gamma-glutamyltransferase increased     Skin and subcutaneous\r   tissue disorders   Alopecia, Pruritus,\r   Skin hyperpigmentation   Petechiae,\r   Ecchymosis, Pain of skin, Palpable purpura, Pigmentation disorder, Pruritus\r   generalised, Purpura, Sweat gland disorder, Urticaria, Dry skin, Rash     Musculoskeletal and\r   connective tissue disorders      Bone pain, Myalgia,\r   Pain in extremity, Back pain     Renal and urinary\r   disorders      Haematuria,\r   Pollakiuria     Reproductive system\r   and breast disorders   Vaginal haemorrhage   Ovarian failure,\r   Menstruation irregular, Premature menopause, Blood follicle stimulating\r   hormone increased, Blood testosterone decreased     General disorders and\r   administration site conditions   Pyrexia, Fatigue,\r   Mucosal inflammation   Face oedema,\r   Hypothermia, Feeling cold, Pain, Xerosis     Investigations      C\u2011reactive\r   protein increased, Aspergillus test positive, Blood potassium decreased,\r   Weight decreased, Blood alkaline phosphatase decreased, Blood magnesium\r   decreased, Forced expiratory flow decreased, Protein total decreased, Blood\r   albumin decreased, Reticulocyte count decreased, Reticulocyte percentage\r   decreased     Injury, poisoning and\r   procedural complications      Transfusion reaction,\r   Skin abrasion   ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none\"><\/p>","ID":"4106e060-bf3c-44da-9b2c-4753b3d23d37","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid;\r text-autospace:none\"><b><span style='font-family:\"Times New Roman\",serif'>Table\r 3              Adverse reactions attributed to Zynteglo<\/span><\/b><\/p>","ID":"fec8d8be-44e2-4e6b-8a1a-fb234db2e4c7","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-after:avoid;\r\ntext-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Table\r 3              Adverse reactions attributed to Zynteglo","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"width:451.75pt;border-collapse:collapse;border:none\" width=\"602\"> <tr style=\"height:14.35pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>SOC<\/span><\/b><\/p> <\/td> <td style=\"width:150.6pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Very Common (\u226510%)<\/span><\/b><\/p> <\/td> <td style=\"width:150.6pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Common (\u22651% - &lt;10%)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:9.4pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Blood and lymphatic\r   system disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:9.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:9.4pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Thrombocytopenia, <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Leukopenia,\r   Neutropenia<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Vascular disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Hot flush<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.05pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.05pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Respiratory, thoracic\r   and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.05pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.05pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Dyspnoea<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Gastrointestinal\r   disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Abdominal pain<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Musculoskeletal and\r   connective tissue disorders<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Pain in extremity<\/span><\/p> <\/td> <\/tr> <tr style=\"height:28.5pt\"> <td style=\"width:150.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.5pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>General disorders and\r   administration site conditions<\/span><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:28.5pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p> <\/td> <td style=\"width:150.6pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:28.5pt\" valign=\"top\" width=\"201\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif;color:black'>Non-cardiac chest\r   pain<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"c7598e87-3aa4-4e8e-9eee-bd9e5ceef191","Styles":"width:451.75pt;border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"   SOC   Very Common (\u226510%)   Common (\u22651% - <10%)     Blood and lymphatic\r   system disorders      Thrombocytopenia,  Leukopenia,\r   Neutropenia     Vascular disorders      Hot flush     Respiratory, thoracic\r   and mediastinal disorders      Dyspnoea     Gastrointestinal\r   disorders   Abdominal pain        Musculoskeletal and\r   connective tissue disorders      Pain in extremity     General disorders and\r   administration site conditions      Non-cardiac chest\r   pain   ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none\"><\/p>","ID":"7c76b9d9-b2e8-4165-854d-1cc60723a7fa","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Description of selected adverse reactions<\/span><\/u><\/p>","ID":"bd30ce2d-6f88-458a-8f1b-5992efbea395","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Description of selected adverse reactions","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"2d96950e-cc25-4f98-859f-ee7fabd908fb","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk4059620\"><i><span style=\"font-size:11.0pt\">Bleeding<\/span><\/i><\/a><\/p>","ID":"2ea82a6a-039f-46b7-82b6-6c41a018ed41","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Bleeding","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"e7f7b8ea-6cef-43bf-bf25-e32f487623c2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Bleeding is a potential complication of\r thrombocytopenia subsequent to myeloablative conditioning and treatment with\r Zynteglo. The majority of all reported bleeding events were nonserious. A risk\r of bleeding exists before platelet engraftment and may continue after platelet\r engraftment in patients who have continued thrombocytopenia.   <\/span><\/p>","ID":"be9f3972-196d-45ab-93c8-0ea86207c677","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Bleeding is a potential complication of\r thrombocytopenia subsequent to myeloablative conditioning and treatment with\r Zynteglo. The majority of all reported bleeding events were nonserious. A risk\r of bleeding exists before platelet engraftment and may continue after platelet\r engraftment in patients who have continued thrombocytopenia.   ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"fcb39348-c4d5-491c-a321-8dcb24e01138","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Following platelet engraftment, all patients\r maintained platelet levels of \u226520 \u00d7 10<sup>9<\/sup>\/L. Median\r (min, max) times to unsupported platelet counts of \u226550 \u00d7 10<sup>9<\/sup>\/L \r and \u2265100 \u00d7 10<sup>9<\/sup>\/L were 51 (20, 268) days (N=45) and\r 63.5 (20, 1231) days (N=42), respectively (see section 4.4 for guidance on\r platelet monitoring and management).<\/span><\/p>","ID":"13717b01-7242-46c9-9352-1dfbcf0c2a6a","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following platelet engraftment, all patients\r maintained platelet levels of \u226520 \u00d7 109\/L. Median\r (min, max) times to unsupported platelet counts of \u226550 \u00d7 109\/L \r and \u2265100 \u00d7 109\/L were 51 (20, 268) days (N=45) and\r 63.5 (20, 1231) days (N=42), respectively (see section 4.4 for guidance on\r platelet monitoring and management).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"f0f9b28c-313e-4faf-8744-58be4a55835b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Hepatic veno-occlusive disease<\/span><\/i><\/p>","ID":"d87ca369-b6b4-467c-b356-84e8330e2566","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hepatic veno-occlusive disease","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"1381846f-f0f6-4cf4-b744-95628b336361","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Serious events of hepatic VOD occurred in 11.1% of\r patients following myeloablative conditioning; 80% of these patients did not\r receive prophylaxis for VOD. All patients who experienced VOD received\r treatment with defibrotide and recovered. Patients with TDT may be at an\r increased risk of VOD following myeloablative conditioning compared with other\r patient populations.  <\/span><\/p>","ID":"3ac4d019-0e4c-4d34-8c13-5b587a04e7e7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Serious events of hepatic VOD occurred in 11.1% of\r patients following myeloablative conditioning; 80% of these patients did not\r receive prophylaxis for VOD. All patients who experienced VOD received\r treatment with defibrotide and recovered. Patients with TDT may be at an\r increased risk of VOD following myeloablative conditioning compared with other\r patient populations.  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"0cc14167-f106-49ce-a3dd-6fa08f3b3a37","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\">Infusion related reactions to Zynteglo<\/span><\/i><\/p>","ID":"07f51ade-9193-4d3a-9d44-e17e4b7efbd4","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Infusion related reactions to Zynteglo","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><\/p>","ID":"2146bae8-1504-45ee-9d36-a231ab9f3a99","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Pre-medication for infusion reactions was managed at\r physician discretion. Infusion related reactions to Zynteglo were observed in\r 13.3% of patients and occurred on the day of Zynteglo infusion. All reactions\r resolved and the majority were mild. Events included abdominal pain, dyspnoea,\r hot flush, and non\u2011cardiac chest pain in 11.1%, 2.2%, 2.2%, and 2.2% of\r patients, respectively.  <\/span><\/p>","ID":"0ff0da47-8b4a-4a9e-82fc-e81b85c7e60e","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pre-medication for infusion reactions was managed at\r physician discretion. Infusion related reactions to Zynteglo were observed in\r 13.3% of patients and occurred on the day of Zynteglo infusion. All reactions\r resolved and the majority were mild. Events included abdominal pain, dyspnoea,\r hot flush, and non\u2011cardiac chest pain in 11.1%, 2.2%, 2.2%, and 2.2% of\r patients, respectively.  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"9f3765a1-1ba9-4e9a-b1d3-cf64b2daa804","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/p>","ID":"77c2dbbc-b553-4d41-a6b9-c0c5cb806ee3","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"0d662b7c-10d0-440c-83a8-a46b8b1bbac6","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk3021378\"><\/a><a name=\"_Hlk2980904\"><span style=\"font-size:11.0pt\">According to available data,\r the frequency, type, and severity of adverse reactions in adolescents 12\u201117 years\r of age are similar to adults with the exception that VOD and pyrexia occurred\r more frequently in adolescents.<\/span><\/a><\/p>","ID":"939b27c5-16bc-49ff-a077-a4bf1c1e0abf","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"According to available data,\r the frequency, type, and severity of adverse reactions in adolescents 12\u201117 years\r of age are similar to adults with the exception that VOD and pyrexia occurred\r more frequently in adolescents.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d27ce668-225e-48ea-9bd2-87e5ff62593f","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Reporting of suspected adverse reactions<\/span><\/u><\/p>","ID":"bea30c61-9e2f-49a2-a3f7-e8452465ac1d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse reactions","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"370e0126-e727-4726-ad1f-fa5184b7a814","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Reporting suspected adverse reactions after\r authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:lightgrey\">the national reporting system listed in <span class=\"MsoHyperlink\">Appendix V<\/span>.<\/span><\/span><\/p>","ID":"f4f6a65d-885d-4644-a3d7-5bddd112c9cb","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected adverse reactions after\r authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"447fb3c9-33a4-4efe-991c-ac200c40a370","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.9     Overdose<\/span><\/b><\/p>","ID":"1aa45965-2b7d-4198-8d9b-5da373601461","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"db8c9e13-1807-4ce1-aaad-3595d656fc47","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">No data from clinical studies are available regarding\r overdose of Zynteglo. <\/span><\/p>","ID":"5704627c-242f-4eb3-993b-2e68535cd92e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No data from clinical studies are available regarding\r overdose of Zynteglo. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d88b0646-1331-47f0-8867-abae4995fcaf","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"b0752927-c652-4581-8020-63dbe4f8045d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.       PHARMACOLOGICAL\r PROPERTIES<\/span><\/b><\/p>","ID":"080f46ce-4afe-4ffa-ba00-0b9cd2762445","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.       PHARMACOLOGICAL\r PROPERTIES","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"39aa9a08-ac2a-4ced-8ecc-018812ec3f8e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.1     Pharmacodynamic\r properties<\/span><\/b><\/p>","ID":"9e59892c-bca2-4e02-bdc0-21ad6035f038","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic\r properties","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"0dd242a7-255b-46bb-a718-cb716903a06a","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Pharmacotherapeutic group: Other haematological\r agents, ATC code: B06AX02<\/span><\/p>","ID":"15b52b88-a34c-4c18-9ab0-4e3c36a635a1","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic group: Other haematological\r agents, ATC code: B06AX02","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"e49d6431-73bf-4ed9-9e16-2a3197192ffb","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Mechanism of action<\/span><\/u><\/p>","ID":"138fd905-ddcf-4f19-b3c6-8c9a510b0f9b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Mechanism of action","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"57e772d2-0f5c-45b3-9ab9-8d7305beb3b4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo adds functional copies of a modified\r \u03b2-globin gene into the patients\u2019 HSCs through transduction of autologous\r CD34<sup>+<\/sup> cells with BB305 LVV, thereby addressing the underlying\r genetic cause of the disease. After Zynteglo infusion, transduced CD34<sup>+<\/sup>\r HSCs engraft in the bone marrow and differentiate to produce RBCs containing\r biologically active <span style=\"color:black\">\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r (a modified \u03b2\u2011globin protein) that will combine with \u03b1-globin\r to produce functional Hb containing <\/span>\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r (Hb<span style=\"color:black\">A<sup>T87Q<\/sup>). <\/span>\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r can be quantified relative to other globin species in peripheral blood using\r high performance liquid chromatography.\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r expression is designed to correct the \u03b2\/\u03b1\u2011globin imbalance in\r erythroid cells of patients with TDT and has the potential to increase total Hb\r to normal levels and eliminate dependence on chronic RBC transfusions. <a name=\"_Hlk2981031\">Following successful engraftment and achievement of\r transfusion independence, the effects of the product are expected to be life\u2011long.<\/a><\/span><\/p>","ID":"ec0d065b-2f33-4473-b3a7-478ec1f2b20b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo adds functional copies of a modified\r \u03b2-globin gene into the patients\u2019 HSCs through transduction of autologous\r CD34+ cells with BB305 LVV, thereby addressing the underlying\r genetic cause of the disease. After Zynteglo infusion, transduced CD34+\r HSCs engraft in the bone marrow and differentiate to produce RBCs containing\r biologically active \u03b2A\u2011T87Q\u2011globin\r (a modified \u03b2\u2011globin protein) that will combine with \u03b1-globin\r to produce functional Hb containing \u03b2A\u2011T87Q\u2011globin\r (HbAT87Q). \u03b2A\u2011T87Q\u2011globin\r can be quantified relative to other globin species in peripheral blood using\r high performance liquid chromatography.\u03b2A\u2011T87Q\u2011globin\r expression is designed to correct the \u03b2\/\u03b1\u2011globin imbalance in\r erythroid cells of patients with TDT and has the potential to increase total Hb\r to normal levels and eliminate dependence on chronic RBC transfusions. Following successful engraftment and achievement of\r transfusion independence, the effects of the product are expected to be life\u2011long.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"9c611f74-a624-4d60-b27a-6359810993a1","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Pharmacodynamic effects <\/span><\/u><\/p>","ID":"b4351ab1-030f-421c-9a2f-bf5533b6d331","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pharmacodynamic effects ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"0ef72f1f-2c90-4532-af25-51cdfb0a3381","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients with TDT with a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype\r who received Zynteglo with at least 3 months of follow-up produced HbA<sup>T87Q<\/sup>\r (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15, HGB\u2011207; N=3, HGB\u2011212).\r For patients with at least 6 months of follow-up, HbA<sup>T87Q<\/sup>\r generally increased steadily after Zynteglo infusion and stabilised by\r approximately Month 6. Patients had a Month 6 median (min, max)\r HbA<sup>T87Q<\/sup> of 4.901 (1.03, 9.59) g\/dL in the Phase 1\/2\r studies (N=14, HGB\u2011204 and HGB\u2011205) and 9.409 (3.35, 10.60) g\/dL\r in ongoing Phase 3 studies (N=16, HGB\u2011207 and HGB-212).  <\/span><\/p>","ID":"99ab06e5-8ece-4db1-a73b-d16e15c619b7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"All patients with TDT with a non\u2011\u03b20\/\u03b20 genotype\r who received Zynteglo with at least 3 months of follow-up produced HbAT87Q\r (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15, HGB\u2011207; N=3, HGB\u2011212).\r For patients with at least 6 months of follow-up, HbAT87Q\r generally increased steadily after Zynteglo infusion and stabilised by\r approximately Month 6. Patients had a Month 6 median (min, max)\r HbAT87Q of 4.901 (1.03, 9.59) g\/dL in the Phase 1\/2\r studies (N=14, HGB\u2011204 and HGB\u2011205) and 9.409 (3.35, 10.60) g\/dL\r in ongoing Phase 3 studies (N=16, HGB\u2011207 and HGB-212).  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"c7504f76-4614-417e-80c2-86ad48bbd37e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HbA<sup>T87Q<\/sup> remained generally stable through\r Month 24 with a median (min, max) of\r 6.444 (1.10, 10.13) g\/dL in the completed Phase 1\/2 studies (N=14,\r HGB\u2011204 and HGB\u2011205) and 8.766 (0.89, 11.40) g\/dL in\r the ongoing Phase 3 studies (N=3, HGB\u2011207). HbA<sup>T87Q<\/sup> continued\r to be stable at last follow-up through Month 60, demonstrating stable\r integration of the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin gene into long\u2011term\r HSCs and stable expression of the \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin\r gene in cells of the erythroid lineage. <a name=\"IDX\"><\/a><\/span><\/p>","ID":"ab368760-f302-441b-8243-a4a63e43feab","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"HbAT87Q remained generally stable through\r Month 24 with a median (min, max) of\r 6.444 (1.10, 10.13) g\/dL in the completed Phase 1\/2 studies (N=14,\r HGB\u2011204 and HGB\u2011205) and 8.766 (0.89, 11.40) g\/dL in\r the ongoing Phase 3 studies (N=3, HGB\u2011207). HbAT87Q continued\r to be stable at last follow-up through Month 60, demonstrating stable\r integration of the \u03b2A\u2011T87Q\u2011globin gene into long\u2011term\r HSCs and stable expression of the \u03b2A\u2011T87Q\u2011globin\r gene in cells of the erythroid lineage. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><\/p>","ID":"fb04698b-e7ca-4772-b86c-3f7380df78cb","Styles":"margin-bottom:0in;line-height:normal;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><a name=\"_Hlk535595211\"><u><span style=\"font-size:11.0pt\">Clinical efficacy <\/span><\/u><\/a><\/p>","ID":"fde4c6fd-1c2c-4334-be61-0db9148c7e0c","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Clinical efficacy ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><\/p>","ID":"e130012c-8d71-4b78-85fa-ca0bb479b3aa","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Efficacy was based on 32 adult and adolescent\r patients with TDT and a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype treated with Zynteglo (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15,\r HGB\u2011207; N=3, HGB\u2011212) (see Table 4). <a name=\"_Hlk2977601\">A few\r patients have been included in the clinical studies with genotypes\r characterised by low endogenous \u03b2\u2011globin production phenotypically\r similar to patients with a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype, such\r as patients homozygous for IVS\u2011I\u2011110 or IVS\u2011I\u20115. <\/a><\/span><\/p>","ID":"3bc602a6-19b3-4845-bbcd-6a677ba8af18","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Efficacy was based on 32 adult and adolescent\r patients with TDT and a non\u2011\u03b20\/\u03b20\r genotype treated with Zynteglo (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15,\r HGB\u2011207; N=3, HGB\u2011212) (see Table 4). A few\r patients have been included in the clinical studies with genotypes\r characterised by low endogenous \u03b2\u2011globin production phenotypically\r similar to patients with a \u03b20\/\u03b20 genotype, such\r as patients homozygous for IVS\u2011I\u2011110 or IVS\u2011I\u20115. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"dd073183-d60b-47f0-858f-8a14597d06cd","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal\"><b><span style=\"font-size:11.0pt\">Table 4              Baseline characteristics for non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r patients with TDT \u226512 years of age treated with Zynteglo (Studies HGB\u2011204,\r HGB\u2011205, HGB\u2011207, HGB\u2011212, LTF\u2011303)          <\/span><\/b><\/p>","ID":"5b6564ae-fd45-4747-9d52-8b47c62bdb5b","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal","Classes":"['C-BodyText']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Table 4              Baseline characteristics for non\u2011\u03b20\/\u03b20\r patients with TDT \u226512 years of age treated with Zynteglo (Studies HGB\u2011204,\r HGB\u2011205, HGB\u2011207, HGB\u2011212, LTF\u2011303)          ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal\"><\/p>","ID":"68f8b4eb-9249-4cda-bac4-9dcbc8fc4337","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\"> <tr style=\"height:48.6pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><b><span style=\"font-size:11.0pt\">Study<\/span><\/b><\/p> <\/td> <td style=\"width:76.65pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Total number\r   of patients <\/span><\/b><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">(young adults\/ adolescents)<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><\/p> <\/td> <td style=\"width:67.6pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><b><span style=\"font-size:11.0pt\">Age<\/span><\/b><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(years)<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">median (min, max)<\/span><\/p> <\/td> <td style=\"width:121.85pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><b><span style=\"font-size:11.0pt\">Pre-enrolment\r   transfusion volumes<\/span><\/b><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(mL\/kg\/year)<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">median (min, max)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:48.6pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><b><span style=\"font-size:11.0pt\">Pre-enrolment\r   transfusion frequency<\/span><\/b><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(number\/year)<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">median (min, max)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:11.9pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011205<\/span><\/p> <\/td> <td style=\"width:76.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">4<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(2)<\/span><\/p> <\/td> <td style=\"width:67.6pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>young\r   adults\/ adolescents*<\/span><\/p> <\/td> <td style=\"width:121.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>181.85<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(138.8,\r   197.3)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>12.50<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(10.5,\r   13.0) <\/span><\/p> <\/td> <\/tr> <tr style=\"height:11.9pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011204<\/span><\/p> <\/td> <td style=\"width:76.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">10<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(2)<\/span><\/p> <\/td> <td style=\"width:67.6pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>19.5<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(16, 34)<\/span><\/p> <\/td> <td style=\"width:121.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>151.28<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(140.0, 234.5)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>13.75<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(10.0, 16.5)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:11.9pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011207<\/span><\/p> <\/td> <td style=\"width:76.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">15<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(6)<\/span><\/p> <\/td> <td style=\"width:67.6pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>20.0<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(12, 34)<\/span><\/p> <\/td> <td style=\"width:121.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>192.92<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(152.3, 251.3)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.9pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>17.50<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(11.5, 37.0)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:12.3pt\"> <td style=\"width:62.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"83\"> <p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011212<\/span><\/p> <\/td> <td style=\"width:76.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">3<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(1)<\/span><\/p> <\/td> <td style=\"width:67.6pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span lang=\"PT\">adults\/ adolescents*<\/span><\/p> <\/td> <td style=\"width:121.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>175.51<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(170.7, 209.6)<\/span><\/p> <\/td> <td style=\"width:125.15pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.3pt\" valign=\"top\" width=\"167\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>21.50<\/span><\/p> <p align=\"center\" class=\"C-BodyText\" style=\"margin:0in;text-align:center;\r   line-height:normal\"><span style=\"font-size:11.0pt\">(17.5, 39.5)<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"e67abf3a-51fa-43b8-8983-d00295a2ddb8","Styles":"border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"   Study   Total number\r   of patients  (young adults\/ adolescents)    Age (years) median (min, max)   Pre-enrolment\r   transfusion volumes (mL\/kg\/year) median (min, max)   Pre-enrolment\r   transfusion frequency (number\/year) median (min, max)     HGB\u2011205   4 (2)   young\r   adults\/ adolescents*   181.85 (138.8,\r   197.3)   12.50 (10.5,\r   13.0)      HGB\u2011204   10 (2)   19.5 (16, 34)   151.28 (140.0, 234.5)   13.75 (10.0, 16.5)     HGB\u2011207   15 (6)   20.0 (12, 34)   192.92 (152.3, 251.3)   17.50 (11.5, 37.0)     HGB\u2011212   3 (1)   adults\/ adolescents*   175.51 (170.7, 209.6)   21.50 (17.5, 39.5)   ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">*Age range is not provided to protect patient identity.<\/span><\/p>","ID":"100c83c3-4561-46f5-a17b-7dbc479ee1a2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"*Age range is not provided to protect patient identity.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"14c459d2-4621-4996-9b2e-1e6742ac8a83","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Transfusion\u2011dependent \u03b2\u2011thalassaemia\r (TDT)<\/span><\/i><\/p>","ID":"7472efde-f387-40f9-a505-a9f2cc627fa1","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Transfusion\u2011dependent \u03b2\u2011thalassaemia\r (TDT)","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk2977740\"><\/a><\/p>","ID":"b5657c3b-7792-4734-9150-5efe97111174","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Patients were considered to be transfusion\u2011dependent\r if they had a history of transfusions of at least 100 mL\/kg\/year of RBCs\r or with \u22658 transfusions of RBCs per year in the 2 years\r preceding enrolment. In the clinical studies, patients received a median (min,\r max) RBC transfusion volume of 175.74 (138.8, 251.3) mL\/kg\/year\r and a median (min, max) number of 14.75 (10.0, 39.5) RBC\r transfusions per year. <\/span><\/p>","ID":"18243c44-6063-45ab-87d9-f354a1bd2936","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Patients were considered to be transfusion\u2011dependent\r if they had a history of transfusions of at least 100 mL\/kg\/year of RBCs\r or with \u22658 transfusions of RBCs per year in the 2 years\r preceding enrolment. In the clinical studies, patients received a median (min,\r max) RBC transfusion volume of 175.74 (138.8, 251.3) mL\/kg\/year\r and a median (min, max) number of 14.75 (10.0, 39.5) RBC\r transfusions per year. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"11924a8b-0b8d-4125-84a2-d6c45c6d7893","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Adolescents were excluded from Phase 3 studies if\r they had a known and available HLA\u2011matched related HSC donor. The median\r (min, max) age in the studies was 19.0 (12, 34) years, 56.3% were\r females, 59.4% were Asian, and 40.6% White\/Caucasian. All patients had a\r Karnofsky\/Lansky performance score \u226580 and the majority (18\/32, 56.3%)\r had a performance score of 100 at baseline. Cardiac T2* at baseline was &gt;20\r msec. The median (min, max) serum ferritin at baseline was 3778.7 (784, 22517)\r pmol\/L and median (min, max) liver iron concentration was 6.75 (1.0, 41.0) mg\/g\r (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15, HGB\u2011207; N=3, HGB\u2011212).<\/span><\/p>","ID":"287bd7c6-c270-4505-af97-4b6b6bf60a34","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adolescents were excluded from Phase 3 studies if\r they had a known and available HLA\u2011matched related HSC donor. The median\r (min, max) age in the studies was 19.0 (12, 34) years, 56.3% were\r females, 59.4% were Asian, and 40.6% White\/Caucasian. All patients had a\r Karnofsky\/Lansky performance score \u226580 and the majority (18\/32, 56.3%)\r had a performance score of 100 at baseline. Cardiac T2* at baseline was >20\r msec. The median (min, max) serum ferritin at baseline was 3778.7 (784, 22517)\r pmol\/L and median (min, max) liver iron concentration was 6.75 (1.0, 41.0) mg\/g\r (N=10, HGB\u2011204; N=4, HGB\u2011205; N=15, HGB\u2011207; N=3, HGB\u2011212).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d234f1a9-4bb6-494c-991f-87ba1f05de4b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Mobilisation and apheresis<\/span><\/i><\/p>","ID":"e9b7cf69-f02f-4802-a39d-36309de3fdb9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Mobilisation and apheresis","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk433984\"><\/a><\/p>","ID":"3ce7cb7a-53f5-4201-aea9-8dcd4e811423","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients were administered G\u2011CSF and\r plerixafor to mobilise stem cells prior to the apheresis procedure. The planned\r dose of G\u2011CSF was 10 \u00b5g\/kg\/day in patients with a spleen, and 5 \u00b5g\/kg\/day\r in patients without a spleen, given on Days 1 through 5 of\r mobilisation in the morning. The planned dose of plerixafor was\r 0.24 mg\/kg\/day, given on Days 4 and 5 of mobilisation in the\r evening. If a third day of collection was needed, plerixafor and G\u2011CSF\r dosing was extended to Day 6. The dose of G\u2011CSF was decreased by\r half if white blood cell (WBC) count was &gt;100 \u00d7 10<sup>9<\/sup>\/L\r prior to the day of apheresis. For most patients, the minimum number of CD34<sup>+<\/sup>\r cells to manufacture Zynteglo was collected with 1 cycle of mobilisation\r and apheresis. <\/span><\/p>","ID":"aecd7431-c33f-406d-a53e-25016ee26b96","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"All patients were administered G\u2011CSF and\r plerixafor to mobilise stem cells prior to the apheresis procedure. The planned\r dose of G\u2011CSF was 10 \u00b5g\/kg\/day in patients with a spleen, and 5 \u00b5g\/kg\/day\r in patients without a spleen, given on Days 1 through 5 of\r mobilisation in the morning. The planned dose of plerixafor was\r 0.24 mg\/kg\/day, given on Days 4 and 5 of mobilisation in the\r evening. If a third day of collection was needed, plerixafor and G\u2011CSF\r dosing was extended to Day 6. The dose of G\u2011CSF was decreased by\r half if white blood cell (WBC) count was >100 \u00d7 109\/L\r prior to the day of apheresis. For most patients, the minimum number of CD34+\r cells to manufacture Zynteglo was collected with 1 cycle of mobilisation\r and apheresis. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d9f2dd05-c98e-48f7-bc40-bcc1156fd332","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\">Pre-treatment conditioning<\/span><\/i><\/p>","ID":"7aa53032-3439-400b-82cb-d77bd59f9faf","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Pre-treatment conditioning","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><\/p>","ID":"da18dcf1-fb81-41eb-8c19-13766c9aea38","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><span style=\"font-size:11.0pt\">All patients received full myeloablative conditioning\r with busulfan prior to treatment with Zynteglo. The planned dose of busulfan\r was 3.2 mg\/kg\/day for patients \u226518 years as a 3\u2011hour IV\r infusion daily for 4 days with a recommended target AUC<sub>0-24h <\/sub>of\r 3800\u20114500 \u00b5M*min. The planned dose of busulfan was 0.8 mg\/kg\r for patients 12\u201117 years of age as a 2\u2011hour IV infusion every\r 6 hours for a total of 16 doses with a recommended target of AUC<sub>0-6h\r <\/sub>of 950\u20111125 \u00b5M*min. The busulfan SmPC was used for information\r on appropriate method for determination of patient weight\u2011based dosing. <a name=\"_Hlk2978225\">Busulfan dose adjustments were made as needed based on\r pharmacokinetic monitoring.<\/a><\/span><\/p>","ID":"4ed0a54c-9ae6-4284-b8ed-5cdb3184cc69","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"All patients received full myeloablative conditioning\r with busulfan prior to treatment with Zynteglo. The planned dose of busulfan\r was 3.2 mg\/kg\/day for patients \u226518 years as a 3\u2011hour IV\r infusion daily for 4 days with a recommended target AUC0-24h of\r 3800\u20114500 \u00b5M*min. The planned dose of busulfan was 0.8 mg\/kg\r for patients 12\u201117 years of age as a 2\u2011hour IV infusion every\r 6 hours for a total of 16 doses with a recommended target of AUC0-6h\r of 950\u20111125 \u00b5M*min. The busulfan SmPC was used for information\r on appropriate method for determination of patient weight\u2011based dosing. Busulfan dose adjustments were made as needed based on\r pharmacokinetic monitoring.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"50d0d158-24ac-47ee-9871-5f2306fa0e66","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The median (min, max) busulfan dose was 3.50 (2.5, 5.0)\r mg\/kg\/day (N=32). AUC<sub>0-24h<\/sub> was measured during Day 1 and\r informed the dose for Day 3; the median (min, max) estimated daily AUC was\r 4394.5 (3030, 9087) \u03bcM*min (N=32). All patients with non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotypes received anti-seizure prophylaxis with agents other than phenytoin\r prior to initiating busulfan. Phenytoin was not used for anti-seizure\r prophylaxis because of its well understood induction of glutathione\u2011S\u2011transferase\r and cytochrome P450 and resultant increased clearance of busulfan, and because\r of the widespread availability of effective anti\u2011seizure medications that\r do not affect busulfan metabolism.<\/span><\/p>","ID":"40a84cc1-29b7-4b03-a911-f062a4d630f4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The median (min, max) busulfan dose was 3.50 (2.5, 5.0)\r mg\/kg\/day (N=32). AUC0-24h was measured during Day 1 and\r informed the dose for Day 3; the median (min, max) estimated daily AUC was\r 4394.5 (3030, 9087) \u03bcM*min (N=32). All patients with non\u2011\u03b20\/\u03b20\r genotypes received anti-seizure prophylaxis with agents other than phenytoin\r prior to initiating busulfan. Phenytoin was not used for anti-seizure\r prophylaxis because of its well understood induction of glutathione\u2011S\u2011transferase\r and cytochrome P450 and resultant increased clearance of busulfan, and because\r of the widespread availability of effective anti\u2011seizure medications that\r do not affect busulfan metabolism.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"53163680-24b3-405b-a30c-c68acb2c8d35","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">In HGB\u2011207 and HGB\u2011212 prophylaxis for\r VOD\/hepatic sinusoidal obstruction syndrome was required per institutional\r practice with ursodeoxycholic acid or defibrotide. <\/span><\/p>","ID":"30fa9782-2e4e-4226-b517-35b4e5705713","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In HGB\u2011207 and HGB\u2011212 prophylaxis for\r VOD\/hepatic sinusoidal obstruction syndrome was required per institutional\r practice with ursodeoxycholic acid or defibrotide. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"4b07e1d2-7c55-46f6-892b-47fa3bb2f3ee","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Zynteglo administration<\/span><\/i><\/p>","ID":"8d0beed3-cf51-4575-9f51-44fb43154310","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Zynteglo administration","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"17782652-1c66-495e-93e3-70e1a2e43c88","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients were administered Zynteglo with a median\r (min, max) dose of 7.80 \u00d7 10<sup>6 <\/sup>(5.0, 19.4) CD34<sup>+<\/sup> cells\/kg\r as an intravenous infusion (N=32).<\/span><\/p>","ID":"f82d6e0d-47e5-47ae-90b6-4e46854b7ad0","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"All patients were administered Zynteglo with a median\r (min, max) dose of 7.80 \u00d7 106 (5.0, 19.4) CD34+ cells\/kg\r as an intravenous infusion (N=32).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"34278651-2b06-4532-88e5-a7025944190e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk956286\"><\/a><a name=\"_Hlk955665\"><i><span style=\"font-size:11.0pt\">After Zynteglo\r administration<\/span><\/i><\/a><\/p>","ID":"4b224c8e-1c64-4bc3-81c8-9a7bb2ffb256","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"After Zynteglo\r administration","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"073c7656-ea7b-4868-8c1e-77f45f661435","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">A total of 31.1% of patients (14\/45; HGB\u2011204,\r HGB\u2011205, HGB\u2011207, HGB\u2011212) received G\u2011CSF within\r 21 days after Zynteglo infusion<\/span><span style=\"font-size:11.0pt\">.\r However, G\u2011CSF use was not recommended for 21 days after Zynteglo\r infusion in Phase 3 studies.<\/span><\/p>","ID":"f4677155-a0aa-4537-9564-97b610371c5c","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"A total of 31.1% of patients (14\/45; HGB\u2011204,\r HGB\u2011205, HGB\u2011207, HGB\u2011212) received G\u2011CSF within\r 21 days after Zynteglo infusion.\r However, G\u2011CSF use was not recommended for 21 days after Zynteglo\r infusion in Phase 3 studies.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"fe340513-e1bb-489b-b52f-8762dd118354","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Studies HGB\u2011204 and HGB\u2011205<\/span><\/u><\/p>","ID":"0ac2b8f5-53d9-4a54-928f-0d529a89dc90","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Studies HGB\u2011204 and HGB\u2011205","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"8483e564-45b7-4d21-a316-9e2bda084a93","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">HGB\u2011204 and HGB\u2011205 were Phase 1\/2\r open-label, single-arm 24\u2011month studies that included 22 patients\r with TDT treated with Zynteglo (N=18, HGB\u2011204; N=4, HGB\u2011205), of\r whom 14 had a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype (N=10,\r HGB\u2011204; N=4, HGB\u2011205) and 8 had a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype in HGB\u2011204. All patients completed HGB\u2011204 and HGB\u2011205\r and enrolled for long\u2011term follow\u2011up in the LTF\u2011303 study.\r The median (min, max) duration of follow-up of patients with a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype was 44.63 (35.8, 61.3)months.\r <a name=\"_Hlk4078994\">All patients remain alive at last follow-up.   <\/a><\/span><\/p>","ID":"e77d8968-7501-4957-877f-27c41f198dc5","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"HGB\u2011204 and HGB\u2011205 were Phase 1\/2\r open-label, single-arm 24\u2011month studies that included 22 patients\r with TDT treated with Zynteglo (N=18, HGB\u2011204; N=4, HGB\u2011205), of\r whom 14 had a non\u2011\u03b20\/\u03b20 genotype (N=10,\r HGB\u2011204; N=4, HGB\u2011205) and 8 had a \u03b20\/\u03b20\r genotype in HGB\u2011204. All patients completed HGB\u2011204 and HGB\u2011205\r and enrolled for long\u2011term follow\u2011up in the LTF\u2011303 study.\r The median (min, max) duration of follow-up of patients with a non\u2011\u03b20\/\u03b20\r genotype was 44.63 (35.8, 61.3)months.\r All patients remain alive at last follow-up.   ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"455c1a8a-88be-4fb2-ab04-a5f52dd01729","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The primary endpoint was transfusion independence (TI)\r by Month 24, defined as a weighted average Hb \u22659 g\/dL\r without any RBC transfusions for a continuous period of \u226512 months\r at any time during the study after infusion of Zynteglo. Of the patients with a\r non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> genotype, 11\/14 (78.6%, 95%\r CI 49.2%\u201195.3%) achieved TI by Month 24 (Table 5). Among these\r 11 patients, the median (min, max) weighted average Hb during TI was 10.51 (9.3, 13.3) g\/dL\r (Table 5). <\/span><\/p>","ID":"91a79d1e-13c3-4ae7-8142-072c8d29939b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The primary endpoint was transfusion independence (TI)\r by Month 24, defined as a weighted average Hb \u22659 g\/dL\r without any RBC transfusions for a continuous period of \u226512 months\r at any time during the study after infusion of Zynteglo. Of the patients with a\r non\u2011\u03b20\/\u03b20 genotype, 11\/14 (78.6%, 95%\r CI 49.2%\u201195.3%) achieved TI by Month 24 (Table 5). Among these\r 11 patients, the median (min, max) weighted average Hb during TI was 10.51 (9.3, 13.3) g\/dL\r (Table 5). ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"ed3868ed-2bf3-48cd-8877-694dbbfc71e9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients who have achieved TI at any time have\r maintained TI at Month 36 with a min, max duration of TI of 28.3+, 57.6+ months\r (N=11). The median (min, max) time to last RBC transfusion was\r 0.46 (0.2, 5.8)months\r following Zynteglo infusion. <\/span><\/p>","ID":"6c0dc1c9-1668-4257-b3c7-30453dda5888","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"All patients who have achieved TI at any time have\r maintained TI at Month 36 with a min, max duration of TI of 28.3+, 57.6+ months\r (N=11). The median (min, max) time to last RBC transfusion was\r 0.46 (0.2, 5.8)months\r following Zynteglo infusion. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"7cefc5a6-2497-4626-b216-fbbc169b4db0","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">In the 3 patients who did not achieve TI, reductions\r of 100%, 86.9% and 26.8% in transfusion volume requirements and of 100%, 85.3%\r and 20.7% in transfusion frequency were observed between Month 6 through\r Month 24 visit when compared to their pre-study levels of RBC\r transfusions. Reductions in volume and frequency were maintained at last follow\u2011up\r in LTF\u2011303.<\/span><\/p>","ID":"2f64c2c4-578d-4741-a5a5-486ed6c79495","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In the 3 patients who did not achieve TI, reductions\r of 100%, 86.9% and 26.8% in transfusion volume requirements and of 100%, 85.3%\r and 20.7% in transfusion frequency were observed between Month 6 through\r Month 24 visit when compared to their pre-study levels of RBC\r transfusions. Reductions in volume and frequency were maintained at last follow\u2011up\r in LTF\u2011303.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d4548d25-f260-4160-88be-ad5afc6dcf43","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The median (min, max) total Hb at Month 6 for\r patients who had not received a transfusion for the prior 60 days was\r 10.60 (7.6, 13.4) g\/dL (N=11). Total Hb remained stable at\r Month 24 with a median (min, max) of 10.60 (8.8, 13.7) g\/dL\r (N=12) and at Month 36 with a median (min, max) of\r 10.60 (7.8, 13.5) g\/dL (N=13). <\/span><\/p>","ID":"0fbee733-0eb7-4c90-bac9-7024aeec7c9f","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The median (min, max) total Hb at Month 6 for\r patients who had not received a transfusion for the prior 60 days was\r 10.60 (7.6, 13.4) g\/dL (N=11). Total Hb remained stable at\r Month 24 with a median (min, max) of 10.60 (8.8, 13.7) g\/dL\r (N=12) and at Month 36 with a median (min, max) of\r 10.60 (7.8, 13.5) g\/dL (N=13). ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"1444bab9-a56b-4d82-aa70-de30787dd409","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoCommentText\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>After Zynteglo\r infusion, patient iron chelation was managed at physician discretion. Of the\r 14 non\u2011\u03b2<sup>0\/<\/sup>\u03b2<sup>0<\/sup> patients treated in HGB\u2011204\r and HGB\u2011205 that completed Month 6, 9 patients (64.3%) reported\r ongoing chelation use at last follow-up. The remaining 5 patients (35.7%)\r had stopped iron chelation, of whom 4 patients (28.6%) have stopped\r chelation for at least 6 months with median (min, max) time from stopping\r chelation to last follow-up of 26.40 (11.5, 42.2) months for these\r 4 patients. Additionally, of the 14 treated patients, 3 patients\r in HGB\u2011205 (21.4%) received phlebotomy to remove iron. For the\r 11 patients that achieved TI, 4 patients (36.4%) stopped chelation for at\r least 6 months and 3 patients (27.3%) received phlebotomy.<\/span><\/p>","ID":"448fa2f4-87e4-4c79-9507-ab11978c8306","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoCommentText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After Zynteglo\r infusion, patient iron chelation was managed at physician discretion. Of the\r 14 non\u2011\u03b20\/\u03b20 patients treated in HGB\u2011204\r and HGB\u2011205 that completed Month 6, 9 patients (64.3%) reported\r ongoing chelation use at last follow-up. The remaining 5 patients (35.7%)\r had stopped iron chelation, of whom 4 patients (28.6%) have stopped\r chelation for at least 6 months with median (min, max) time from stopping\r chelation to last follow-up of 26.40 (11.5, 42.2) months for these\r 4 patients. Additionally, of the 14 treated patients, 3 patients\r in HGB\u2011205 (21.4%) received phlebotomy to remove iron. For the\r 11 patients that achieved TI, 4 patients (36.4%) stopped chelation for at\r least 6 months and 3 patients (27.3%) received phlebotomy.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"365a15fb-a44c-45b1-9d52-d1302124c372","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk4398701\"><span style=\"font-size:11.0pt\">At 48 months after infusion of Zynteglo for\r patients who achieved TI, the median reduction (min, max) in serum ferritin\r levels from baseline was 70.00% (39.2, 84.8) (N=5, HGB\u2011204;\r N=2, HGB\u2011205). The median reduction in liver iron content from baseline\r was 62.50%, ranging from an 83.3% reduction to a 269.2% increase (N=5, HGB\u2011204;\r N=2, HGB\u2011205).<\/span><\/a><\/p>","ID":"0fd10348-9d31-4f27-b8d6-43382dc43ebf","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"At 48 months after infusion of Zynteglo for\r patients who achieved TI, the median reduction (min, max) in serum ferritin\r levels from baseline was 70.00% (39.2, 84.8) (N=5, HGB\u2011204;\r N=2, HGB\u2011205). The median reduction in liver iron content from baseline\r was 62.50%, ranging from an 83.3% reduction to a 269.2% increase (N=5, HGB\u2011204;\r N=2, HGB\u2011205).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"41418999-cba7-4153-8b11-6f3260c9c3ef","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Studies HGB\u2011207 and HGB\u2011212<\/span><\/u><\/p>","ID":"1a73fa7e-370f-47c7-b91e-2d5b1874f1e9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Studies HGB\u2011207 and HGB\u2011212","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"e8a8448a-5def-4654-b08f-1c59839ccdeb","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk774161\"><span style=\"font-size:11.0pt\">HGB\u2011207 and HGB\u2011212 are ongoing\r Phase 3 open\u2011label, single-arm 24\u2011month studies that are\r planned to include approximately 39 adults, adolescents, and children with\r TDT (N=23, HGB\u2011207; N=16, HGB\u2011212), of whom 29 have a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype (N=23, HGB\u2011207; N=6, HGB\u2011212) and 10 have a \u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype in HGB\u2011212. <\/span><\/a><span style=\"font-size:11.0pt\">These\r studies are conducted with improved transduction compared to Phase 1\/2\r studies, resulting in increased average number of functional copies of the\r transgene (\u03b2<sup>A\u2011T87Q<\/sup>\u2011globin) integrated in the\r autologous CD34<sup>+<\/sup> cells. <a name=\"_Hlk4244937\">Eighteen adults and\r adolescents with TDT with a non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r genotype have been treated with Zynteglo in Phase 3 studies (N=15, HGB\u2011207; N=3, HGB\u2011212)\r and their median (min, max) duration of follow-up was\r 15.92 (5.6, 26.3) months.<\/a> <a name=\"_Hlk4079020\">All patients\r remain alive at last follow\u2011up.<\/a><\/span><\/p>","ID":"c97fbfb4-91e0-40cc-80dd-5a1ebf8a368c","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"HGB\u2011207 and HGB\u2011212 are ongoing\r Phase 3 open\u2011label, single-arm 24\u2011month studies that are\r planned to include approximately 39 adults, adolescents, and children with\r TDT (N=23, HGB\u2011207; N=16, HGB\u2011212), of whom 29 have a non\u2011\u03b20\/\u03b20\r genotype (N=23, HGB\u2011207; N=6, HGB\u2011212) and 10 have a \u03b20\/\u03b20\r genotype in HGB\u2011212. These\r studies are conducted with improved transduction compared to Phase 1\/2\r studies, resulting in increased average number of functional copies of the\r transgene (\u03b2A\u2011T87Q\u2011globin) integrated in the\r autologous CD34+ cells. Eighteen adults and\r adolescents with TDT with a non\u2011\u03b20\/\u03b20\r genotype have been treated with Zynteglo in Phase 3 studies (N=15, HGB\u2011207; N=3, HGB\u2011212)\r and their median (min, max) duration of follow-up was\r 15.92 (5.6, 26.3) months. All patients\r remain alive at last follow\u2011up.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"77f24675-d903-439d-8b6f-b4aa3a61e7b7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The primary endpoint was transfusion independence (TI)\r by Month 24, defined as a weighted average Hb \u22659 g\/dL without\r any RBC transfusions for a continuous period of \u226512 months at any\r time during the study after infusion of Zynteglo. Ten patients are evaluable\r for assessment of TI. Of these, 9\/10 (90.0%, 95% CI 55.5\u201199.7%)\r achieved TI at last follow\u2011up. Among these 9 patients, the median\r (min, max) weighted average Hb during TI was 12.22 (11.4, 12.8) g\/dL\r (Table 5). <\/span><\/p>","ID":"746d45ae-6131-4e12-8e7d-5f21b2343426","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The primary endpoint was transfusion independence (TI)\r by Month 24, defined as a weighted average Hb \u22659 g\/dL without\r any RBC transfusions for a continuous period of \u226512 months at any\r time during the study after infusion of Zynteglo. Ten patients are evaluable\r for assessment of TI. Of these, 9\/10 (90.0%, 95% CI 55.5\u201199.7%)\r achieved TI at last follow\u2011up. Among these 9 patients, the median\r (min, max) weighted average Hb during TI was 12.22 (11.4, 12.8) g\/dL\r (Table 5). ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"4173b736-b996-4bd4-9f4f-b75d46c5cd50","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">All patients who have achieved TI have maintained TI\r with a min, max duration of TI of 12.1+, 21.3+ months (N=9). The\r median (min, max) time to last RBC transfusion was\r 1.08 (0.5, 2.2) months following Zynteglo infusion. <\/span><\/p>","ID":"0a03fc7b-b633-45ec-8c78-c359d1c364e5","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"All patients who have achieved TI have maintained TI\r with a min, max duration of TI of 12.1+, 21.3+ months (N=9). The\r median (min, max) time to last RBC transfusion was\r 1.08 (0.5, 2.2) months following Zynteglo infusion. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"9664139d-1edf-4090-9ee2-e54b63b775f8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk517114053\"><span style=\"font-size:11.0pt\">For the only patient who\r did not achieve TI, a reduction of 51.5% in transfusion volume requirements and\r a reduction of 43.4% in transfusion frequency were observed from Month 12 to\r Month 24 when compared to their pre-study levels of RBC transfusions. <\/span><\/a><\/p>","ID":"1898d523-7a5c-48b5-b3af-4cee5255ef60","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the only patient who\r did not achieve TI, a reduction of 51.5% in transfusion volume requirements and\r a reduction of 43.4% in transfusion frequency were observed from Month 12 to\r Month 24 when compared to their pre-study levels of RBC transfusions. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"f1cd738a-6840-460a-b4af-424f6542216d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The median (min, max) total Hb at Month 6 for\r patients who had not received a transfusion for the prior 60 days was 11.85 (8.4, 13.3) g\/dL\r (N=18). Total Hb remained stable at Month 24 with a median (min, max) of\r 12.85 (12.5, 13.2) g\/dL (N=2).<\/span><\/p>","ID":"089a2d91-cb8f-45bd-a746-6e7e39832933","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The median (min, max) total Hb at Month 6 for\r patients who had not received a transfusion for the prior 60 days was 11.85 (8.4, 13.3) g\/dL\r (N=18). Total Hb remained stable at Month 24 with a median (min, max) of\r 12.85 (12.5, 13.2) g\/dL (N=2).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"5ad349f8-c126-4d7c-a1df-bc03705735ab","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Hlk536092762\"><span style=\"font-size:11.0pt\">After Zynteglo infusion,\r patient iron chelation was managed at physician discretion. Of the 18 non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup>\r patients treated in HGB\u2011207 and HGB\u2011212 that completed\r Month 6, 5 patients (27.8%) reported ongoing chelation use at last\r follow-up. The remaining 13 patients (72.2%) had stopped iron chelation,\r of whom 9 patients (50.0%) have stopped chelation for at least\r 6 months with median (min, max) time from stopping chelation to last\r follow-up of 16.89 (6.9, 25.4) months for these 9 patients.\r Additionally, of the 18 treated patients, 5 patients in HGB\u2011207\r (27.8%) received phlebotomy to remove iron. For the 9 patients that\r achieved TI, 6 patients (66.7%) stopped chelation for at least\r 6 months and 2 patients (22.2%) received phlebotomy.<\/span><\/a><\/p>","ID":"9d956a27-0089-4ce8-a3b6-ceee841bdbcc","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After Zynteglo infusion,\r patient iron chelation was managed at physician discretion. Of the 18 non\u2011\u03b20\/\u03b20\r patients treated in HGB\u2011207 and HGB\u2011212 that completed\r Month 6, 5 patients (27.8%) reported ongoing chelation use at last\r follow-up. The remaining 13 patients (72.2%) had stopped iron chelation,\r of whom 9 patients (50.0%) have stopped chelation for at least\r 6 months with median (min, max) time from stopping chelation to last\r follow-up of 16.89 (6.9, 25.4) months for these 9 patients.\r Additionally, of the 18 treated patients, 5 patients in HGB\u2011207\r (27.8%) received phlebotomy to remove iron. For the 9 patients that\r achieved TI, 6 patients (66.7%) stopped chelation for at least\r 6 months and 2 patients (22.2%) received phlebotomy.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"> <\/p>","ID":"d6668818-a335-4794-86e2-224942d1b5c6","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Exploratory analyses were performed to evaluate\r resolution of dyserythropoiesis, the fundamental pathophysiological\r characteristic of TDT, in the bone marrow. Bone marrow biopsies taken before\r treatment were consistent with a diagnosis of TDT, including a low\r myeloid\/erythroid ratio (N=15, HGB\u2011207; N=3, HGB\u2011212), reflective\r of erythroid hyperplasia. For 9 patients who achieved TI and had a\r Month 12 bone marrow assessment, myeloid\/erythroid ratios increased from a\r median (min, max) of 0.2 (0.1 to 0.7) at baseline to a median (min,\r max) of 0.83 (0.6 to 1.9) at Month 12 after Zynteglo infusion,\r suggesting that Zynteglo improves erythropoiesis in patients with TDT. <\/span><\/p>","ID":"3d480750-166e-4e81-99b1-7903c86ba807","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Exploratory analyses were performed to evaluate\r resolution of dyserythropoiesis, the fundamental pathophysiological\r characteristic of TDT, in the bone marrow. Bone marrow biopsies taken before\r treatment were consistent with a diagnosis of TDT, including a low\r myeloid\/erythroid ratio (N=15, HGB\u2011207; N=3, HGB\u2011212), reflective\r of erythroid hyperplasia. For 9 patients who achieved TI and had a\r Month 12 bone marrow assessment, myeloid\/erythroid ratios increased from a\r median (min, max) of 0.2 (0.1 to 0.7) at baseline to a median (min,\r max) of 0.83 (0.6 to 1.9) at Month 12 after Zynteglo infusion,\r suggesting that Zynteglo improves erythropoiesis in patients with TDT. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><a name=\"_Ref442134\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/a><\/p>","ID":"5b141425-34ba-4242-96ea-cd3b84721a9e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><u><span style=\"font-size:11.0pt\">Overall results<\/span><\/u><\/p>","ID":"f7a49c88-6085-4d80-89fb-51a7944b8d78","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Overall results","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal;page-break-after:avoid\"><\/p>","ID":"05838a56-d504-471f-ba7f-73445f00df02","Styles":"margin:0in;line-height:normal;page-break-after:avoid","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoCaption\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;line-height:normal\"><span style=\"font-size:11.0pt\">Figure <\/span><span style=\"font-size:11.0pt\">1            Median total haemoglobin over time in\r non-\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> TDT patients treated with Zynteglo\r who have achieved transfusion independence (Studies HGB\u2011204, HGB\u2011205,\r HGB\u2011207, LTF\u2011303)<\/span><\/p>","ID":"6c19026e-c983-4da5-958b-9fd7574819d8","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;line-height:normal","Classes":"['MsoCaption']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Figure 1            Median total haemoglobin over time in\r non-\u03b20\/\u03b20 TDT patients treated with Zynteglo\r who have achieved transfusion independence (Studies HGB\u2011204, HGB\u2011205,\r HGB\u2011207, LTF\u2011303)","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"Default\" style=\"text-align:justify;text-justify:inter-ideograph\"><span lang=\"EN-GB\"><img height=\"336\" id=\"Picture 3\" src=\"data:image\/jpg;base64,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\" width=\"576\"\/><\/span><\/p>","ID":"bbb46150-2e28-45ea-a592-cdf8da5bb1a9","Styles":"text-align:justify;text-justify:inter-ideograph","Classes":"['Default']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><i><span style='font-family:\"Times New Roman\",serif'>Bars represent\r interquartile ranges.<\/span><\/i><\/p>","ID":"f79cf298-acc0-414e-86d0-86a183f88cc7","Styles":"margin-bottom:0in;line-height:normal;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Bars represent\r interquartile ranges.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><a name=\"_Hlk31017224\"><i><span style='font-family:\"Times New Roman\",serif'>Total\r Hb represents those without any acute or chronic RBC transfusions within 60\r days prior to the measurement date.<\/span><\/i><\/a><\/p>","ID":"42090eb9-9aa4-4994-8d5a-ab2963d31ae2","Styles":"margin-bottom:0in;line-height:normal;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Total\r Hb represents those without any acute or chronic RBC transfusions within 60\r days prior to the measurement date.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><a name=\"_Hlk4231781\"><\/a><\/p>","ID":"0b3afa8e-f177-4642-b663-29101be609b5","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always\"><b><span style='font-family:\"Times New Roman\",serif'>Table 5              Efficacy\r outcomes for non\u2011\u03b2<sup>0<\/sup>\/\u03b2<sup>0<\/sup> TDT patients\r treated with Zynteglo (Studies HGB\u2011204, HGB\u2011205, HGB\u2011207, HGB\u2011212,\r LTF\u2011303)<\/span><\/b><\/p>","ID":"f1f939a8-0fae-43ff-b000-35c8293eab62","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal;page-break-before:always","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Table 5              Efficacy\r outcomes for non\u2011\u03b20\/\u03b20 TDT patients\r treated with Zynteglo (Studies HGB\u2011204, HGB\u2011205, HGB\u2011207, HGB\u2011212,\r LTF\u2011303)","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:1.0in;text-indent:-1.0in;line-height:normal\"><\/p>","ID":"5591d44a-0ca7-4120-bd13-c664fe82f4db","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:1.0in;text-indent:-1.0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\" width=\"591\"> <thead> <tr style=\"height:71.3pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>HbA<sup>T87Q<\/sup>\r    at 6 months<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median\r    (min, max)<\/span><\/p> <\/td> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>HbA<sup>T87Q\r    <\/sup>at 24 months<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Hb\r    at 6 months*<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Hb\r    at 24 months*<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <td style=\"width:.75in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>TI**<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>n\/N^\r    <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span lang=\"FR\" style='font-family:\"Times New Roman\",serif'>(%)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span lang=\"FR\" style='font-family:\r    \"Times New Roman\",serif'>[95% CI]<\/span><\/p> <\/td> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span lang=\"DA\" style='font-family:\"Times New Roman\",serif'>WA\r    Hb during TI <\/span><\/b><span lang=\"DA\" style='font-family:\"Times New Roman\",serif'>(g\/dL)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:71.3pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><b><span style='font-family:\"Times New Roman\",serif'>Duration\r    of TI<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(months)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>n<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>median<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r    line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(min,\r    max)<\/span><\/p> <\/td> <\/tr> <\/thead> <tr style=\"height:2.35pt\"> <td colspan=\"7\" style=\"width:443.5pt;border:solid windowtext 1.0pt;\r   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:2.35pt\" valign=\"top\" width=\"591\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>HGB-205<\/span><\/p> <\/td> <\/tr> <tr style=\"height:37.55pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>7.543<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(4.94,\r   9.59)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8.147<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(6.72,\r   10.13)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.73<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(7.6,\r   13.4)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.91<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(8.8,\r   13.6)<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3\/4 <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(75.0%)<br\/>\r   [19.4, 99.4]<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>11.35<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(10.5,\r   13.0)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.55pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NR <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(38.2+,\r   57.6+)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:1.85pt\"> <td colspan=\"7\" style=\"width:443.5pt;border:solid windowtext 1.0pt;\r   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:1.85pt\" valign=\"top\" width=\"591\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>HGB-204<\/span><\/p> <\/td> <\/tr> <tr style=\"height:37.4pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>4.153<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(1.03,\r   8.52)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>5.418<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(1.10,\r   9.60)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>7<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>9.20<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(7.7,\r   13.3)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.35<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(9.1,\r   13.7)<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8\/10\r   (80.0%)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>[44.4,\r   97.5]<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.27<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(9.3,\r   13.3)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NR <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(28.3+,\r   51.3+)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:5.3pt\"> <td colspan=\"7\" style=\"width:443.5pt;border:solid windowtext 1.0pt;\r   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:5.3pt\" valign=\"top\" width=\"591\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>HGB-207<\/span><\/p> <\/td> <\/tr> <tr style=\"height:37.4pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>13<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>9.324<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(3.35,\r   10.60)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>8.766<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(0.89,\r   11.40)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>15<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>11.80<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(8.4,\r   13.3)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>2<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>12.85<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(12.5,\r   13.2)<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>9\/10<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(90.0%)<br\/>\r   [55.5, 99.7]<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>9<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>12.22<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>(11.4,\r   12.8)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>9<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NR<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(12.1+,\r   21.3+)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:.2in\"> <td colspan=\"7\" style=\"width:443.5pt;border:solid windowtext 1.0pt;\r   border-top:none;background:#D9D9D9;padding:0in 5.4pt 0in 5.4pt;height:.2in\" width=\"591\"> <p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r   avoid\"><span style='font-family:\"Times New Roman\",serif;color:black'>HGB-212<\/span><\/p> <\/td> <\/tr> <tr style=\"height:37.4pt\"> <td style=\"width:.9in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>10.094<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(5.06,\r   10.33)<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>3<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>12.10<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>(8.5,\r   12.2)<\/span><\/p> <\/td> <td style=\"width:65.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"87\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal;text-autospace:none\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <td style=\"width:.9in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:37.4pt\" valign=\"top\" width=\"86\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:0in;text-align:center;\r   line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>NA***<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"eae49e8c-f920-40fb-990c-50b4ecfcaa05","Styles":"border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"    HbAT87Q\r    at 6 months (g\/dL) n median\r    (min, max)   HbAT87Q\r    at 24 months (g\/dL) n median (min,\r    max)   Hb\r    at 6 months* (g\/dL) n median (min,\r    max)   Hb\r    at 24 months* (g\/dL) n median (min,\r    max)   TI** n\/N^\r     (%) [95% CI]   WA\r    Hb during TI (g\/dL) n median (min,\r    max)   Duration\r    of TI (months) n median (min,\r    max)      HGB-205     4 7.543 (4.94,\r   9.59)   4 8.147 (6.72,\r   10.13)   4 10.73 (7.6,\r   13.4)   4 10.91 (8.8,\r   13.6)   3\/4  (75.0%)\r   [19.4, 99.4]   3 11.35 (10.5,\r   13.0)   3 NR  (38.2+,\r   57.6+)     HGB-204     10 4.153 (1.03,\r   8.52)   10 5.418 (1.10,\r   9.60)   7 9.20 (7.7,\r   13.3)   8 10.35 (9.1,\r   13.7)   8\/10\r   (80.0%) [44.4,\r   97.5]   8 10.27 (9.3,\r   13.3)   8 NR  (28.3+,\r   51.3+)     HGB-207     13 9.324 (3.35,\r   10.60)   3 8.766 (0.89,\r   11.40)   15 11.80 (8.4,\r   13.3)   2 12.85 (12.5,\r   13.2)   9\/10 (90.0%)\r   [55.5, 99.7]   9 12.22 (11.4,\r   12.8)   9 NR (12.1+,\r   21.3+)     HGB-212     3 10.094 (5.06,\r   10.33)   NA***   3 12.10 (8.5,\r   12.2)   NA***   NA***   NA***   NA***   ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif;color:white'>*Patients\r who have not received transfusions in the prior 60 days. <\/span><\/p>","ID":"4a6e2073-6464-4598-8016-c2a497112700","Styles":"margin-bottom:0in;line-height:normal;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"*Patients\r who have not received transfusions in the prior 60 days. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif'>**Transfusion\r independence (TI): a weighted average Hb \u22659 g\/dL without any RBC\r transfusions for a continuous period of \u226512 months at any time during the\r study after medicinal product infusion.<\/span><\/p>","ID":"4a835154-a645-4545-9992-5f4b9ec7ad05","Styles":"margin-bottom:0in;line-height:normal;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"**Transfusion\r independence (TI): a weighted average Hb \u22659 g\/dL without any RBC\r transfusions for a continuous period of \u226512 months at any time during the\r study after medicinal product infusion.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif'>***No patients are\r currently evaluable for these endpoints.  <\/span><\/p>","ID":"d544c3ed-3d9f-4495-8e22-3102cd3fc048","Styles":"margin-bottom:0in;line-height:normal;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"***No patients are\r currently evaluable for these endpoints.  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;text-autospace:\r none\"><span style='font-family:\"Times New Roman\",serif'>N^ represents the total\r number of patients evaluable for TI, defined as patients who have completed\r their parent study (i.e., 24 months of follow\u2011up), or achieved TI, or\r will not achieve TI in their parent study. <\/span><\/p>","ID":"f2498146-2291-4ecf-a33f-3c63822c3989","Styles":"margin-bottom:0in;line-height:normal;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"N^ represents the total\r number of patients evaluable for TI, defined as patients who have completed\r their parent study (i.e., 24 months of follow\u2011up), or achieved TI, or\r will not achieve TI in their parent study. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"Default\"><span style=\"font-size:11.0pt\">NR = Not reached. NA = Not\r applicable. Hb = Total Hb. WA Hb = Weighted average Hb.<\/span><\/p>","ID":"73ce7d7e-df47-4df2-ad28-6aa5fbc96cd7","Styles":"None","Classes":"['Default']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"NR = Not reached. NA = Not\r applicable. Hb = Total Hb. WA Hb = Weighted average Hb.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"37e229b6-2b9c-4d4b-8a0d-0456bde72980","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/p>","ID":"27392161-dc80-4f98-befa-1e758ae090ae","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"25637d2c-f749-450b-bbcc-2ea78e339a97","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The European Medicines Agency has deferred the\r obligation to submit the results of studies with Zynteglo in one or more subsets\r of the paediatric population in \u03b2\u2011thalassaemia (see section 4.2 for\r information on paediatric use).<\/span><\/p>","ID":"62a5ebf0-ac0a-4480-bd24-bd8f4c037ca4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The European Medicines Agency has deferred the\r obligation to submit the results of studies with Zynteglo in one or more subsets\r of the paediatric population in \u03b2\u2011thalassaemia (see section 4.2 for\r information on paediatric use).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"33a60a7e-5b9d-43ca-b395-f9ab669ec08d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">This medicinal product has been authorised under a\r so-called \u2018conditional approval\u2019 scheme. This means that further evidence on\r this medicinal product is awaited. The European Medicines Agency will review\r new information on this medicinal product at least every year and this SmPC\r will be updated as necessary.<\/span><\/p>","ID":"2adb17dc-6043-4920-8ad9-decddd1d8cdd","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"This medicinal product has been authorised under a\r so-called \u2018conditional approval\u2019 scheme. This means that further evidence on\r this medicinal product is awaited. The European Medicines Agency will review\r new information on this medicinal product at least every year and this SmPC\r will be updated as necessary.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"35cef599-59bf-48f0-8395-794664e191ed","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.2     Pharmacokinetic\r properties<\/span><\/b><\/p>","ID":"2d06cb5b-c238-40f8-a6fd-be57e016f878","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2     Pharmacokinetic\r properties","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"c0a265c3-7f7f-4c13-92ff-734648f21688","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is an autologous gene therapy medicinal\r product consisting of autologous cells that have been genetically modified <i>ex\r vivo<\/i>. The nature of Zynteglo is such that conventional studies on\r pharmacokinetics, absorption, distribution, metabolism, and elimination are not\r applicable.<a name=\"_Hlk500249629\"><\/a><\/span><\/p>","ID":"90ec1b43-8bd0-4188-8ee6-b6397ea23477","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo is an autologous gene therapy medicinal\r product consisting of autologous cells that have been genetically modified ex\r vivo. The nature of Zynteglo is such that conventional studies on\r pharmacokinetics, absorption, distribution, metabolism, and elimination are not\r applicable.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"9b5f5e99-204f-4909-ae9f-abbf34c5807a","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.3     Preclinical\r safety data<\/span><\/b><\/p>","ID":"52c6cc6d-dbb2-49d9-a719-9681f2dec8f5","Styles":"margin-bottom:0in;line-height:normal;page-break-after:\r\navoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3     Preclinical\r safety data","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"c52c1d68-9e92-4cb7-8818-473de165c7d6","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Conventional mutagenicity, carcinogenicity and\r reproductive and developmental toxicity studies have not been conducted.<\/span><\/p>","ID":"f1138805-1220-49ec-b0ca-c5aa064704d7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Conventional mutagenicity, carcinogenicity and\r reproductive and developmental toxicity studies have not been conducted.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"27ec64bf-797b-49a6-af4a-a67c28067aa3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The pharmacology, toxicology and genotoxicity of the\r BB305 LVV used for transduction in the manufacture of Zynteglo were evaluated <i>in\r vitro<\/i> and <i>in vivo<\/i>. An <i>in vitro<\/i> immortalisation (IVIM) assay\r conducted with BB305 LVV\u2011transduced mouse bone marrow cells (BMCs) showed\r minimal mutagenic potential (Fitness Score \u2248 0.1 \u00d7 10<sup>-4<\/sup>).\r Insertion site analysis (ISA) of pre-transplantation transduced mouse BMCs and\r human CD34<sup>+<\/sup> HSCs showed no enrichment for insertion in or near\r cancer-related genes. A pharmacology, biodistribution, toxicity and\r genotoxicity study was conducted in a mouse model of \u03b2\u2011thalassaemia.\r In this study, there was no evidence of toxicity, genotoxicity or oncogenesis\r (tumorigenicity) related to BB305 LVV integration, and no toxicity related to\r production of \u03b2<sup>A\u2011T87Q<\/sup>\u2011globin. ISA of\r post-transplantation BMCs demonstrated no preferred integration in the\r proximity of or within genes associated clinically (for gamma retroviral\r vectors) with either clonal dominance or leukaemia, and no evidence of clonal\r dominance was observed. Additional studies with human CD34<sup>+<\/sup> HSCs\r administered to immunodeficient, myeloablated mice demonstrated no toxicity,\r tumorigenicity or genotoxicity.<\/span><\/p>","ID":"6bb2e490-e043-47c3-8d07-057371f06c58","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pharmacology, toxicology and genotoxicity of the\r BB305 LVV used for transduction in the manufacture of Zynteglo were evaluated in\r vitro and in vivo. An in vitro immortalisation (IVIM) assay\r conducted with BB305 LVV\u2011transduced mouse bone marrow cells (BMCs) showed\r minimal mutagenic potential (Fitness Score \u2248 0.1 \u00d7 10-4).\r Insertion site analysis (ISA) of pre-transplantation transduced mouse BMCs and\r human CD34+ HSCs showed no enrichment for insertion in or near\r cancer-related genes. A pharmacology, biodistribution, toxicity and\r genotoxicity study was conducted in a mouse model of \u03b2\u2011thalassaemia.\r In this study, there was no evidence of toxicity, genotoxicity or oncogenesis\r (tumorigenicity) related to BB305 LVV integration, and no toxicity related to\r production of \u03b2A\u2011T87Q\u2011globin. ISA of\r post-transplantation BMCs demonstrated no preferred integration in the\r proximity of or within genes associated clinically (for gamma retroviral\r vectors) with either clonal dominance or leukaemia, and no evidence of clonal\r dominance was observed. Additional studies with human CD34+ HSCs\r administered to immunodeficient, myeloablated mice demonstrated no toxicity,\r tumorigenicity or genotoxicity.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"28bb1078-7c62-4a39-8c24-b4b201ae5ebd","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"13a1f740-9b6a-4fac-a2a4-2b2005e91ca7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.       PHARMACEUTICAL\r PARTICULARS<\/span><\/b><\/p>","ID":"f1054df7-7c64-4ba3-ac2f-d7dbafd85fb3","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.       PHARMACEUTICAL\r PARTICULARS","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"4196ea64-7287-4ba8-b638-2af0e0f79bd4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.1     List of\r excipients<\/span><\/b><\/p>","ID":"2a6fba84-5936-46a4-b323-59c45538ffa5","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1     List of\r excipients","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"5bc2ec5d-0ae5-4ebd-ad96-351f8d2419e3","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Cryostor CS5<\/span><\/p>","ID":"f188f1d5-603e-426c-a3bf-7729ba401985","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cryostor CS5","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Sodium chloride<\/span><\/p>","ID":"50df6455-f8fb-40ae-a96c-de3b370ab929","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Sodium chloride","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"0ee001e4-0a6f-4ef0-9719-b804b37d9e66","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.2     Incompatibilities<\/span><\/b><\/p>","ID":"d5f17a63-e962-4057-8cc4-e0f4375c36f9","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2     Incompatibilities","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"9eb3f7c5-2159-4ee5-b026-39d0cde26b87","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">In the absence of compatibility studies, this\r medicinal product must not be mixed with other medicinal products.<\/span><\/p>","ID":"7cc295c0-5f0b-4d39-b11f-4d81a8bc80c8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In the absence of compatibility studies, this\r medicinal product must not be mixed with other medicinal products.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"2a3c81df-526b-4635-8779-3db757178243","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.3     Shelf life<\/span><\/b><\/p>","ID":"22c2a69b-ad9d-41d7-8520-9d3b128e971d","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3     Shelf life","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"2acd798b-158e-4044-9266-1292ebbf9826","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Frozen: 1 year at \u2264-140\u00b0C.<\/span><\/p>","ID":"1ac17e9f-fb48-49fa-898a-b1033781df17","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Frozen: 1 year at \u2264-140\u00b0C.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Once thawed: maximum 4 hours at room temperature\r (20\u00b0C\u201125\u00b0C).<\/span><\/p>","ID":"54f7f0b8-a265-4491-bdf0-20fad534cc1d","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Once thawed: maximum 4 hours at room temperature\r (20\u00b0C\u201125\u00b0C).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"597e6ea5-d6eb-46c6-a875-2d1dcb84c539","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.4     Special\r precautions for storage<\/span><\/b><\/p>","ID":"e4174dad-3791-46b9-aad7-6b93cbb3afb3","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4     Special\r precautions for storage","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"673dfc98-1ae2-4566-80c5-ea5fb9fc1938","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Store in the vapour phase of liquid nitrogen at\r \u2264-140\u00b0C until ready for thaw and administration. <\/span><\/p>","ID":"03ff79df-71c6-4e5d-9233-62de941b3dcd","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Store in the vapour phase of liquid nitrogen at\r \u2264-140\u00b0C until ready for thaw and administration. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"7aff7e5d-dc4c-4638-8e7d-2157f6dd8cf2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Keep the infusion bag(s) in the metal cassette(s). <\/span><\/p>","ID":"6b43f3b9-68d4-4863-bf07-e8015aa088b9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Keep the infusion bag(s) in the metal cassette(s). ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"d42288e0-293d-426d-9a65-108f3db697b2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Do not re-freeze after thawing.<\/span><\/p>","ID":"43f20224-2508-447c-83ec-e6ef2bd863b8","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Do not re-freeze after thawing.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"aa0aff18-c2fb-4717-af9a-2e1a408a30d5","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.5     Nature and\r contents of container <\/span><\/b><\/p>","ID":"931b0ad4-835c-416d-bbbc-fbad84490bc6","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5     Nature and\r contents of container ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"fe21178d-241b-4a66-916c-b108342951a9","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">20 mL fluorinated ethylene propylene infusion\r bag(s), each packed in a transparent pouch inside a metal cassette. <\/span><\/p>","ID":"3d01e4da-5111-4a94-b92c-634f2da8f843","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"20 mL fluorinated ethylene propylene infusion\r bag(s), each packed in a transparent pouch inside a metal cassette. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"2dfb01ca-a431-4c9f-8c41-0e50fe720d82","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Zynteglo is shipped from the manufacturing facility to\r the infusion centre storage facility in a cryoshipper, which may contain\r multiple metal cassettes intended for a single patient. Each metal cassette\r contains one infusion bag with Zynteglo. A patient may have multiple infusion\r bags. <\/span><\/p>","ID":"5c68a346-d4b8-46e0-9812-1af0b6edf5e5","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Zynteglo is shipped from the manufacturing facility to\r the infusion centre storage facility in a cryoshipper, which may contain\r multiple metal cassettes intended for a single patient. Each metal cassette\r contains one infusion bag with Zynteglo. A patient may have multiple infusion\r bags. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"90dc33e0-556f-452b-b808-027b88efae31","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.6     <a name=\"_Hlk31012748\">Special precautions for disposal and other handling<\/a><\/span><\/b><\/p>","ID":"06894273-1041-45f5-b130-f5b201693422","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6     Special precautions for disposal and other handling","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"1aa1dcab-ff30-4256-85c0-ce7931714166","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">Irradiation could lead to inactivation of the product.<\/span><\/p>","ID":"24a68dbc-408c-41bf-aa78-317089ad89a4","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irradiation could lead to inactivation of the product.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"324faafb-7c6b-487e-818a-27d369c5ab1b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Precautions to be taken before handling or\r administering the medicinal product<\/span><\/i><\/p>","ID":"fedb696e-cd4e-4c97-8cac-8b8557565203","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Precautions to be taken before handling or\r administering the medicinal product","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-.25in;line-height:normal\"><span style=\"font-size:\r 11.0pt;font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">This medicinal product contains\r genetically modified human blood cells. Healthcare professionals handling\r Zynteglo should take appropriate precautions (wearing gloves, protective\r clothing and eye protection) to avoid potential transmission of infectious\r diseases.  <\/span><\/p>","ID":"4fcdb0b1-47f0-418e-9530-a0cc41d55eaf","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;text-indent:-.25in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7This medicinal product contains\r genetically modified human blood cells. Healthcare professionals handling\r Zynteglo should take appropriate precautions (wearing gloves, protective\r clothing and eye protection) to avoid potential transmission of infectious\r diseases.  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"4a455f98-10ce-4831-b312-0d220dc81718","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Preparation for the infusion<\/span><\/i><\/p>","ID":"ac56014b-a036-419d-afb0-90308c7765b2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Preparation for the infusion","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Remove each metal cassette from liquid nitrogen\r storage and remove each infusion bag from the metal cassette.<\/span><\/p>","ID":"e837c885-2f8b-4145-901e-946c02db8149","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Remove each metal cassette from liquid nitrogen\r storage and remove each infusion bag from the metal cassette.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Confirm that Zynteglo is printed on the infusion\r bag(s).<\/span><\/p>","ID":"d77422aa-607d-46c7-9164-8716e2c90c87","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Confirm that Zynteglo is printed on the infusion\r bag(s).","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Confirm that patient identity matches the unique\r patient identification information located on the Zynteglo infusion bag(s). Do\r not infuse Zynteglo if the information on the patient specific\u2011label on\r the infusion bag does not match the intended patient.<\/span><\/p>","ID":"4653d212-3668-4abd-9d2c-8427b36d05c8","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Confirm that patient identity matches the unique\r patient identification information located on the Zynteglo infusion bag(s). Do\r not infuse Zynteglo if the information on the patient specific\u2011label on\r the infusion bag does not match the intended patient.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Account for all infusion bags and confirm each\r infusion bag is within the expiry date using the accompanying Lot Information\r Sheet. <\/span><\/p>","ID":"0fb35662-3ca4-4102-9a6c-d5ebcb8b1db1","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Account for all infusion bags and confirm each\r infusion bag is within the expiry date using the accompanying Lot Information\r Sheet. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Each infusion bag should be inspected for any breaches\r of integrity before thawing and infusion. If an infusion bag is compromised,\r follow the local guidelines and contact bluebird bio immediately.<\/span><\/p>","ID":"ba4c2db9-5d2b-4fa3-a4ba-94c2a9bc843e","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Each infusion bag should be inspected for any breaches\r of integrity before thawing and infusion. If an infusion bag is compromised,\r follow the local guidelines and contact bluebird bio immediately.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"156be764-e5c6-4f9b-a2c5-3aabf87994a7","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><i><span style=\"font-size:11.0pt\">Thaw and administration<\/span><\/i><\/p>","ID":"ae996b28-2534-42d7-b734-445af51c2a8b","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Thaw and administration","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Thaw Zynteglo at 37\u00b0C in a water\r bath or dry bath. Thawing of each infusion bag takes approximately 2 to 4 minutes.\r Do not overthaw the medicinal product. Do not leave the medicinal product\r unattended and do not submerge the infusion ports if thawed in a water bath.<\/span><\/p>","ID":"106714cd-4136-41e4-bc1a-735998ae70d1","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;text-indent:-13.5pt;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Thaw Zynteglo at 37\u00b0C in a water\r bath or dry bath. Thawing of each infusion bag takes approximately 2 to 4 minutes.\r Do not overthaw the medicinal product. Do not leave the medicinal product\r unattended and do not submerge the infusion ports if thawed in a water bath.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">After thaw, mix the medicinal\r product gently by massaging the infusion bag until all of the contents are\r uniform. Expose the sterile port on the infusion bag by tearing off a\r protective wrap covering the port. <\/span><\/p>","ID":"234ddb92-e594-4a9a-9b66-9fc162fff2f6","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;text-indent:-13.5pt;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7After thaw, mix the medicinal\r product gently by massaging the infusion bag until all of the contents are\r uniform. Expose the sterile port on the infusion bag by tearing off a\r protective wrap covering the port. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Access the medicinal product\r infusion bag and infuse per the administration site\u2019s standard procedures for\r administration of cell therapy products. Do not use an in-line blood filter or\r an infusion pump.<\/span><\/p>","ID":"9780f367-04b2-4aa0-b426-eb11d314d7c8","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;text-indent:-13.5pt;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Access the medicinal product\r infusion bag and infuse per the administration site\u2019s standard procedures for\r administration of cell therapy products. Do not use an in-line blood filter or\r an infusion pump.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Do not sample, alter, or irradiate\r the medicinal product.<\/span><\/p>","ID":"10277d67-3a2a-49b5-9b56-326b4cbd3435","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;text-indent:-13.5pt;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":true,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Do not sample, alter, or irradiate\r the medicinal product.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Administer each infusion bag of\r Zynteglo via intravenous infusion over a period of less than 30 minutes.\r If more than one infusion bag is provided, administer each infusion bag\r completely before proceeding to thaw and infuse the next bag.<\/span><\/p>","ID":"2f39c2b5-9f48-4071-b2ac-598a0558b803","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;text-indent:-13.5pt;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Administer each infusion bag of\r Zynteglo via intravenous infusion over a period of less than 30 minutes.\r If more than one infusion bag is provided, administer each infusion bag\r completely before proceeding to thaw and infuse the next bag.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-Bullet\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in;text-indent:-13.5pt;line-height:normal\"><span style=\"font-family:Symbol\">\u00b7<\/span><span style=\"font-size:11.0pt\">Infuse Zynteglo as soon as\r possible and no more than 4 hours after thawing. Flush all Zynteglo\r remaining in the infusion bag and any associated tubing with at least\r 50 mL of 0.9% sodium chloride solution to ensure as many cells as possible\r are infused into the patient.<\/span><\/p>","ID":"38e6ea49-47d5-4a0d-8f3f-0dcbfd72b778","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in;text-indent:-13.5pt;line-height:normal","Classes":"['C-Bullet']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"\u00b7Infuse Zynteglo as soon as\r possible and no more than 4 hours after thawing. Flush all Zynteglo\r remaining in the infusion bag and any associated tubing with at least\r 50 mL of 0.9% sodium chloride solution to ensure as many cells as possible\r are infused into the patient.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"a98a8f2d-d7cc-4ef8-8b5c-a3244334e9e3","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\">Precautions to be taken for the disposal of the\r medicinal product<\/span><\/u><\/p>","ID":"bdc9a33e-5763-4986-ad3f-aa58517db180","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Precautions to be taken for the disposal of the\r medicinal product","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><u><span style=\"font-size:11.0pt\"><\/span><\/u><\/p>","ID":"5fb4260d-ffb4-41c1-b348-655ee74cb179","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">The medicinal product contains genetically\u2011modified\r cells. Local guidelines on handling human-derived material should be followed\r for unused medicinal products or waste material. All material that has been in\r contact with Zynteglo (solid and liquid waste) should be handled and disposed\r of as potentially infectious waste in accordance with local guidelines on\r handling human-derived material. <\/span><\/p>","ID":"70b55bdf-0e1c-4844-8e63-a3c7d1b38881","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The medicinal product contains genetically\u2011modified\r cells. Local guidelines on handling human-derived material should be followed\r for unused medicinal products or waste material. All material that has been in\r contact with Zynteglo (solid and liquid waste) should be handled and disposed\r of as potentially infectious waste in accordance with local guidelines on\r handling human-derived material. ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"ce68b21f-473a-45c0-82b5-4015d6ababd2","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"979d967b-3814-4717-9c70-ade888a0fcf5","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/p>","ID":"b03dae66-9e7a-491f-8073-5be8c589cd46","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.       MARKETING\r AUTHORISATION HOLDER","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p>","ID":"3c86e9a2-75e1-48d0-82e9-ac99adfe97e7","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span style=\"font-size:11.0pt\">bluebird bio (Netherlands) B.V.<\/span><\/p>","ID":"794ea61d-7c9c-4fd1-a02f-ba548849bf59","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"bluebird bio (Netherlands) B.V.","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stadsplateau 7<\/span><\/p>","ID":"b47f16f8-695e-46ed-bda1-198a8dc5e0b9","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Stadsplateau 7","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">WTC Utrecht<\/span><\/p>","ID":"179ad6d8-c4e8-42dc-b357-70459853ae5e","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"WTC Utrecht","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">3521AZ Utrecht<\/span><\/p>","ID":"71c1c10c-668c-4c35-8d04-399415a1f0ec","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3521AZ Utrecht","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The Netherlands<\/span><\/p>","ID":"fb7ef382-6349-4df4-824a-4104ab3fa747","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The Netherlands","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"e4166218-3f1b-4ae6-b5bf-b0a375f08691","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"C-BodyText\" style=\"margin:0in;line-height:normal\"><\/p>","ID":"c4b52ca8-e9a2-44ac-8466-0cba87478127","Styles":"margin:0in;line-height:normal","Classes":"['C-BodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>8.       MARKETING\r AUTHORISATION NUMBER(S) <\/span><\/b><\/p>","ID":"d7c4102b-e88c-4605-992c-01351615b8db","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.       MARKETING\r AUTHORISATION NUMBER(S) ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p>","ID":"28101b23-fce2-4dae-b787-56ae9f8498c5","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>EU\/1\/19\/1367\/001<\/span><\/p>","ID":"06fa42c8-44d6-438e-aba7-761744395e7a","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/19\/1367\/001","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p>","ID":"3551658e-928c-4a7f-ba7d-3aedbb4d556c","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p>","ID":"6d4ea698-f003-4a48-9a8f-20fc72b970a7","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>9.       DATE OF FIRST\r AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p>","ID":"eee997a4-cff7-42e2-823d-e0b9563e344d","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.       DATE OF FIRST\r AUTHORISATION\/RENEWAL OF THE AUTHORISATION","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p>","ID":"c126ec22-292e-4988-b286-4b05dc95fb72","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>Date of first authorisation: 29 May\r 2019<\/span><\/p>","ID":"4f66f683-2201-48a4-a91b-8b87b76367cc","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first authorisation: 29 May\r 2019","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p>","ID":"406038f6-73f6-418e-b6c8-d44a9ecff27b","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><\/p>","ID":"3f8f338c-7ce2-43fe-9492-889acb69f97f","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt;line-height:normal\"><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>10.     DATE OF REVISION\r OF THE TEXT<\/span><\/b><\/p>","ID":"1e1a6178-def1-4edf-bb9d-a38ea97a6a32","Styles":"margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt;line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.     DATE OF REVISION\r OF THE TEXT","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><\/p>","ID":"f068c70c-79ad-49b6-8ee8-d9d84f9dae82","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:0in;line-height:normal\"><span style='font-family:\"Times New Roman\",serif'>{DD month YYYY}<\/span><\/p>","ID":"5c6cd4b9-b761-4422-a32f-7b883a3e7660","Styles":"margin-bottom:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"{DD month YYYY}","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"58e7c2c0-7c93-4b14-92be-ae5b9f96dff2","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Detailed\r information on this medicinal product is available on the website of the\r European Medicines Agency <\/span><a href=\"http:\/\/www.ema.europa.eu\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>http:\/\/www.ema.europa.eu<\/span><\/a><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>&lt;, and on the website\r of {name of MS Agency (link)}&gt;. <br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/p>","ID":"35b19828-be1a-491b-8ffd-8f7f66f10e5d","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed\r information on this medicinal product is available on the website of the\r European Medicines Agency http:\/\/www.ema.europa.eu<, and on the website\r of {name of MS Agency (link)}>.  ","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"286ae38c-32ce-405c-8ab6-ae297d40601b","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"dd5835db-5e19-40fd-b092-b5b27e4c34c9","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"46293946-839c-424a-ba0b-f4bb833c4bb7","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"eadaad52-4ed1-495f-8448-0a60450e003c","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"5b6dfcfb-1949-448c-889f-f6d50633aec7","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"9cfaf827-ad99-46c2-894d-fe327352cb02","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"c23499ff-b157-4f8f-8b60-051c27d1c847","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"9e1cdc05-6041-4eb5-a6f9-4f7b85b2a4be","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"9b7cbb6e-e771-4497-b28d-7e4f65bf29a5","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"8a520e1c-f074-47d1-870d-2f9f23537b0d","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"22021b36-c350-4b7f-83c2-6f1a1e9fa9ae","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"01b68f0f-c97f-44d6-b51c-202439509117","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"4e3614b3-d699-4c87-bd50-8639426e0357","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"2afc5822-ea2f-46c0-b2bf-4fd304e528d8","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"6ea40499-20ef-468f-bb74-9aaee8eae41f","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"cbdc11fd-c6a5-48b1-ad73-4f2447370559","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"1854241f-5459-4f8e-8f58-134bdc89c2a9","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:0in;line-height:normal\"><\/p>","ID":"8c731ac6-e5ac-431c-b370-63e5ad28cda4","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:0in;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><\/p>","ID":"89d1b176-b206-4be4-bcb9-b76b93759f09","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:27.0pt;text-indent:-27.0pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><\/p>","ID":"cefad6dc-c809-4122-9dfb-49ae14654420","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:27.0pt;text-indent:-27.0pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><\/p>","ID":"dad7c5cc-d798-4a18-921a-e7e59b1b7d6b","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:27.0pt;text-indent:-27.0pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:27.0pt;text-indent:-27.0pt;line-height:normal\"><\/p>","ID":"9800a2b7-2e6c-4a37-92d3-dd5606eb681a","Styles":"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r\nmargin-left:27.0pt;text-indent:-27.0pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;\r margin-bottom:0in;margin-left:27.0pt;text-align:center;text-indent:-27.0pt;\r line-height:normal\"><\/p>","ID":"374b9f96-ade9-44c7-86b3-07624334a208","Styles":"margin-top:0in;margin-right:-.1pt;\r\nmargin-bottom:0in;margin-left:27.0pt;text-align:center;text-indent:-27.0pt;\r\nline-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"29f465f1-cfca-48b7-b426-ef815c7da2e6"}]